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CHAPTER 1 
General introduction 
General introduction 
1.1 History and lifecycle 
Toxoplasma gondii is an obligatory intracellular parasite. The parasite is a 
member of the phylum Apicomplexa and is further classified in the class of 
Sporozoa, the subclass of Coccidia, the order of Eucoccidia and the suborder 
of Eimeria [24]. 
The knowledge of T. gondii has a rather short history. T. gondii was 
discovered in 1908 by Nicolle and Manceaux [27] in mononuclear cells of the 
spleen and liver of the rodent Ctenodactylus gundi. Because it resembled other 
Leishmania, the parasite was initially named Leishmania gondii. But after 
studying the morphology more carefully, the parasite was renamed into 
Toxoplasma (toxon = arc, plasma = form, Greek) gondii, after its crescent 
shape. 
In 1923, Janku [22] recognized the first case in humans, when he found 
parasitic cysts in the retina of a child with hydrocephalus and microphthalmia. 
However, it was not until 1937 that the parasite was associated with 
congenital infection in man [44]. Three years later, Pinkerton and Weinman 
[31] discovered that T. gondii was able to cause fatal toxoplasmosis in adults. 
While progress was made in characterizing the parasite and its relation to 
disease in animals and man, the main routes of transmission remained a 
mystery. In 1954, Weinman and Chandler [42] suggested that transmission 
occurred through the ingestion of undercooked meat. Experiments by Jacobs 
et al [21] and Desmonts et al [7] provided the evidence for this hypothesis. 
Jacobs and co-workers showed that proteolytic enzymes dissolved the cyst 
wall of T. gondii tissue cysts, and that once released, T. gondii parasites 
survived long enough to infect the host. Transmission by ingestion of infected 
meat was experimentally tested in children in a tuberculosis hospital in Paris 
by Desmonts et al [7]. They found that the acquisition rate of T. gondii 
antibody rose to 100% after feeding these children undercooked meat as a 
valuable source of vitamins. Although an important part of the transmission 
route was elucidated by these experiments, the finding of T. gondii antibody 
in strict vegetarians and herbivores [32] remained to be explained. 
The discovery of T. gondii in cat feces by Hutchison [18] was an important 
step in resolving the complete life cycle of the parasite. Initially, it was 
thought that T. gondii was spread enclosed within the egg of the nematode 
Toxocara cati [19], but this was disproved by the finding of T. gondii in 
worm-free cats [13]. The knowledge of the T. gondii life cycle was completed 
in 1969 when the sexual stage of the parasite was found in the small intestine 
of the cat [3,28,29,41], followed by the discovery of T. gondii oocysts in cat 
feces by several groups of investigators [10,11,14,20,37,43]. 
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T. gondii exists in three infectious forms; the oocyst that produces 
sporozoites, the tachyzoite which is the proliferative form of the parasite, and 
the tissue cyst that harbours the non proliferative form or bradyzoite. 
The parasite can transform alternately from the sexual cycle in the definitive 
host (feline species) to the asexual cycle in the intermediate host. The 
intermediate hosts include a wide range of warm blooded vertebrates from 
birds to humans. The parasite can also pass through a number of asexual 
cycles in different intermediate hosts by means of a predator-prey system. The 
life cycle of T. gondii is presented in Figure 1. 
After the ingestion of tissue cysts by the cat e.g. by ingestion of an infected 
bird or mouse, the tissue cyst wall is dissolved by the proteolytic enzymes in 
the stomach and small intestine. The bradyzoites so released penetrate the 
epithelial cells of the intestine, undergo schizogony and gametogony and 
eventually develop into male gametes (microgametes) and female gametes 
(macrogametes) [9,29,30]. The microgametes penetrate a macrogamete to 
form a zygote. After penetration a resistant wall is formed around the zygote. 
This wall characterizes the oocyst. The unsporulated oocysts are shed in the 
feces for periods varying from 7 to 20 days. After a period of incubation in 
the external environment, the zygote divides into two sporoblasts. A wall than 
develops around each sporoblast which become sporocysts, within which two 
further divisions take place to produce four sporozoites [2,12]. The fully 
sporulated oocyst is infective to both definite and intermediate hosts when 
ingested. 
Infection of the intermediate host may occur by two different routes. Directly 
by oocysts from cat feces through contact with contaminated soil, vegetables 
or cat boxes, or indirectly by tissue cysts through ingestion of infected meat. 
After ingestion, the sporozoites and bradyzoites from oocysts and tissue cysts 
respectively are released into the small intestine where they develop into 
tachyzoites. The tachyzoites enter host cells, either by active invasion or by 
phagocytosis and start to multiply by repeated endodyogeny [36]. In the acute 
stage of infection mononuclear cells and macrophages mostly serve as host 
cells. Later, the parasite penetrates other nucleated cells, probably to evade 
the immune system. The tachyzoites differentiate within these cells into slowly 
replicating bradyzoites and form tissue cysts. The factors influencing tissue 
cyst formation are not known. Initially, it was assumed that tissue cyst 
formation was triggered by the development of antibodies to T. gondii, but 
this is unlikely to be the sole mechanism, since tissue cysts are found in 
animals infected for only 3 to 4 days, as well as in tissue culture systems 
devoid of antibody. The parasite eventually disseminates affecting virtually 
every organ, although the brain and skeletal and cardiac muscle appear to be 
the most common sites of latent infection [33]. 
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Definite host: Feline species 
(sexual life cycle of Toxoplasma gondii) 
Transplacental 
infection 
Intermediate host: humans, mammals and birds 
(asexual life cycle of Toxoplasma gondii) 
The life cycle of Toxoplasma gondii. Copied from G. Desmonts. 1971. La 
Presse Médicale 79:471-474 (with permission). 
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1.2 Clinical manifestation 
Infections caused by the parasite T. gondii occur frequently in humans and 
animals with the prevalence differing greatly from one geographic area to 
another from 2 to 90% [8]. The frequency of infection also increases with 
age. 
The infection is usually benign, without obvious symptoms and requires no 
treatment. Occasionally, infection is accompanied by malaise, fever, headache 
or lymphadenopathy. In extreme cases, infection may lead to serious and even 
fatal disease involving different organs, leading to encephalitis, myocarditis, 
pneumonitis or hepatitis [8]. The parasite can cause life-threatening disease in 
two groups of individuals: the immunocompromised patient (transplant 
recipients, patients with AIDS and those who receive immunosuppressive 
treatment), and in the fetus with a still developing immune system when the 
mother acquires an primary infection during pregnancy. The study described 
in this thesis focuses on the latter group of patients. 
1.2.1 Toxoplasmosis in the immunocompromised patient 
After the acute infection, cysts of T. gondii persist in the central nervous 
system as well as in extraneural tissues. Immunocompromised hosts, 
particularly those with AIDS, are vulnerable to reactivation and dissemination 
of infection. Reactivation leads to clinically apparent disease that usually 
presents as encephalitis with headache being a prominent symptom, often 
accompanied by altered mental status, seizure and hemiparesis [25,26]. 
Because toxoplasmic encephalitis is usually caused by reactivation of a latent 
infection, patients with toxoplasmic encephalitis are almost invariably (>97%) 
seropositive for T. gondii [25,26]. However, the level of antibody is not a 
good indicator of disease. Immunoglobulin M antibody is rarely found in sera 
of these patients. In addition, a rise in titer of IgG antibody occurs only in 
about one-third of cases. Intrathecal production of antibody to T. gondii has 
proven to be a specific indicator in no more than 50% of patients [25,26]. 
Diagnosis is based mainly on a high index of suspicion rather than on a 
proven infection and relies largely on symptomatology in combination with 
characteristic lesions found by computed tomography (CT) or magnetic 
resonance imaging (MRI). A response to treatment, both clinically and as 
demonstrated by brain imaging, is taken as support for the diagnosis but when 
treatment fails, toxoplasmic encephalitis cannot be excluded. Proof of 
infection has to be obtained by direct demonstration of T. gondii. Diagnostic 
techniques for the direct demonstration of the parasite, however, show pitfalls; 
Microscopy is rather insensitive, detecting antigens is neither sensitive nor 
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specific enough and tissue culture and mouse inoculation can be time 
consuming. In addition, not every laboratory is equipped with the facilities for 
tissue culture and animal research. Among the newer molecular techniques 
direct demonstration of the parasite by the polymerase chain reaction (PCR) 
shows the most promise [34,40]. Burg et al [1] described a PCR which was 
based on the detection of a 35-fold repetitive gene, the BI-gene which is 
specific for T. gondii. PCR was applied to cerebrospinal fluid samples 
obtained from patients with AIDS who were suspected of having cerebral 
toxoplasmosis. The PCR showed the highest diagnostic yield when compared 
to intrathecal antibody production and response to treatment [34]. 
1.2.2 Toxoplasma infection in the congenially infected fetus 
When a mother has acquired primary T. gondii infection during pregnancy, 
the fetus may become infected as well. The risk of fetal infection is related to 
the gestational stage at the time of maternal infection. Studies from Desmonts 
and Couvreur [5] have shown that the transmission rate increases from 25% to 
54% to 65% after infection in the first, second, and third trimester, 
respectively. The severity of congenital infection also depends on the stage of 
pregnancy at which infection is acquired and the earlier it occurs, the more 
severe the infection [6]. T. gondii infection can cause non-specific symptoms 
such as intrauterine growth retardation, hepato-splenomegaly, purpura, and 
jaundice. A minority of congenitally infected fetuses will have severe 
manifestations such as hydrocephalus, microcephalus, chorioretinitis and 
intracranial calcifications of the fetus and may even lead to death. 
1.3 Diagnosis of congenital T. gondii infection 
Early diagnosis of fetal infection is important in order that an informed 
decision can be made about treatment or therapeutic abortion. However, 
prenatal diagnosis of congenital T. gondii infections is hampered by the lack 
of a reliable, sensitive and rapid diagnostic test. Serology, for instance, must 
rely solely on the presence of fetal IgM antibodies, because these antibodies 
do not cross the placental barrier, as do IgG antibodies. Antibody production, 
however, often fails or is delayed in the fetus with a still developing immune 
system. Congenital T. gondii infection should therefore be proven by 
demonstrating the presence of the parasite but the diagnostic tests exhibit the 
same limitations as have been described for diagnosing cerebral toxoplasmosis 
in the immunocompromised patient. It is therefore encouraging that the PCR 
on the BI-gene [1] appears to be a sensitive and specific test for the detection 
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of T. gondii in the amniotic fluid [15], cerebrospinal fluid and tissues of 
congenitally infected fetuses [40]. The PCR on the BI-gene, however, failed 
to detect T. gondii in amniotic fluid samples and blood samples which were 
found positive by mouse inoculation [35]. Therefore, further investigations are 
necessary to enhance the sensitivity of the PCR and thus improve the prenatal 
diagnosis of congenital T. gondii infections. 
1.4 Treatment of congenital T. gondii infection 
Congenital toxoplasmosis is treated with spiramycin, pyrimethamine and 
sulfadiazine, or a combination of these two drug regimens. The macrolide 
antibiotic spiramycin is mainly used in France. Spiramycin is given to 
pregnant women as soon as seroconversion has occurred. The antibiotic is 
known to be a safe drug during pregnancy. Benificial effects of the antibiotic 
have been claimed. Placental infection is less frequently found in women 
treated with spiramycin [4,6]. A reduction in the incidence of congenitally 
infected infants born to treated versus untreated mothers is found as well [6]. 
Although these findings indicate that treatment with spiramycin reduces the 
risk of fetal infection, it is not known whether the antibiotic prevents 
transmission of infection or whether it has also a therapeutic effect on the 
infected fetus. The latter is probably not the case since spiramycin does not 
modify the pattern of clinically apparent infection in the fetus probably 
because spiramycin does not reach therapeutic concentrations in the fetus. 
At present the synergistic combination of pyrimethamine and sulfadiazine is 
the treatment of choice for congenital toxoplasmosis and has been given to 
pregnant women for nearly 30 years. Several investigators report a significant 
reduction in the incidence of congenital infection after treatment with the 
pyrimethamine-sulfadiazine combination [16,23,38,39]. The drug regimen 
appears more effective than spiramycin in eradicating T. gondii parasites from 
the placenta [4]. Moreover, pyrimethamine-sulfadiazine treatment leads to a 
reduction in the number of severely affected babies and a shift to less severe 
and subclinical forms [17]. The effect of pyrimethamine-sulfadiazine has been 
claimed to be superior to spiramycin but no prospective, randomized trials 
have been conducted. Further research should therefore focus on treating 
congenital T. gondii infections. 
1.5 AIM OF THE STUDY 
Before introduction of the PCR, prenatal diagnosis of congenital T. gondii 
infections was unreliable and so a woman who acquired a primary T. gondii 
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infection during pregnancy was forced to decide between treatment or 
terminating her pregnancy without knowing whether the fetus was infected. 
Moreover, clinicians could not guarantee that treatment would be effective nor 
could they be reasonably sure that the fetus was infected in which case 
treatment would merely be preventive. 
Therapeutic abortion is legally permissible until 26 weeks gestation, when the 
rate of transmission to the fetus is <25%. Thus, the choice of termination of 
pregnancy would lead to a high number of unnecessary abortions. It is 
therefore important to improve the prenatal detection of T. gondii infections 
and also to conduct prospective, randomised studies on the effectiveness of 
treatment of the infected fetus. 
The study described in the present thesis thus served a dual purpose: 
(1) How can fetal infection with T. gondii be established when there is 
serological evidence of primary infection in the mother? 
(2) What is the effect of chemotherapeutic treatment of the mother during 
gestation in the congenitally infected fetus? 
1.6 OUTLINE OF THE THESIS 
The direction wherein a new diagnostic test for the direct demonstration of T. 
gondii was sought was that of a Polymerase Chain Reaction (PCR). This 
technique has already proven applicable to diagnosing a variety of other 
microbiological infections. 
The principle of a diagnostic PCR is in vitro amplification of specific target 
DNA sequences on the genome of interest (in this case T. gondii). This way, 
it is theoretically possible to detect a single molecule within the abundance of 
host DNA. 
To develop a PCR for T. gondii, a new target sequence on the genome was 
chosen. In addition, the PCR was modified to a "nested PCR" to improve the 
sensitivity of the test. A nested PCR is characterised by performing two 
PCR's subsequently, using the amplified product of the first reaction as the 
target for the second reaction. The development of this PCR and the 
motivation to select a new target sequence is described in chapter 2. The 
evaluation of the nested PCR is described in chapter 3. Chapter 3 also 
describes the suitability of the rhesus monkey to serve as a model for human 
congenital T. gondii infections. These experiments were carried out in rhesus 
monkeys (Macaca mulatta) for logistic and practical reasons. Moreover, 
transmission of infection was expected to be similar for rhesus monkeys and 
humans because they both possess a placenta of the hemochonal type 
The traditional therapy for congenital T. gondii infections is pyrimethamine in 
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combination with a sulfonamide, usually sulfadiazine. Spiramycin is less 
active than the pyrimethamine-sulfadiazine combination, but it is capable of 
inhibiting the growth of free and intracellular parasites. The studies described 
in this thesis focussed on these two drug regimens since it was still unclear 
whether or not these anti-Toxoplasma drugs reach therapeutic concentrations 
in already infected fetuses. Both drug regimens necessitated pharmacokinetic 
studies in the rhesus monkey since no data were available for this animal 
species. The results of the pharmacokinetics of spiramycin and the 
effectiveness of this antibiotic in the infected fetus are described in the 
Chapters 4 and 5, respectively. The effect of pyrimethamine in combination 
with sulfadiazine on congenital T. gondii infection is described in Chapter 6. 
This chapter also contains pharmacokinetic data of pyrimethamine and 
sulfadiazine in rhesus monkeys. 
The pharmacokinetic studies of sulfadiazine in the rhesus monkey revealed the 
presence of 5 metabolites. The isolation, characterisation, and determination 
of the 5 metabolites is described in Chapter 7. It was not known whether these 
metabolites possessed anti-Toxoplasma activity and thus whether they 
contributed to effective treatment. Therefore, anti-Toxoplasma activity of these 
metabolites was studied in vitro. The results are presented in Chapter 8. The 
therapeutic consequences of these findings, finally, are discussed in the 
general discussion of the present thesis in Chapter 9. 
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Abstract 
In this report the applicability of in situ hybridization (ISH) and the 
polymerase chain reaction (PCR) is described for the diagnosis of 
toxoplasmosis. 
The presence of T. gondii cysts in the brain of experimentally infected mice 
was clearly demonstrated by ISH using digoxigenin labeled oligonucleotide 
probes directed against the Bl gene. With this technique, the parasite could 
be localized within the morphological structure of the infected tissue. 
A novel PCR assay was developed with the small subunit ribosomal RNA 
(16S-like rRNA) as a target. The abundance of rRNA target sequences 
enabled a single parasite to be detected with this RNA based amplification 
system. 
The usefulness of these molecular assays for the diagnosis of T. gondii 
infections will be further outlined in this report. 
Introduction 
Diagnosis of toxoplasmosis is problematic both in congenital infection and in 
recurrent infection, as occurs in immunocompromised patients. Serology is 
frequently unreliable, and more direct approaches to detect T. gondii in 
clinical specimens by microscopy, antigen detection, or inoculation of samples 
into mice or tissue culture are either insensitive or time-consuming [Remington 
& Desmonts, 1990]. Since early treatment is mandatory in such infections, 
we, and other research groups, have sought to develop alternative diagnosis by 
molecular techniques. 
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In situ hybridization (ISH) has become an established technique for the 
detection and identification of infectious agents in diagnostic microbiology 
and pathology (Warford & Lauder, 1991). The method preserves 
morphological structures and permits the exact localization of T. gondii 
within the tissue. The ISH differs from other molecular techniques in that the 
nucleic acids are not isolated from the clinical sample. In contrast to many 
other microorganisms, conventional molecular hybridization methods as dot-
spot and Southern-blot analysis have rarely been applied to the detection of 
T. gondii. This is, most probably, due to the low sensitivity of these assays. 
In fact, Weiss et al. (1991) described a detection level of 10,000 parasites 
using Southern-blot analysis, too high to be useful in diagnosis of 
toxoplasmosis. Over the last few years much attention focused on the use of 
PCR for the detection of T. gondii. Although theoretically a single parasite 
can be detected, in practice, the detection level is about 10 parasites (Burg et 
al., 1989; Weiss et al., 1991). Thus, even in some instances of proven 
infection, detection of T. gondii in cerebrospinal or amniotic fluid may fail 
due to low densities of parasites (Cristina et al., 1992; Schoondermark-Van 
de Ven et al., 1992c). Therefore the sensitivity of the PCR should be 
increased. Computer alignment studies of ribosomal RNA (rRNA) sequences 
have revealed the existence of regions with highly conserved sequences 
among eukaryotes but also regions which display sequence variability (Gray 
et al., 1984). This should allow the selection of T. gondii specific primers 
for the PCR. Besides the unique sequence features, rRNA molecules are 
present in all ribosomes. Thus rRNA is naturally present in high copy 
number, up to 10,000 molecules per parasite (Waters & McCutchan, 1990), 
and provides a target for a highly sensitive PCR assay. We have therefore 
recently elucidated the sequence of the complete 16S-like rRNA of T. gondii 
(Schoondermark-Van de Ven et al., 1992b). We selected T. gondii specific 
primers and examined the specificity and sensitivity of this primer set for the 
detection of T. gondii. 
Materials and methods 
In situ hybridization 
The ISH assay was tested on brain of mice infected with the cyst forming T. 
gondii strain T626. The mouse brains were harvested 3 months after 
infection, fixed in buffered formalin, embedded in paraffin and processed for 
ISH as previously described (Melchers et al., 1989). The deparaffinized 
sections were treated with proteinase К for 10 minutes to obtain an optimal 
equilibrium between probe accessibility to the cell and tissue deterioration. 
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Hybridization was performed with an oligonucleotide probe (5'-
GGCGACCAATCTGCGAATACACC-3') directed against the Bl gene 
(position 831-853, Burg et al., 1989). The probe was tailed with 
digoxigenin-dUTP (Boehringer-Mannheim) with terminal deoxynucleotidyl 
transferase (TdT) according to standard conditions (Ausubel et al., 1989), 
and diluted in the hybridization mixture (Melchers et al., 1989) at a 
concentration of 3 ng/ul. Hybridization, washing and immunological 
detection was performed according to the manufacturer instructions, modified 
for ISH (Boehringer-Mannheim). 
ÉÊà 
mr' 
Figure 1. Demonstration of T. gondii bradyzoites in infected mouse brain by 
in situ hybridization using a digoxigenin tailed oligonucleotide directed 
against the В1-gene. 
Polymerase chain reaction 
The complete nucleotide sequence of the small subunit ribosomal RNA of T. 
gondii was elucidated (EMBL Acc.nr X65508, Schoondermark-Van de Ven 
et al., 1992b). T. gondii specific primers were selected using the 
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CAOS/CAMMSA computer analysis program. One primer was selected in 
the second variable region (V2: 5'-GTTGACTTCGGTCTGCGACG-3') and 
the other primer in the third variable region ( З: 5'-
TTCCAATCACTAGAAATGAA-3') of the 16S-like rRNA of T. gondii. 
cDNA synthesis with the V3 primer was performed as previously described 
(Zoll et al., 1992). The thermal profile involved 40 cycles of denaturation at 
94° for 1 min, primer annealing at 42° for 30 sec, and primer extension at 
72° for 2 min, and resulted in the amplification of a 238 bp product. The 
amplified products were analysed by agarose gel electrophoresis and 
Southern-blot analysis as previously described (Van de Ven et al., 1991). 
T. gondii parasites were grown on HEp-2 cells and RNA was isolated by the 
RNAzolB method (Cinna/Biotecx, Veenendaal, The Netherlands). 
Results 
1. In situ hybridization 
As shown in Figure 1, ISH on brains infected with T. gondii resulted in the 
hybridization with the cysts. A clear purple granular hybridization signal can 
be observed specifically in the bradyzoites. No substantional back-ground 
staining or staining of the cyst wall was observed, demonstrating the 
specificity of the probe and the <DIG> detection system. 
2. Polymerase chain reaction 
a. Sensitivity of the PCR assay 
Both chromosomal DNA and undegraded rRNA were isolated from purified 
T. gondii parasites (Figure 2). This enables a direct comparison in sensitivit 
between the amplification of rDNA and reverse transcribed rRNA. To 
determine the sensitivity of the PCR assay, serial dilutions of purified T. 
gondii nucleic acids were made. Without prior transcribing the RNA, a 
sensitivity of 10 pg was obtained, as detected by gel electrophoresis and 
ethidium bromide staining (Figure 3). This corresponds to approximately 100 
parasites. However, when the rRNA was first transcribed by reverse 
transcriptase into cDNA, the detection level was 0.1 pg, corresponding to a 
single parasite (Figure 3). Using a rRNA based PCR assay it is thus possible 
to detect the nucleic acid content, equivalent to a single T. gondii parasite by 
agarose gel electrophoresis. In fact the sensitivity is approximately a factor 
10 higher when Southern-blot analysis is performed (data not shown). 
27 
b. Specificity of the PCR assay 
The specificity of the V2/V3 primer combination was investigated with 5 
characterized T. gondii strains (RH and T626 from Nijmegen, The 
Netherlands and, C, P, and RH, kindly provided by dr. J. Boothroyd, 
Stanford, USA), and 12 wild-type isolates from European patients. From all 
strains a specific fragment of 238 bp was generated with the V2/V3 primer 
set (data not shown). 
No specific amplification was observed when the primer set was tested with 
human DNA nor with a broad spectrum of microorganisms (N=32) among 
which microorganisms causing congenital, cerebral, and opportunistic 
infections and parasites related to T. gondii. 
genomic DNA ^ 
large subunit r ibosomal RNA^ 
smal l subunit r ibosomal RNA+ 
Figure 2. Isolation of total nucleic acids (A) or RNA (В) of T. gondii. 
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Figure 3. Amplification of T. gondii rDNA directly (top) or after reverse 
transcription of the rRNA into cDNA (bottom) in a sample containing total 
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Lanes 1-10: 100 ng, 10 ng, 1 ng, 100 pg, 10 pg, 1 pg, 100 fg, 10 fg, 1 fg, 
and 0.1 fg of T. gondii DNA. Lane if: negative control (distilled water), 
and lane 12: 30 ng T. gondii DNA (positive control). 
Discussion 
PCR has already proven its usefulness for the detection of T. gondii in brain 
biopsy samples and cerebrospinal fluid of immunocompromised patients with 
cerebral toxoplasmosis (Holliman et al., 1991; Lebech et al., 1992; Van 
de Ven étal., 1991; Schoondermark-Van de Ven et al., 1992a). Congenital 
toxoplasmosis has also been demonstrated by PCR in amniotic fluid, 
cerebrospinal fluid, and post-mortem material (Grover et al., 1990; Van de 
Ven et al., 1991; Schoondermark-Van de Ven et al., 1992c; Verhofstede et 
al., 1990). Besides this, PCR can be applied to both fresh and formalin fixed 
clinical material which makes transportation and storage of materials much 
easier (Van de Ven et al., 1991). 
Although these PCR assays could detect as few as ten parasites, in some 
instances PCR failed to detect T. gondii in toxoplasma infections as proven 
by parasite isolation (Cristina et al., 1992). This negative PCR result might 
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be caused by the presence of components in the clinical sample which inhibit 
the enzymatic amplification. However, the possibility that the detection limit 
of 10 parasites, as obtained by PCR, is not sensitive enough to detect a T. 
gondii infection cannot be excluded. In fact, the latter possibility is supported 
by our experience in a monkey model of congenital toxoplasmosis: using the 
PCR on the BI gene, T. gondii could not be detected in amniotic fluid 
samples which were positive by mouse inoculation. These samples, however, 
were positive by a nested PCR assay (Schoondermark-Van de Ven et al., 
1992c). The rRNA based amplification may be an approach to improve the 
sensitivity of PCR. By making use of the abundance of rRNA target 
sequences, a sensitivity can be achieved that is comparable to that of nested 
PCR. And indeed, prelimenary results show that the rRNA-PCR is as 
sensitive as nested PCR for the detection of T. gondii in clinical specimens. 
For diagnostic applications, a single (rRNA-PCR) has the preference since 
care must be exercised to avoid contamination. The applicability of this 
rRNA-PCR on clinical specimens is currently investigated. 
The necessity of ISH for the detection of T. gondii may not be that obvious, 
but in specific cases the test can be a valuable diagnostic tool. The diagnosis 
of cerebral toxoplasmosis is complicated. The results on the detection of T. 
gondii in cerebrospinal fluid of AIDS patients by PCR are very promising 
(Schoondermark-Van de Ven et al., 1992a), but still, in some patients a 
brain biopsy is inevitably required for diagnosis. Discrimination between 
latent (cyst stage) and active (tachyzoite stage) cerebral toxoplasmosis in a 
brain biopsy is only possible by microscopical examination. Identification 
may be assisted by the use of immunofluorescence, a technique which is as 
specific and sensitive as ISH but much faster and less laborious. The value 
of ISH is therefore not directly as a diagnostic tool for toxoplasmosis but 
rather in basic research, for instance, in the study of specific gene-expression 
in the bradyzoite and tachyzoite stages of infection and the metabolic 
differences during the parasite life cycle. 
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SCHOONDERMARK VAN DE VEN E MELCHERS W GALAMA J CAMPS W ESKES 
Τ AND MFUWISSEN J 1993 Congenital toxoplasmosis An experimental study in rhesus 
monkeys for transmission and prenatal diagnosis Experimental Parasitology 77, 200-211 
This paper describes a rhesus monkey model to study congenital transmission and the 
prenatal diagnosis of Toxoplasma gondii infection Transmission to the fetus was investi 
gated after maternal infection in the second (Day 90) or third trimester (Day 130) of preg 
nancy A parasitemia was induced and lasted for about 10 days as proven by mouse inoc 
ulation and nested PCR on whole blood samples and peripheral blood mononuclear cells 
Transmission of Τ gondii was proven in 4 of 9 (44%) fetuses in the second trimester and in 
3 of 9 fetuses in the third trimester of gestation Six of the 7 proven fetal infections could be 
diagnosed antenatally Poslnalally 4 additional fetuses that most likely were congenially 
infected were found although this could not formally be proven The mothers of these 4 
fetuses were infected in the third trimester If we accept this group as being antenatally 
infected an overall transmission rate is found of 11 of 18 cases (61%) This rate is similar to 
that found in humans This is the first description of a monkey model for congenital toxo 
plasmosis that is suitable to study the approach of antenatal diagnosis and the effectivity of 
treatment with obvious relevance for Toxoplasma infections in humans с 1993 Academic 
Prtss Ine 
iNDrx DESCRIPTORS AND ABBREVIATIONS Toxoplasma gondii (T gondii) RH strain 
Congenital toxoplasmosis Antenatal diagnosis Fetal blood sampling Amniotic fluid 
Rhesus monkey model Polymerase chain reaction (PCR) Deoxyribonucleic acid (DNA) 
Ribosomal ribonucleic acid (rRNA) Deoxynbonucleotide triphosphates (dNTPs) Penph 
eral blood mononuclear cells (PBMC) Immunoglobulin (Ig) Enzyme linked immunosor 
bent assay (ELISA) Bovine serum albumin (BSA) Guanidinium thiocyanate (GuSCN) 
Genetic computer group (GCG) 
INTRODUCTION 
The incidence of a Toxoplasma gondii in­
fection acquired during pregnancy vanes 
with the geographic area, ranging from 2 to 
14 per 1000 pregnancies (Remington and 
Klein 1990) A high incidence of 10 per 1000 
pregnancies is found in France (Desmonts 
and Couvreur 1974) The incidence in The 
Netherlands is estimated to be 5 per 1000 
pregnancies (Conijn-van Spaendonck 
1991) Transmission of the infection to the 
fetus can cause severe damage to the un 
born child, such as hydrocephalus, micro 
cephalus, blindness, mental retardation 
and may even lead to fetal death Some 
manifestations, such as chorioretinitis, can 
even occur later in life (Koppe el al 1986, 
Wilson et al 1980) 
The frequency of transmission increases 
from 17% during the first trimester to 65% 
in the third trimester of pregnancy (Des­
monts and Couvreur 1974) Because mater­
nal infection does not always lead to trans­
mission, a rapid diagnosis of infection in the 
fetus is mandatory if one is to make an in­
formed decision about therapeutic abortion 
or therapeutic treatment 
In addition to a rapid diagnosis, antenatal 
detection of Τ gondii in the fetus may be 
helpful to monitor the effectivity of treat­
ment in the fetus 
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Studies on the effectivity of treatment are 
scarce and there is still discussion about the 
optimal combination of anti Toxoplasma 
drugs, both in respect of effectivity and of 
safety for the fetus (Quentin et al. 1983; 
Horvath et al. 1988; Hayama and Kokue 
1985). An animal model for congenital T. 
gondii infection may be suitable to study 
the effect of medication in the infected fe­
tus. 
In order to be adequate, the animal 
model should allow fetal blood sampling to 
be performed and placentation should be 
homologous to that in humans. The animal 
should furthermore be susceptible to T. 
gondii infection. The rhesus monkey 
(Macaca mulatta) fullfills some important 
requirements: placentation is hemochorial 
(Ramsey and Harris 1966) and susceptibil­
ity to infection by T. gondii has been re­
ported (Araujo et al. 1973). Although trans­
mission of the parasite to the fetus has 
never been reported for rhesus monkeys, it 
can be expected to occur since transplacen­
tal T. gondii infection was found in Macaca 
arctoides, a related species (Wong et al. 
1979). 
In the present study, transmission of T. 
gondii was studied in rhesus monkeys after 
maternal infection at Day 90 of pregnancy, 
which is comparable to the second trimes­
ter of organogenetic development in hu­
mans, or at Day 130 of pregnancy, which is 
comparable to the third trimester of orga­
nogenetic development. A procedure was 
developed to collect amniotic fluid and fetal 
blood, 10 days after inoculation of the 
mother. These samples were used for ante­
natal detection of T. gondii infection of the 
fetus. 
The diagnosis of fetal infection was es­
tablished by various techniques (serology, 
mouse inoculation, and PCR). A nested 
PCR on the small-subunit ribosomal DNA 
gene (Schoondermark-Van de Ven et al. 
1993) has been developed and applied in 
this study. 
MATERIALS AND METHODS 
The animal experiments were performed after ac­
creditation by the ethical committee of the Faculty of 
Medical Science, according to the Law on Animal Ex­
perimentation in the Netherlands 
Housing and feeding of the rhesus monke\s Toxo­
plasma seronegative female rhesus monkeys, age 4 to 
5 years, were derived from "The laboratory animals 
breeding experimental farm of Shunde Guangdong," 
Bejing, China The monkeys, weighing 4 to 5 kg. were 
housed individually, in steel cages measuring 60 χ 60 
χ 85 cm (lxwxh). at night and at feeding times During 
the day (11 hr of artificial light), two female monkeys 
shared two interconnected cages to increase freedom 
of movement Male monkeys age 8 to 12 years, weigh­
ing about 10 kg, were housed separately in three in­
terconnected cages The temperature in the cage room 
was kept at 20-22°C and the relative humidity was 
maintained at about 50-60% 
The monkeys were fed 100 g of a standard monkey 
chow (Hope Farms. G Ο , Woerden, The Nether­
lands) twice a day and mixed fruit twice a week, sup­
plemented with minerals and vitamins once a week. 
Water was available ad libitum 
Breeding the monkevs From November until Feb-
iuary the rhesus monkey has a regular sexual cycle of 
28-30 days During the mating season, the female 
monkeys were checked daily for menstruation Mating 
was allowed 10 days after the first sign of menstrual 
bleeding The female monkey remained with the male 
for 5 to 7 days 
Because a menstrual bleeding cannot be distin­
guished from an implantation bleeding, the monkeys 
were tested for pregnancy by rectal palpation 1 month 
after mating The duration of pregnancy in these 
macaques vanes between 165 and 175 days (Bourne 
1975) 
Monitoring of maternul infection Τ gondii para­
sites of the RH strain were harvested from mouse peri­
toneal exudate Parasites, 5 χ 106, were injected in­
travenously into the rhesus monkey The female mon­
keys Al to A9 were infected on Day 90 (comparable to 
the second trimester of organogenetic development in 
humans) and Bl to B9 on Day 130 (comparable to the 
third trimester of organogenetic development) of preg­
nancy (Fig 1) To ascertain that the monkeys had not 
been infected before with Τ gondii, clotted blood was 
taken prior to infection and tested for the presence of 
Toxoplasma-specific IgG and IgM antibodies As neg­
ative controls, two mice (male Swiss Webster) were 
inoculated with 1 ml of peripheral blood (citrate was 
used as anticoagulans) and 1 mouse with the PBMC 
isolated from 1 ml of peripheral blood by Ficoll-
isopaque centnfugation (Boyum 1968) to test the effect 
of monkey blood in mice 
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second 
trimester 
third 
trimester 
1ЭО 140 160 165 175 days 
л 
С I FBS I FBS CS 
FIG I Time schedule of sample collection during 
pregnancy of the rhesus monkey С conception, I, 
infection, FBS fetal blood sampling, and CS, cesarean 
section 
Eight days and 10 days after infection and during 
cesarean section blood was sampled again and tested 
for parasitemia by inoculation of mice, as described 
above (see Table 1) For hematological examination 
the blood was diluted 1 10 in Turk solution (1 mg/ml 
gentian violet В (Merck, Amsterdam, The Nether­
lands) in Wc acetic acid to lyse the erythrocytes 
Thereafter the number of leucocytes was counted in a 
Burker Turk hemocytometer Differential counting of 
the leucocytes (200 cells) was performed on thin blood 
smears which were air dried and stained with May-
Grunwald Giemsa solution (Merck) 
ELISA for antibodies to Toxoplasma gondii IgG 
and IgM class antibodies against Τ gondii were tested 
by ELISAs that were developed for use in humans 
These tests were found to be adequate since crossre 
activities of 95% for IgG and 50% for IgM occur be 
tween man and rhesus monkey (Shuster el al 1969) 
We have confirmed the crossreactivity by Immuno­
electrophoresis with anlisera against human immuno­
globulins (data not shown) 
IgG class antibody was detected by a quantitative 
ELISA on a single serum dilution (1 1000) The out 
come was related to a standard curve and expressed in 
international units as described previously (van Loon 
el al 1981) The cutoff value of this ELISA is 10 IU 
IgM class antibodies against Τ gondii were detected 
by means of an immunocapture ELISA (van Loon et 
al 1983) The serum dilution was 1 50 for the adult 
monkeys and 1 50 or, if enough serum was available 
1 10 for the baby monkeys 
Fetal blood sampling The rhesus monkey pos 
sesses two placentas which are interconnected by 
blood vessels of fetal origin (Ramsey and Hams 1966 
Arts et al 1972) Fetal blood was collected from such 
TABLLI 
Collection of Clinical Samples 
Time of sample collection 
Before infection at 
Day 90 or 130 of pregnancy 
Control parasitemia at 
Day 98 or 138 of pregnancy 
Fetal blood sampling at 
Day 100 or 140 of pregnancy 
Cesarean section at 
Day 160 of pregnancy 
Postnatal 
0-14 days of age 
twice a week 
Postnatal 
2 weeks-3 months of age 
once a week 
Postnatal 
from 3 months of age 
monthly 
Autopsy 
Mother monkey 
5 ml clotted blood and 
10 ml citrate blood 
5 ml clotted blood and 
10 ml citrate blood 
5 ml clotted blood and 
10 ml citrate blood 
5 ml clotted blood and 
10 ml citrate blood 
placental tissue 
Fetus/neonate 
I ml EDTA blood from interplacental 
blood vessel 5 ml amniotic fluid 
5 ml EDTA blood from umbilical 
cord 5 ml amniotic fluid 
0 5-1 0 ml venous blood 
(EDTA) 
1 0 ml venous blood 
(EDTA) 
1 0 ml venous blood 
(EDTA) 
Heart 
Brain 
Liver 
Lung 
Spleen 
Kidney 
Eyes 
Skeletal muscle 
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an interplacenldl blood vessel, at Day 100 (second tri­
mester) or Day 140 (third trimester), 10 days after ma­
ternal inoculation (Fig. 1). Because the fetal blood ves­
sels are deeply located, the uterus had io be illumi­
nated with Iwo stenle 12-V lamps to visualize them. 
The decidua and chorionic membrane had to be care­
fully opened until the amniotic membrane with the fe­
tal blood vessel was exposed. The vessel was canu-
lated with a PVC catheter and fetal blood was col­
lected Amniotic fluid was also collected during the 
fetal blood sampling procedure. After fetal blood sam­
pling the uterus wall was closed and pregnancy was 
allowed to continue until cesarean section was per­
formed or birth occurred spontaneously. 
Collection und pro( es sin g of samples Clinical sam­
ples were collected antenatally as well as postnatally 
(see Table I) and several tests were performed to di­
agnose a fetal infection. Antenatally, 1 ml of fetal 
blood and 5 ml of amniotic fluid were collected Two 
mice were each inoculated intrapenloneally with 200 
μΐ of fetal blood The DNA was extracted from 100 μΙ 
for PCR analysis. The remaining blood (0 5 ml) was 
centnfuged for 10 mm at 800# in order to collect 
plasma for serology. The sediment was resuspended in 
3 vol of physiological salt solution and PBMC were 
isolated (Boyum 1968) and resuspended in a final vol­
ume of 200 μΐ of physiological salt solution Fifty mi­
croliters of this suspension was directly injected into a 
mouse. From another 50 μΐ the DNA was extracted for 
the PCR The remaining 100 μΐ was stored at -80°C 
To examine the presence of Τ gondii in the amniotic 
fluid, two mice each were inoculated with I ml of this 
fluid. The remaining 3 ml of amniotic fluid was centn­
fuged for 10 min at 800 g and the pellet was resus­
pended in 200 μΙ of physiological salt solution One 
hundred microliters was used for DNA isolation. The 
other 100 μΐ was stored at -80°C After fetal blood 
sampling pregnancy was allowed to continue until Day 
160 (Fig. 1). Cesarean section was performed to ensure 
thai fetal infection had been acquired in mero instead 
of being caused by birth trauma (Adams el al 1949) 
The processing of cord blood and amniotic fluid col­
lected during cesarean section was the same as those 
described for fetal samples, with the notion thai five to 
six limes larger volumes could be obtained and were 
lesled Placental tissue was homogenized as described 
previously (Van de Ven et al. 1991) and tested for the 
presence of parasites by inoculation of two mice. Fur­
thermore, DNA was isolated from the placenta (Van 
de Ven et al 1991) and tested for the presence of Τ 
gondii by PCR. 
In case of birth before Day 160, amniotic fluid was 
lost in five of eight cases but placental tissue was still 
available lor examination (monkeys A4, Λ6, B4, B5, 
and B7) 
After birth the baby monkeys were kept alive and 
tested for infection and postnatal antibody production 
to T. gondii Baby monkeys who were not accepted by 
their mother were artificially reared on surrogate 
mothers (Timmermans et al. 1988) and bottle-fed for a 
period of 3 months by co-workers of the Central Ani­
mal Laboratory of the University of Nijmegen. During 
this period venous blood was collected from the baby 
monkeys at regular time intervals (Table I) The blood 
samples were centnfuged for 10 min at 800 g where­
after the plasma was removed for serological testing. 
The plasma was then replaced by the same volume of 
physiological salt solution and 0 1-0.2 ml was injected 
in two mice each. From 0 I ml blood the DNA was 
isolated and the remainder was frozen at -80°C 
The baby monkeys were sacrificed at 3 months of 
age Three monkeys (A4, B2, and B8), accepted by 
their biological mothers, were kept alive for a longer 
period of lime 
After stillbirth or sacrifice, autopsy was performed 
and the heart, brain, spleen, liver, and lungs were ex­
amined for the presence of Τ gondii, both by inocu­
lation in mice (20) and by PCR Kidney, skeletal mus­
cle, and eyes were tested only by PCR. 
Polymerase i ham rem lion The DNA from whole 
blood, PBMC, and amniotic fluid was isolated by 
GuSCN and silica particles, exactly as described by 
Boom et al (1990) EDTA or citrate were used as 
blood anticoagulans because heparin may inhibit the 
PCR (Holodniy et al 1991). DNA from tissue samples 
was isolated as described previously (Van de Ven et 
al. 1991) and 1.0 μg of the purified DNA was tested in 
the PCR 
All DNA samples were lesled for the presence of T. 
gondii by a nested PCR (16S-like nbosomal DNA gene). 
In the first reaction of the nested PCR a 583-bp frag­
ment was generated using "general eukaryolic pnm-
ers" which were selected using the sequence analysis 
software package from the GCG at the University of 
Wisconsin implemented on a VAX computer. 
The general eukaryolic primer set consisted of a 
primer complementary to the 5'-end of the rDNA, 5'-
CCTGGTTGATCCTGCCAGTA-3', and the other one 
in the constant region between the variable areas 3 and 
4, 5-GCAACAACTTTAATATACGC-3' (Dams et al. 
1988) 
Within Ihe 583-bp fragment two T. gondu-sptc\fic 
primers were selected, one in the second variable re­
gion, 5-GTTGACTTCGGTCTGCGACG-3'. and one 
in the third variable region, 5'-TTCCAATCACTA-
GAAATGAA-3' This primei set generated a T. gon-
Jíí-specific product of 238 bp (Schoondermark-Van de 
Ven et al 1993). 
The nested PCR was performed in 100 μΐ reaction 
mixture containing 50 mM Tns-HCl pH 9.0 (25°C), 50 
mM KCl. 7 mM MgCI2, 0 2 mM dNTPs each, 0.2 mg/ 
ml BSA, 16 mM ammonium sulfate, 50 pmol of Ihe two 
primers each, and 0.2 U superTaq (HT Biotechnology, 
Cambridge. England). 
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Ten microliters of the first reaction mixture was 
transferred to 90 μΙ of fresh reaction mixture for the 
second (nested) reaction The thermal profile of both 
reactions of the nested PCR involved 40 cycles of de-
naturation at 94°C for 1 min, primer annealing at 42°C 
for 30 sec, and primer extension at 72°C for 2 mm 
After amplification, 30 μΐ of the reaction mixture 
was examined on I 5% agarose gel for the presence of 
the amplified products. The specificity of the PCR 
product was confirmed by Southern blotting and sub­
sequent hybridization with an internal oligonucleotide 
probe as previously described (Van de Ven el al 
1991) T h e p r o b e 5 ' - A T T C C G G AG A AG-
GAGCCTGA-3' (l6S-hke ribosomal DNA gene) was 
end-labeled with ' 2 P (sp act >5000 Ci/mmol, Amer-
sham, Great Britain) 
For prevention of contamination, strict spatial par­
titioning of the different technical steps of PCR, the 
use of pipets with disposable pistons, and frequent 
changes of gloves were included (Kwok and Higuchi 
1989). 
RESULTS 
Maternal infection. A pilot experiment 
with three nonpregnant female monkeys 
showed that after intravenous inoculation 
of 5 x 106 tachyzoites a parasitemia oc­
curred that lasted for about 10 days. Para­
sitemia was demonstrated by daily sam­
pling and inoculation of mice over a period 
of 3 weeks with either whole blood or 
PBMC (data not shown). 
Nine female monkeys (Al to A9) were 
inoculated in the second trimester (Day 90) 
and 9 (Bl to B9) in the third trimester (day 
130) of pregnancy (Tables II and III). On 
the basis of the pilot study, parasitemia was 
tested 8 days postinoculation by mouse in­
oculation with whole blood or PBMC. It 
was proven that a parasitemia occurred in all 
18 monkeys. These blood samples, both 
whole blood as well as PBMC samples, that 
were positive by mouse inoculation, were 
also tested by PCR and found positive. 
IgM antibodies to T. gondii were detect-
TABLE II 
Maternal Infection with Toxoplasma gondii at the Second Trimester of Pregnancy 
Monkey 
Al 
A2 
A3 
A4 
A5 
A6 
A7 
A8 
A9 
Birth 
CS 
SB 
CS 
SD 
CS 
SB 
CS 
SD 
CS 
Samples" 
All 
All 
All 
All 
All 
AF 
PL 
Heart 
Liver 
Lung 
AF 
PL 
AF 
AF 
AF 
PL 
Sampling 
time 
FBS 
SB 
Autopsy 
Autopsy 
Autopsy 
CS 
CS 
FBS 
FBS 
CS 
CS 
Mouse 
inoculation 
-
-
-
-
-
-
+ 
-
+ 
-
+ 
+ 
+ 
-
+ 
+ 
Nested PCR 
-
-
-
-
-
+ 
+ 
+ 
-
+ 
+ 
+ 
-
+ 
+ 
+ 
Serology 
ND 
ND 
-
-
-
ND 
+ 
+ 
-
Note SB, stillbirth, SD, spontaneous delivery, ND, not done. 
" All samples obtained at fetal blood sampling (FBS). cesarean section (CS), and autopsy were tested for the 
presence of Τ gondii All refers to the following samples fetal blood and amniotic fluid (AF) obtained at FBS, 
fetal blood, amniotic fluid and placental tissue (PL) obtained at CS. fetal blood and placental tissue (if available) 
obtained after stillbirth or spontaneous delivery, heart, brain, spleen, liver, and lung obtained at autopsy Of five 
monkeys all samples tested were found negative for Τ gondii (on top) Of four monkeys Γ gondii was detected 
in some samples (bottom) Only samples positive for Τ gondii are specified in the Table 
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TABLE III 
Matemal Infection with Toxoplasma gondii at the Third Trimester of Pregnancy 
Monkey 
Bl 
B2 
B3 
B4 
B5 
B6 
B7 
B8 
B9 
Birth 
CS 
CS 
CS 
SD 
SB 
SB 
SB 
SD 
CS 
Sample" 
All 
All 
PL 
PL 
PL 
AF 
PL 
Heart 
Brain 
Spleen 
Liver 
Lung 
AF 
PL 
AF 
AF 
AF 
PL 
Sampling 
time 
CS 
SD 
SB 
FBS 
CS 
Autopsy 
Autopsy 
Autopsy 
Autopsy 
Autopsy 
FBS 
SB 
FBS 
FBS 
CS 
CS 
Mouse 
inoculation 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
1 
+ 
+ 
+ 
-
Nested PCR 
-
-
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
ND 
+ 
+ 
+ 
Serology 
ND 
-
-
ND 
ND 
ND 
ND 
+ 
+ 
Noie SB, stillbirth; SD, spontaneous delivery: ND. not done °, Inconclusive result because mice died of 
bacterial infection. 
" All samples obtained at fetal blood sampling (FBS). cesarean section (CS), and autopsy were tested for the 
presence of T. gondii. All refers to the following samples, fetal blood and amniotic fluid (AF) obtained at FBS; 
fetal blood, amniotic fluid, and placental tissue (PL) obtained at CS. fetal blood and placental tissue (if available) 
obtained after still birth or spontaneous delivery, heart, brain, spleen, liver, and lung obtained at autopsy Of two 
monkeys all samples tested were found negative for Τ gondii (upper 2). Of seven monkeys T. gondii was 
detected in some samples (lower 7). Only samples found positive for 7". gondii are specified in the Table 
able around Day 7 after inoculation and fol­
lowed shortly thereafter by IgG antibodies. 
The female monkeys behaved normally 
and appeared healthy. The only systemic 
reaction observed was a relative lymphocy­
tosis between Days 8 and 10. 
Outcome of pregnancies. In the group of 
monkeys infected in the second trimester, 
two fetuses were stillborn (A2 and A6) and 
one (Al) died within 30 min after cesarean 
section because of respiratory failure. Two 
baby monkeys (A4 and A8) were spontane­
ously born before Day 160, and they were 
both accepted by their biological mothers. 
The remaining four monkeys (A3, A5, A7, 
and A9) were born by cesarean section and 
were reared on surrogate mothers and bot­
tle-fed by co-workers (Tabic II). 
Table III shows the outcome after infec­
tion in the third trimester of pregnancy. 
Three fetuses were stillborn (B5, B6, and 
B7), one (B4) died 2 days after a spontane­
ous birth, and one (Bl) died 2 hr after ce­
sarean section because of respiratory fail­
ure. Of the remaining three baby monkeys 
born by cesarean section, two were ac­
cepted by their biological mother (B2 and 
B3) and one was bottle-fed by a co-worker 
(B9). Monkey B8 accepted her baby, which 
was born spontaneously, 2 days after fetal 
blood sampling. 
Detection ofT. gondii by PCR. Using the 
nested PCR, eight amniotic fluid samples 
from six monkeys, obtained either at the 
moment of fetal blood sampling or during 
cesarean section, were found positive for T. 
gondii. Five of these were confirmed by 
mouse inoculation. On the other hand, two 
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amniotic fluid samples positive by mouse 
inoculation were negative by PCR (Tables 
II and III). T. gondii was furthermore de­
tected by nested PCR in the placenta of 
nine monkeys. Seven of these nine placen­
tas were also positive by mouse inocula­
tion. Postnatally, the parasite was found in 
tissues of two monkeys (A6 and B6) (Fig. 2, 
Tables II and III). Detection by PCR failed, 
however, in three organs that were positive 
by mouse inoculation (the liver of A6 and 
the heart and brain of B6). T. gondii was 
never detected in fetal and neonatal blood, 
either by mouse inoculation or by PCR. 
Detection of antibodies to T. gondii in 
the offspring. Both antenatally and during 
the first 3 months of life, Toxoplasma se­
rology was performed in the offspring. At 
the time of fetal blood sampling, 10 days 
after maternal inoculation, specific antibod­
ies to T. gondii could not yet be detected in 
the fetal blood. 
Due to stillbirth or sudden death after a 
premature birth, postnatal serum samples 
were not available from 8 of the 18 monkeys 
(see also Tables II and III). In 6 of the re­
maining 10 baby monkeys a decline of IgG 
antibodies to T. gondii was found (A3, A4, 
A5, A9, B2, and B3). Figure 3a shows the 
decline of IgG antibodies in monkey A5, 
with a half-life of approximately 30 days. 
The IgG antibody pattern of baby monkey 
B9 with a congenital T. gondii infection is 
shown in Fig. 3b. This pattern, in which the 
IgG antibody titer is maintained at a certain 
level, was also found for the baby monkeys 
A7 and A8. 
In case B8 maternal IgG antibodies were 
not present at the time of birth because the 
baby monkey was born prematurely, 12 
days after inoculation of the mother. The 
IgG antibodies found were produced by the 
neonate as illustrated in Fig. 3c. None of 
the infected baby monkeys had detectable 
IgM antibodies to T. gondii. 
Vertical transmission ofT. gondii infec­
tion. A congenital infection was considered 
proven if the parasite was detected in the 
amniotic fluid or fetal blood, both by PCR 
and mouse inoculation. If the results of the 
PCR and mouse inoculation were not in 
agreement with each other, the finding of T. 
gondii in the tissues (autopsy) or the pro­
duction of specific antibodies in the baby 
monkey were also taken as evidence for fe­
tal infection (Tables I and III). 
A congenital infection was considered as 
most likely if the parasite was detected in 
the placenta. 
According to the criteria mentioned 
above, it was proven that four of nine mon­
keys, with a maternal infection at the sec­
ond trimester of pregnancy, transmitted T. 
gondii to the fetus (A6, A7, A8, and A9). Of 
B9 B 6 A7 
238 B P ^ 
8 9 10 11 12 13 14 15 16 17 18 
1631 BP 
517 506 
396 
344 
298 
221/220 
154 
FIG. 2. Samples of the monkeys A7, B6, and B9 tested for the presence of T. gondii by nested PCR 
on the rDNA gene after Southern blot hybridization. Of the tissue samples 1.0 μg DNA was tested. 
Lanes: 1 and 9, spleen; 2 and 10, heart; 3 and 11, brain; 4 and 12, liver; 5 and 13, lung; 6, 14, and 16, 
placenta; 7, amniotic fluid obtained at cesarean section, 8, 15, and 18, amniotic fluid obtained at fetal 
blood sampling. - , Distilled water (negative control); +, 30 ng T. gondii DNA (positive control). 
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FIG. 3. Patterns of IgG antibodies to Т. цопай in the baby monkey A5 (a), B9 (b), and B8 (c). The 
time intervals between maternal infection and cesarean section are 90 days for monkey A5 (a) and 30 
days for monkey B9 (b). The time interval between maternal infection and spontaneous birth of 
monkey B8 (c) was 12 days. 
the nine monkeys with a maternal infection 
at the third trimester of pregnancy three 
had a proven congenital infection (B6, B8, 
and B9). After infection at the third trimes­
ter, four additional monkeys (B3, B4, B5, 
and B7) may possibly be congenitally in­
fected since the parasite was detected in the 
placenta. 
All baby monkeys that stayed alive 
showed no clinical signs of toxoplasmosis. 
Antenatal diagnosis of T. gondii infec­
tion. In 16 of the 18 pregnancies fetal blood 
sampling was successful. In the 2 cases 
where it failed (A9 and B8), an interplacen-
tal blood vessel could not be found because 
of the close proximity of the two placentas. 
T. gondii was not detected in any of the 
16 fetal blood samples available. However, 
the parasite could be detected in the amni­
otic fluid obtained at the time of fetal blood 
sampling. Antenatally T. gondii was de­
tected in six amniotic fluid samples of the 
seven proven cases of transmission. In two 
cases a positive result was found by mouse 
inoculation alone (A8 and B8), in two cases 
by PCR alone (A6 and A9), and in another 
two cases by both techniques (B6 and B9). 
Although monkey B7 did not belong to 
the group of proven cases, antenatal detec­
tion in the amniotic fluid by PCR was also 
successful in this monkey. 
In the case of monkey A7 T. gondii was 
detected in the amniotic fluid not earlier 
than at cesarean section. 
DISCUSSION 
This paper describes a rhesus monkey 
model for congenital toxoplasmosis. Like 
humans, rhesus monkeys possess a hemo-
chorial placenta (Ramsey and Harris 1966). 
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Therefore, the rhesus monkey can be used 
as an animal model to study transmission of 
infection and transfer of medications across 
the placenta 
The model serves dual purpose First, to 
develop a rapid and sensitive detection 
method for the antenatal diagnosis of fetal 
infection Second, to study the effectivity 
of antenatal treatment in the congenitally 
infected fetus From what is known about 
transmission of Τ gondii in humans, it is 
expected that the rate of transmission will 
be much lower in the first trimester than in 
the later ones (Desmonts and Couvreur 
1974) For this reason and because fetal 
blood sampling cannot be performed before 
the second trimester, the study was limited 
lo the later stages of pregnancy 
The PCR was chosen for the antenatal 
diagnosis of infection and compared with 
classical mouse inoculation Congenital in­
fection was considered to be proven if the 
parasite was detected in amniotic fluid and/ 
or fetal blood (Desmonts et al 1985, Daffos 
et al 1988, Hohlfeld et al 1989) It has been 
described for humans that the parasite 
could be isolated from fetal blood by mouse 
inoculation (Desmonts et al 1985, Daffos et 
al 1988) In the rhesus monkey model, 
however, Τ gondii could not be detected in 
fetal blood, either after fetal blood sampling 
or at the moment of cesarean section The 
limited amount of blood available from 
these small fetuses is probably not the rea­
son for the negative results, since the par­
asite could be detected in as little as 100 μΙ 
of maternal whole blood by nested PCR 
Perhaps the timing of fetal blood sam­
pling may be too early to find a parasitemia 
in the fetus However, it seems plausible 
that the parasite was already transmitted to 
the fetus at the time of fetal blood sampling 
since the parasite was isolated from 7 of the 
18 amniotic fluid samples collected at this 
time The presence of Τ gondii in the am­
niotic fluid in combination with the absence 
in the fetal blood was also described for two 
cases in humans The paiasite was detected 
in the fetal blood in a later sample of these 
two patients (Desmonts et al 1985) In the 
rhesus monkey model, the period between 
the moment of fetal blood sampling and ce­
sarean section may be too long to find a 
parasitemia 
The results imply that transmission oc­
curs already during maternal parasitemia, 
as has also been suggested by Work et al 
(1970) from their experiments on congenital 
toxoplasmosis in pregnant sows Similarly 
Buxton and Finlayson (1986) found that 
transmission occurred between 10 and 15 
days after infection of pregnant sheep A 
comparison, however, should be made with 
reservation since pigs and sheep have an­
other kind of placentation Further support 
for transmission during maternal parasit­
emia comes from a study in humans by Daf­
fos et al (1988) They found a higher level 
of fetal parasitemia when the period be­
tween maternal infection and the sampling 
of fetal blood was shorter compared to 
other groups of patients, for which the lime 
interval was estimated to be longer The ex­
act timing to find a fetal parasitemia in the 
rhesus monkey needs further examination 
For monkey A7 the parasite was found in 
the amniotic fluid not earlier than at the mo­
ment of cesarean section, which means that 
the detection failed or that the Iransmission 
took place somewhere between 10 and 70 
days after maternal infection A delay be­
tween maternal infection and transmission 
to the fetus may point to a delay in trans­
mission from the placenta to the fetus It 
has been proposed by Thalhammer (1971) 
that there exists a so-called "prenatal incu­
bation period," an undefined period during 
which the parasite resides in the placenta 
The presence of Τ gondii in the placenta, 
as found for the monkeys B3, B4, B5, and 
B7, is therefore not definite proof of trans­
mission Mouse inoculation remained in­
conclusive in case of the placenta of mon­
key B7 The positive result of the PCR 
could not be confirmed by mouse inocula­
tion because both mice died of bacterial 
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contamination Hence, a definitive diagno­
sis could not be established for the mon­
keys B4 and B5 because they were sponta­
neously born and the amniotic fluids were 
lost for further examination Due to an 
early death of both monkeys further exam­
ination by a serological follow-up was not 
possible Although a positive serology will 
prove infection, negative serology, as 
found for monkey B3, does not exclude 
transmission since the antibody response 
may be delayed after birth Monkey A9, for 
example, showed no antibody production 
within the 3 months of observation but was 
otherwise proven to be infected The pro­
gressive fall of IgG levels during the first 3 
months of life, followed by a rise between 3 
and 12 months of age, was reported for tour 
human neonates in whom infection was di 
agnosed antenatally by Daffos et al (1988) 
Similar observations in humans have also 
been reported by Remington and Klein 
(1990) 
Postnatally IgM to Τ gondii was never 
found Reduced antibody production in the 
baby monkey and perhaps a limited cross-
reactivity between rhesus and human IgM 
may explain the negative outcome On the 
other hand, specific IgM responses were 
measured in the adult monkeys despite the 
limited cross-reactivity 
In 9 of 18 cases spontaneous delivery oc-
cured before Day 160, ι e , before cesarean 
section was planned Spontaneous birth (4 
cases) or stillbirth (5 cases) may be related 
to congenital infection but can also be 
caused by other factors, such as stress 
caused by the procedure of fetal blood sam­
pling 
The baby monkeys showed no clinical 
signs of infection or abnormalities at birth 
This is not surprising, since the risk of dis­
orders, due to the infection, in the second 
and third trimester is relatively low (Krog-
stad 1989) But the possibility remains that 
chorioretinitis occurs later on in life as de­
scribed for humans (Koppe et al 1986, Wil­
son et al 1980) In one case with a proven 
infection (baby monkey B8), we had the op­
portunity to perform ophthalmological ex­
amination at the age of 9 months, but no 
retinal scars were found Furthermore, no 
cerebral lesions were found by magnetic 
resonance imaging (data not shown) 
In previous studies it was determined 
that the PCR on the Bl gene of Τ gondii 
could detect as few as 10 parasites in clini­
cal specimens (Burg et al 1989) However, 
amniotic fluid samples and maternal blood 
samples found positive after inoculation 
into mice were found negative by the single 
PCR Apparently these samples contained 
about 10-50 parasites or less It appears 
from the present study that the single PCR 
is not sensitive enough Therefore, we have 
developed a nested PCR The failure to de­
tect Τ gondii in samples proven positive by 
mouse inoculation, as also found by other 
researchers (Grover et al 1990 Cristina et 
al 1992), may be that the number of para­
sites, present in the sample, is below the 
detection level of a single PCR 
Using the nested PCR, Τ gondii could be 
detected in nearly all amniotic fluid samples 
and maternal blood samples found positive 
by mouse inoculation Some additional 
samples which were found negative by 
mouse inoculation were found positive by 
nested PCR This discrepancy may be ex­
plained by sampling error due to the low 
number of parasites 
A disadvantage of nested PCR may be 
that the double procedure will increase the 
risk of contamination and false-positive re­
actions (Kwok and Higuchi 1989) There­
fore, attention should focus on the develop­
ment of single amplification systems Sev­
eral reports have described the use of 
rRNA sequences for the specific amplifica­
tion of microorganisms (Boddinghaus et al 
1990, Wilson et al 1990, van Kuppeveld et 
al 1992) By making use of the abundance 
of rRNA target sequences, a sensitivity 
should be achieved that is comparable to 
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that of a nested PCR At the moment we are 
investigating this possibility for Τ gondii 
detection 
It can be concluded that the rhesus mon­
key is an adequate model to study the an­
tenatal diagnosis of Τ gondii infection. 
Since the frequency of transmission of in­
fection in this primate model equals that in 
humans, this rhesus monkey model may be 
suitable to study the effectivity of treatment 
in infected fetuses 
In the rhesus monkey amniotic fluid is 
the sample of first choice for the prenatal 
diagnosis of Τ gondii infection The nested 
PCR, which is as sensitive as mouse inoc­
ulation, is preferred over mouse inoculation 
because of the gain of time, but combined 
testing will certainly produce the highest 
yield 
The rhesus monkey model is currently 
used to study transplacental passage of 
anti-7". gondii drugs and the pharmacoki­
netics in the fetus 
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CHAPTER 4 
Pharmacokinetics of spiramycin in the rhesus monkey: 
Transplacental passage and distribution in tissue 
in the fetus 
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Pharmacokinetics of Spiramycin in the Rhesus Monkey: 
Transplacental Passage and Distribution in Tissue in the Fetus 
ESTHER SCHOONDERMARK VAN DE VFN '* JOFP GALAMA ' WIL CAMPS ' TOM VREE 
FRANS RÜSSEL λ JOEP MEIJWISSEN AND WILLEM MELCHbRS' 
Department of Meditai Microbiologe ' Department oj Clinical Hharmac\ and Departnunt of Pharmaeoloey 
Umumt\ Hospital Sint Radboud Nijmegen 6Ю0 Hli Nijmegen The \ahcrland\ 
Received Is December 19<П Returned lor modifie ilion 4 \pnl 199-1 \ccepled 2s lune 199-1 
Transplacental transfer of spiramycin was investigated in a rhesus monkey model to study whether the 
antibiotic reaches therapeutic levels in the fetus Spiramycin concentrations were measured hv hioassav and 
high-performance liquid chromatography Pharmacokinetic parameters were determined for bioactive spira 
mycin as measured by the biuassay Pharmacokinetic pilot studies showed that spiramycin distribution follows 
a two-compartment model in rhesus monkeys following a single intravenous dose of SO or 2^0 mg 
dose dependent kinetics were observed At a dose of 50 mg 10% of the dose was excreted unchanged in the 
urine At the higher dose of 250 mg, an oliguric effect was observed Spiramycin concentrations in fetal serum 
were measured over lime while the maternal concentration was maintained at a constant level During a S-h 
experiment a maximum fetal maternal serum ratio of 0 27 was lound In three letuses concentrations in 
serum and tissue were measured following intravenous administration of 50 mg of spiraimcin twice dail\ to the 
mother for at least 7 days The fetal maternal serum ratios were found to be 0 4 to 0 58 after intravenous 
administration of the final dose of 50 mg to the mother It appeared that spiramycin accumulated in the »oft 
tissues, especially in the liver and spleen of both the mother and the fetus lhe concentration in placental 
tissue appeared to be 10 to 20 tunes that of the concentration in fetal serum I he concentration ul spiramycin 
in amniotic Huid was about five times higher than the concentration in letal serum Another important 
observation w<is thai absolutely no spiramycin was found in the brain 
Spiramycin is a m icrolide antibiotic produced bv $ticptom\ 
ces ambofaeiem (11) th U consists ol ι complex of three 
components spiramycins I II md 111 (41) Spir imvcm is 
mamlv bactenosiatic idecling ι broad r mue ol b к ten ι while 
the parasite toxoplasma gondii is also suscepliblL to lhis 
antibiotic (22 41) I he mech inism ol iction ol spirimvun is 
not precisely known It is believed thai spiramycin inhibits 
bacterial protein synthesis by stimulating the dissociation ol 
pcptidvl tRNA trom nbosonus durimi ir insloc mon (6) 
Spiramycin is effective in \i\o lor ι ν metv ol infections 
despite the f ict that its levels m serum ire often below the MIC 
lor lhe infecting orginisms (19) This с in be expl mied in ρ irl 
bv lhe ibihlv of чрігmucin to icliicv«. concentrations in tissues 
and cells 111 il ire a f icior 10—or even more—lllkhel than the 
corresponding eonccnlr ttion in serum I IIL.II coneeiltr ltions of 
spirimvun hive been found in lem ile pcKie tissues (I) 
respir ilorv ir iel (1) he irl liver lung spleen mil кісІпсл (2S 
10) tissues nid m icroph iges ( 19 12 44) The phenomenon ol 
m irked tissue penelnlion his ilso been described for lhe 
m icrolide inlibiotic izithromvcm ( ID 29 18) The hmhiniri 
eellul ir eonccnlr nions ol these m icrohdes m ι\ c\pl im iheir 
good mlibiolic ictiviiv щ unsi susceptible mlracellul ir ort, in 
isms 
Toxoplasma gondii is such ι susceptible obliL itorv mirice I 
lui ir urLinism I his ρ ir isite с m с luse severe disorders such 
as hvclroceph dus chorioretinitis md mental rei irci ilion in 
coiuenilallv inltcled Ictuses (IS) Effective Ire ilmeiil is m in 
d itorv to reduce the risk ol severe disorders 
D it ι concerning tr inspl icent il tr insler ol spiramycin h ive 
С »rrespnnihm; iiithor V) uhm. uklress (Kpirimeiii ol Medie I 
MKI hiokwv I rmers tv Ih spil il Suit Κ ι Ih u il N ] nie цеп PO 
Box J НИ ftSOO MB NiimcL.cn The Nclherl iruls Pli nie "4M)614W 
Fi\ H SO 14021 ft 
been se ircc In 14hS G i n n e t il (1*)) published the results oí 
iss ivs of levels m hum in Linihihc.nl eoid ind m itcrnal blood 
ifter ire liment with spi г mucin ( 1 9. cl iv ) The levels in limbi I 
ic il cord blood were h ilf ol those m m item il blood 111 ІУЧ7 
lorestier LI il (П) reinvestii, ited the li mspl iceiital ρ iss щс 
ol spiramvcin in hum ms Al birlh thev found ι fet il m iteinal 
serum ratio ol 0 74 In icklilion ihcv cximiiicd simples 
obi uned belween the 'M si nul 24th weeks ol ptcgimicv nul 
lound a let il malern il scrum г ilio of Π 47 Bv usui., m in vitro 
pcrlusion model ol isol lied pi icent il et ivledons Ouenlin ci 
il (13) round a miss transkr dünn- ι 1 h experiment ol 
ippioxim ilelv Ψ ( ol the m itcrnal circuì itine coiicentr liions 
lhe concentrations measured in lelil serum do not re ich 
therapeutic levels ι e levels th it equ il lhe MIC lound in vitro 
toi Τ {ondú (41) It is possible th it cttcUivc mlracellul ir 
coiicentr liions nnd coneeiltr nions m tissue are ic iched in the 
fetus bui suell d l t l hlVe not beeil reported ІІІеГсІОГе I 
rhesus monkey ( Mm ш a mulatto) model vv is used to sludv the 
li inspl icciil il tr-tnslci ind tissue distribution ol spn imvun in 
the Ictus l h e consequences of the find mus toi the lie ilmcnl 
ol colludili il Τ ^шиіп infections will be discussed 
M \ 1 r RIALS \NL) Mt 1 HODS 
\nimals In ιοί il ) Ί rhesus monkevs vveic used in lhe 
expci ime ills Гепі ile 4 lo *•> ve ir с» kl ihesus monkeys we uh NIL. 
iboiil ^ k^ were obi lined hom lile I iboriloiv \ninuls 
Breeding Lxpenmeiil I l· irm ol Shundc GLI uud пьг Bcipni* 
People s Republic ol Chin ι Brcedini. housiru nul lenirne, of 
the monkevs occurred ex icllv is described pieviouslv (17) 
Anesthesia \ll experiments were с irriecl oui under ¿eiier il 
inesihesi ι Aller ι 24 h 1 îsiiiu period incsihcsi ι w is induced 
with U) mi* ol ketamine (Nim Пек Ad L seni Velenn irv С uvk 
The Nethcrlinds) per k_ md (I "^ nu ol ilropine sull ile 
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T \ B L h ] I X s i L n ( I L \ j x r i m L n i s w n h ihesiis monkevs 
M nkit 
A l 
л: 
A l 
A4 
A s 
А Л 
А7 
B I 
в: 
η 
» ч к і 
i M I 
4 Ml 
4 10 
"?(] 
4 )•> 
s ι·> 
^^ 
4 4 ι 
••SII 
( 0 
Ι ρ н η KL 1 
S in^ l t Μ) niL dost 
S i n j j t ">(l m¿. dost 
Smuk s|) m i . tl ISL 
SinUi. "'M) niL lose 
Smut. ''MJ ni^. dose 
Sin 'Ie "'M) mg dose 
[ o id inu dost. ( 1 7s mu ki_) 1 i lUmt. i l h\ 
Lonl int ious i i i lus ion (l) ! m ^ k ç m i n ) 
I o iti iriL dost. (1 ^s n i L k » ) f l l t m u l h\ 
Lont inuous intus inn (I l 1 m ^ k ü n i i n l 
Lo i t im i , dost. ( * 2"> muk¿.) l o l l i m c d hv 
Lon l inuous mlus ion ((1 1 n i u k u m i n ) 
101) niL tl i\ in Ί i i i u r m i n e i l l dost. s l m 7 d i\s 
Π4 ( 00 |l)() п і ц і і ι\ in Ί m i c r n i i u e n i doses lor 'M 
d ivs i h c n S I H ^ I L S|| П К dose on d ι\ 2s 
Bs ( 111 1(H) m d \ η Ί m l u m I k n i d >ses i ι 24 
d \s then s iu,lc su U I L d isc m d i\ 2s 
\ ι iipr LI nu В p a n ni 
L г ικ |Н Πι ι ι m и I ik I i l i n ι mit I ( hl 
(Ph un i ichemic B V Η ι i r k m The Netherlands) u v u i mir ι 
muscul irlv I hL tr iche ι w is in iuh i ied with ι ι ι or fi min 
insidi, di imclcr i r i d i c i tube \Mihuul ι cuff (Kusth Rom 
nielsh lusen G e m i n i v i G u i e r i l mcslhcsi ι w IS maint mied hv 
usint ι mixture ot nitrous oxide md OXVLCII f-1 H a n d 1 t o ' 1 
u i f l u r i i K ( L i h i MIL \ b h o t i AnisieKeeii The Nett ic i ! nuls) 
П К i n i m i k w e r c n l i h t i i l l\ venni ned il ι ι Hi ot 20 hu. Ulis 
[iLг mm with ui \msterd mi Ini ml Venni mon i p p n i u i s 
Design of the experiments The design ol the 12 cxpciimenls 
is shown in Τ ink 1 
Pharmacokinetic studies wilh seien .idull. nonpregnant 
шоп kt ν s Spii im ve in (Rov mucine Rhone Poulenc I* ins 
Γ π η ί ι ) w i s i d m n i M e r t d mir ivcnousK ( ι \ ) because LO id 
m ι nisi r i l ion wilh lood e in in luce hioav nl ibihl\ h\ M) (14) 
DOSL lindniL. experiments и».re pei toi med wi ih seven mon 
k i \s \1 io \7 Monkevs \| \2 mil \ b \ t n j \ m ι sintjc 
ι ν dose of MI т ц I ht com L mr nions m se rum di oppi d below 
UIL detection hmil fi h il I I ι idmmistr i l uni ol the M) n u dosL 
I he dose foi monkevs A4 \s and Ad w is mere ISLII IO 2M) n u 
lo en ihle irle. isLircmciil ol delect i h k concenti nions m serum 
lor a longer unie Monkev \7was iveii ι l o a d u u dose ot I 7*> 
n u ol spir m m m pel k¿_ lol low ed b\ continuous infusion ot 0 1 
n u k . , nun lo ichicve ι constant ILVLI in strum ol ipproxi 
m itel\ ^ I) io ** μ ι : ml \ le\el ol ^ 0 io % s
 μ _ ml m serum \\ is 
chosen hec iiise this concenlral ion is norm i l k ichieved in 
hum ms Liven s pir imvcin lo ire ι ι Τ і,оіиІи m k e i ions (22 4*) 
The lo i d i i u dose wis с dcul Uni wi lh I H L toi m u l i ( 
/) Ι ( Г is the sic id\ st i le e ìncenlr i l ion imi I , is the 
volume ol chsliihution ili ihe celi l i il comp II ime.nl ) wi l l l С 
">() lo ^ s μ ΐ ϋ ΐ ι Ι imi ι volume ol distr ibution in ihc cel i l i il 
comp i i l n u n t 1 0 ss hier к^ nul w is 1 7s n u k., 1 he m un 
len nice dose w is subscqucnllv с ι le LI 1 Ucci with the lormul ι С 
0 ( 7 x CL) ( Г is lime nul Cl is с к η mee) with С "Hl 
lo Я s
 μ _ ml and Π - <Ί f> ml min к^ nul w is l) I n u mm k_ 
The volume ol distribution m the l e i i t r i l comp ι rime ni nul С L 
weic derived hom ihe s i n j c dose studies with s() n u ol 
spii tmvcin 
To ohi un ι мі іГкісШІ hi_h nid с о і ы ml urine tìow urine 
pioduelion w is simuli l ied in monke\s \2 \ ^ \ i md V i h\ 
ι ν idministt mon ol •» ^ ol m inni iol pei h ^U ml of ι IM ц ml 
solution was iclnunislered v i i the v e i n s i p h c n i with in 
miusion pump Urine samples were collected with ι c i t h e t t r 
(II 6 b\ 4(1 cm А п л к Sherwood Medic il) 
Pharmacokinetic studies with fetuses І ransplacent il Irans 
1er of spir imvcin \v is me »MIred in five monkevs ( B l lo B i ) 
under ν mous conditions The dui i t ion ol prcgn mcy in rhesus 
monkevs is ihout 170 d ivs The tr inslcr experiments were 
performed at d i\ 140 of ргсцпапс which is comp ir i b k to the 
third trimesler ot o i m n o g e n c t n developmenl in humans 
( onceii ir nions m k l il serum were measured in monkevs B l 
and B2 in a 1 dav experiment while the m i t t r n a l antibiotic 
concLiitr ition was m uut uned al ι const int level b\ me ins ol 
ι loadiii.. dose ol ì 2^ mL. k_ followed b\ continuous infusion 
ol 0 I mg,kg,mm for ^ and "> h rcspectiVLlv As a result ol 
р і е л і mcv the d is lnbul ion volume ol the e e n l r i l comp ir lment 
is mere iscd consider ibl\ in the. third trimester ol gest m o n It 
w is thcrclore necessarv to mere ise the lo uhne dose in these 
monkevs Tr uispl iceiil il t ru isfer ot spn i m u i n it ι sieadv 
s i i le in ihe mother was liso studied in monkev ВЧ This 
monkev w is Li\eii s() т ц In venous puticli ire twice ι d iv lor I 
week before si i r l i n _ the experiment lo achieve m iximum 
concenti nions in tissue (24) A loading dose o l 1 2*> тц/kg was 
idminisieied since Ihe trough level dropped lie i r k to zero 
M iximum c o n c e n t r i o n s m tissue were also ichieved in 
monkevs B4 ind B*< bv idnunistration ol ^0 me ι ν twice a d ι\ 
lor •» weeks I ranspl iceiil il t i a n s k r w i s studied in these 
monkevs titer idminisir i l ion o l ι Im il ι ν dose ol Μ) т ц 
Collection ul samples Spn imvcin w is idmmisiered in elu 
cose isotonic solution ν ι ι ihe \en ι s iphen ι and blood s imples 
wei e l i k e n trom the vena |ut>iil ins Ihe blood vessel w i s 
с innul iled with ι h c p i n n i / c d с uheter nul connected to ι 
thiee w ι\ stopcock (ViiiLO Н с К т е Ь о г с Sweden) anil s im 
p k s of "· lo Ч ml ol blood weic collected The fluid b il nice w is 
m uni m u d bv i L p l i c i i u OIL IIIOOLI with ι phvsiolnsic il sail 
solution 
S imples ot 0 s ml ol let il blood wele collected Irom ι blood 
vessel th it mlLiioniiLCls the iwo pi iceiil il lobes ih π are 
picsenl phvsiolo_ic illv m this monkev species exut lv as 
previousK desmbed (^7) In briel in mterpl icenl il blood 
vessel w i s v isu i lued bv i l lumin it ion ol ihe utcius with two 
sienle I imps Mier e i ieful incision ol the l items w i l l md the 
decidui lile ІПІсГрІ iceiil ll blood Vessel which is ol k i l l 
o i u i n w is exposed The vessel was e innul l ied with i t l inc ic i 
md the s imples weie collected The blood was lcpl iced with ι 
phvsioloLie il s iU solution to maint un the Huid b il inte 
Dui u u Mie ir mspl icenial l i i n s k r expei imeni blood trom 
Ihe mother blood п о т ihe k l u s nul amniotic Huid samples 
weic collected it s e m i lime nilerv ііъ (see T i b i e 2) Fi о т 
monkev M urine s imples were collected o\er 0 to 4 4 to S 
md 8 to 24 h At nunc re-,ul u lime intcrv ils urine simples 
weic also collected from monkevs A2 A4 A"i mcl A 6 In the 
la l lere iscs urine production w is stimul Heil hv 4 idmmisier 
п и с ol mannilol per h ( T i b i e 2) The ш и к volume w i s 
nie ìsuieil and in il iquot w is kept lor delermit i ttion ol the 
spu imvcin toi icei i i r it ion 
A l the t n d ol ihe expennici i l babv monkevs І И B4 nul B*> 
weie delivered hv ces ne m sc e l ion md ι m me eh itclv saciiliced 
riiL liL iris livLts spleens hi uns md pi »ceni is were collected 
to determine the spir imvcm conccniiations 
Determination ol aiitihiolic concenlr.ilions Pure spira 
mvcin w i s kuullv piovided b\ Rhone Poulenc Centre de 
lLcherches de V Un Mforlvi l lc I мпсе \ccordme lo the 
m inul ictuier the spn m u c i n used (lot no R P i ^ 7 ) com uncd 
УОіКг spu mucin Ι І І Л spir imvcin И mil 6 V , spir imvcin 
I I I is d i l c i m u k d bv h u h per lo imuice l iquid с h rom lUuraphv 
( I I P L C ) 
Antibiotic contenti itions WLTC i k t e r m i n c d bv bio issav 
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T A B L r 2 Colleetion of samples 
M i nkL\ Ь impk S mnlim. ume(s) (mm I 
Al Strum (I 2 ι 10 l i KI 6(1 W 12(1 INI 
2-10 48» I 44(1 
Urine (I 24(1 48(1 ] 44(1 
Л2 Serum U 2 ι 1(1 l i Ю 4i 60 4(1 12(1 IUI 
ІЫ) 210 240 270 WO 140 IMI 
1 120 1 ι(ΗΙ 1 SIK) 
Lrine 0 l i 40 41 60 40 120 l id IMI 
210 240 270 100 ПО IMI 1 120 
I îOO 1 WK) 
AI Serum 0 2 "i IO l i 10 4i 60 40 120 IK) 
IMI 21(1 240 270 100 HO 160 
17i 1 120 1 1(1(1 1 680 I S60 
Urine' 0 l i 10 60 40 120 210 240 270 
100 110 160 17i I 120 I i(XI 
1 6S0 I 160 
\4 Scrum 0 2 ι 10 l i 10 (.0 90 120 Ы ) 
ISO 240 100 160 420 1 440 
Ai Serum 0 2 ι 10 l i Ю 4i 60 90 120 liO 
180 210 240 270 100 110 160 
1 240 1 47(1 1 810 2 710 
l rine 0 20 60 160 1 290 1 470 1 ЬШ 
2 710 
A6 Si_rum (I 2 ι 10 l i 10 60 90 12(1 IMI 
180 
L n n c ' (I 1(1 
Л7 Strum 0 ι ι 10 l i Ю 60 90 120 ISO 
240 100 160 
Matern L] serum 
Гсі il serum 
M iternal scrum 
1 cidi scium 
Maternal serum 
belai scrum 
Amnione finid 
Fetal tissues 
Matern il scrum 
Fetal serum 
Amnione [luid 
Геі il tissues 
M item il scrum 
Tel il sei um 
\mmoiic fluid 
1 e u l nssues 
0 
0 
0 
0 
0 
0 
0 
10 60 
10 Ml 
10 6 0 
10 60 
10 60 
10 6(1 
«Hl 
κ κι 
0 
0 
0 
i o 60 
i o 60 
20(1 
200 
0 
0 
0 
10 6 0 
10 
60 
60 
120 
120 
120 
140 
120 
120 
120 
120 
22ι 
T ) ^ 
ISO 
ISO 
1H0 
ISO 
180 
180 
H t in l i u r hi un spln-ii in j pl iL^ Mt ι nssLits \м.гі. ι btairutl и шіор-л 
IherL W I S H iiiiiiiL i\ иі ihk и IM) uid 1Ж1 mm 
T h t a л is nu unni. ^ ni lili. Ы.і«ч.п fill md Vil) mm 
Then, w is no unru iv il ihk ліКг ill mm 
and/or HPLC In ihe bioassav tlic spiramycin concentration 
was determined h\ dillusion in Yr Difco agar medium no 11 
( p H 8 0 Urunschwig С hemic Amsterdam I he Netherlands) 
with Sai с ma lutai AlCC <Ш1 is the test org inism (Vi) Ihe 
concentrations of spirarmun in the сііпкаі samples were 
determined b\ comparimi the inhibition zones to those ol the 
standards Standards weic prepared as follows Л stock solu 
tion ol 2 mg of pure spiramvcin per ml was dissolved in 2iYf 
meth mol and 8(Kc physiological salt solution Standards ot 10 
ι 2> 10 ( h (12ч ind (Ï Ι μι» ml were prepared Mom the 
stock solution b\ dilution with physiological salt A negative 
control of ph\siological salt with 0 l rc methanol did not inhibit 
S luiia growth The sensitivity ol the assav was 0 1 μΰ, ml The 
bioassav was linear in the concentration range between 0 2^ 
and 10 μg ml Intrada\ and inlerda\ coefficients of \anation 
were found to be 2 0 ind 2 6 rr lor 10 μ£ ml 1 ι and 2 1(V tor 
S μg ml 1 7 and 0 lf7 for 2 Ί μ£πι! Я S and S Ύ< for 1 0 
μgml Я 4 and ч 2r< for 0 S μgml ^ 7 and 1 Wf lor 0 2s μg/ml 
and Я I and 4 Yt lor 0 Ι μ^ιηΐ respectivelv 
Determination of spiramycin bv HPL С was performed on 
LiChrosorb ( Ρ Spher CIS (2^ cm bv 4 6 mm [inside diameter]} 
with a solvent of 4 g of Η,ΡΟ,,-Ο S g ül Lclramclhvlammonium 
chloride in MX) ml ol water mixed with МЮ ml of acelomtrilL 
with UV detection at 2Ή nm and operation at a temperature 
ot 21 С (27) The quantitation level of the HPLC was 0 I 
μ£ΐηΙ The intrada\ and inlcrdav coefficients of \ariation were 
lound to be 2 1 and Я 0r<- respectively 
Preparation of samples Tissue samples were homogenized 
in physiological salt solution (4 ml g [wet weight] of tissue) with 
an Ullraliirax apparatus (Ystral GmbH Dotlingcn Germany) 
The crude homogenate was pelleted bv 20 mm of centrifuga 
tion at 1 000 X g Ihe supernatant was used for the bioassav 
and HPLC determination The supernalants and scrum ьат 
pies were kept at -20CC until determination After thawing 
100 μΙ of the supernatant serum sample or urine sample was 
tested in the bioassav The samples were diluted with distilled 
water il necessari 
For HPLC determination tissue extracts were deproteinucd 
with O U M perchloric acid and eentntuged al 4 000 X ц A 
200-μΙ volume of plasma or serum was deproteimzcd with 2(H) 
μΐ of aeetonilnlt vortexed and centnfuged al 4 000 Χ ι; Urine 
samples were diluted M) limes with distilled water Aliquots 
(100 μΐ) ol the prepared samples were injected onto the 
analvtical column 
Pharmacokinetic analvsis The serum concentration time 
curves ot the experiments with SO and 2*5(1 mg iv boluses of 
spiramycin were fitted best to a linear о pi. η two-compartment 
model as determined with the I ratio test Basic pharmacoki 
neue parameters were estimated both from single dose expel 
imeiits and from sic idv state experiments in accordance with 
stand ird procedures (17) Renal clearance was estimated bv 
the total excretion method in which the cumulative amount ot 
spiramvcin excreted in 24 h into the urine was used Cuive 
luting was done by least squares nonlinear rcgiession anaKsis 
in which data were rcciprocallv weighted ( 1 С ) with the aid of 
the PCNONI IN computer program (26) 
RLSL1IS 
Determination of spiramvcin In two experiments (monkevs 
Al and A4) levels ot total spiramvcin (1 II and III) in serum 
were deteimined by both bioassav and HPl С The results 
lound bv both detection methods were rouizhlv similar lor 
those serum samples that were collected within 60 mm after 
administration of the dose Го г scrum samples that were 
collected alter 60 mm the bioassav eavc higher concentrations 
than did 1IPIC (Table λ) 
Fx imination ol spiramycin concentr liions in serum bv 
HPI ( revealed thai mainlv component I was me isurcd (У1 to 
y-i'V) Ihe concentration ol spiramycin II was below the 
qu mutation level Thus the г с т а і т т . ~> to 7(< w is mainlv 
component III 
Dose-hnding experiments Single dose kinetics were detei 
mined after administration ot Ml or 2MI ты ol spirimvcin to 
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TABLE 1 Concent г itions of spirdiuvun in si-rum niL isurtd bv 
bioasMv ind HPLC 
( 11 ι m m iik<.\ A l С пеп m m inke\ \-l 
SLMI 11 11 l u Ml m м.штп jlti_r "'"'(I rriL 
Him (mm) 
1) 
ι 
s 
I I I 
1·· 
10 
(.() 
40 
PO 
IM) 
IMP 
"•411 
IUI 
(ill 
- Л І 
1 4-411 
U i ·, ν 
II 
I S s 
( ) •" 
4 4 
' 4 
1 4-> 
OS 
0 ss 
114 
II ^ 
Il Ih 
0 I 
П Р И 
0 
' 1 7 
9 7 
s ι 
1 9 
1 ( s 
O h i 
0 44 
0 14 
ü 111 
(I 1(1 
υ 1 
H s % 
I) 
лк 
24 
•'s 
ли 
Ρ 
7 1 
4 ι 
4 1 
1 7S 
1 7s 
I h 
1 ι 
1 4 i 
. I b 
114 
HPLC 
0 
τ: 
24 
24 
1 4 4 
7 •> 
2< 
Ι ι 
0 % 
(I4H 
Il s 
II Чі 
0 Ih 
II I 
Il I 
Il I 
ihL ihcsus monkevs I he concenlr nions in seium illcr idniin 
isir а к т ol ι ilosc ol M) mg iri_ presented ni Fie 1 The scrum 
concenlr ilion lime curve followed ι lwo сопіртппіспі imitici 
The kinelic parameters are shown in Table 4 Alter ι SIIILJC 
dose ut MI m_ К' ol the dose ol spit mULin I idnunisltrcd 
w is recovered trom the uriiiL of monkev \l over ι period ol 
24 h Aller siimul.ilion ot urine pioduclion with in innilol 8 
and \-\'( were recovered Ironi nionkcvs \2 md \1 respec 
livelv A constant tirine flow wis induced in monkc\s A2 ind 
Al ind the rates were found to be 041 ind 041 ml min 
respecli\cl\ 
Single dose kinetics were liso determined in monkevs A4 
A"> ind Af> iller idnnnisir ilion ol i n n dose ol 2">0 mi. A 
prolonged serum сіішшніоіі h ilf hie ol ipproximalelv 16 s h 
was lound ind the toi il hoch ele и incc decre ised to (S 
ml k^/inin Despite idmuuslr ilion ol manmtol to monkev As 
its urine production ι ile dropped tir ist le illv to 0 04ίι ml min 
and ι unii ιιν excretion ol 0 7s ¡ o u r 24 11 was lound A low 
serum cone spiramycin [ug/ml] 
time [hours] 
H O I ( on ten l r ш и п (coiK ) o f spu i i l i v u n i l l monkev Λ 1 serum 
all»-1 ι sintílc 11 dose ol s0 me The cuneei l l rd l ions nl spir i ime l l l were 
ПК isi ired b\ Ьі ι ISS h 
urine production rite of ООП mlVmin was also found for 
monkev Ah under the s ime experimental conditions (data not 
shown) 
A pilot experiment with nonpregnant monkev A7 with a 
lo idine dose ol I 7s mg. kg tolloued bv continuous infusion of 
0 1 mg kg/tnin showed that a me in stc idv state conceiitr mon 
m serum of 3 1 ± 047 μ(7πιΙ was reached within 10 min (data 
not shown) The total bod\ clear mcc it steadv si ite w is 26 2 
ml kg,mm (Tabic 4) 
Plaiental transfer Transfer of spirimvcin from mother to 
lelus was studied at a nrget level in serum ol 1 U to 3 s μg ol 
spiramycin per ml in the mother The concentrations in serum 
at steadv state are shown in Tibie *> As с ilculated irom the 
steadv st He concentrations in serum lol il bodv clearances ol 
24 4 114 and 2s 0 ml kg,min were found lor monkevs BI B2 
md B1 respectively These ν lines ire in good accordance with 
those e ilcul iteti trom the single dose experiments in which ^0 
т ц w is given ι \ (Tibie 4) 
Figure 2 shows Ihe concenlr топь ol spiramycin in m item il 
ind felli sen wilh const int inliision lor monkev Bl In Ihe 
felusol monkev Bl > ч | о 7 У ' г ol the corresponding conccn 
и ilion in the mother s serum was tound during a 1 h expert 
nient ( liso Tibie s) 1 г insplacental tr instel w is ilso studied 
in monkev ΒΊ I hls monkev had alreadv received ι dose ol 100 
mg dailv lor 7 davs betore ihe continuous infusion wis si irled 
I he concentration in telai scrum ol monkev B2 w is dso lound 
lo be iboul 6'f ol the corresponding ni itern il concenlr mon 
dünnt, the first 2 h Atter 2 h the concentrinoli in fet il serum 
si irted to mere ise and the concentration re icheel ibout 22{ t 
01 the corresponding m itern il concenti ilion il 4 and s h 
(lable S) 
Similar kinetics were ilso found for monkev Bl The pre 
dose concenlr ilion in ihe serum of Ihe monkev Bl Ictus was 
below the detection limit hut the fet il levels at Ml and (id mm 
were huhcr ( 14 /) thin those lound in monkev B2 (Fit. 1 md 
I iblc s) At the end of the experiment the kinetics ot monkev 
Bl differed shjulv from the kmelics ol monkev B2 The 
concenlr mon ol spir inivcin in serum increased in the mother 
where is the fel il concenlr mon decreased (Fie 1) bee uise the 
lelus most prob iblv died liter collection ot the blood simple it 
4 h 
\ftci siutlvinj pi iceni il translcr ot spir imvcin it ι const mi 
level in m Hern il serum transfer was studied in monkeys B4 
ind Bs liter ι single dose ol sii mg Puoi lo Ihe experiment 
the moiikevs received s() me. ot spiramycin ι ν Iwice d ulv lor 24 
tl ivs Ihe results tor monkev B4 ire piesented in Fit. 4 A 
trough level ol 0 14 μί,ηιΙ v. is lound for ihe lelus This was 
sS'< ol the eeirrespondmg m itern il concenlr ιΐκιη (0 24 μ£ 
ml) 1 he concentration in fel il scrum mere ised slightly to 
ibout 0 ΚΙ μι,ml and remimeli consl nit lor 1 h The translcr 
experiment w is terminited after 1 h md in aulopsv ot tctus 
B4 was performed Spu imvcm concenlr liions were deter 
mined in tetal tissues The results ire presented m Fit. s High 
spiramycin conceiitr nions were lound in the spleen ( 1st limes 
the concentration in serum) liver (12 limes the concentration 
in serum) and pi icent ι ( 10 times the concentration in scrum) 
Ihe concentration in tl с îmniolic Iluid was relatively ste idv 1 
h ittcr idmimsti ition ol Ihe (in il dose Ihe concentration in 
imniotic Huid w is four times the concentration in letal serum 
hut compired with the prcdosc concentration in the imniotic 
Huid the concentration was hardlv raised No detectable 
eonccntr ition of spiramycin was tound in the brain 
С omp irihlc concentr liions in tissue were also found for 
monkev Bs (Fig h) Unlorlunaiclv this monkey turned out to 
possess only one pair ol interplaccntal blood vessels As ι 
consequence the lelus died approxim Helv 10 nun ifler can 
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Τ \ Β Ι _ Γ 4 Hh i r n i j L o k i i K t k p a r a m e t e r s L.IILIII n e d I m m s i n g k dust, a n d Mcad\ siali, < . \pí . r iments 
Мічікеч 
A l 
A : 
A l 
M L Lin 
A4 
A ï 
A6 
M t in 
A7 
BI 
Π 2 
B I 
Mi_.Ul 
* SI) 
_ SD 
* SD 
»ι 
Sim>k 
Single 
Single 
Singk 
Sinek 
Single 
Single 
Single 
Steadv 
Steadv 
Sie.idy 
Sle.uK 
Sle.nK 
(IL r.tlllllLtl 
S()-mg dose 
SO me dose 
s() mg dose 
so-nig do .e 
2S0-me dose 
2S0 m g dose 
2S0 mg cinse 
2S0-mg tlnsL 
stale mlus ion 
stale m l u s i o n 
st.ile mlus ion 
state mlus ion 
state m l u s i o n 
f, 
(mini 
f>4 
2(11 
X2 
12(1 ± 7(1 
1 141) 
1 220 
WO 
1 000 - s|fl 
MR f 
(min) 
i ì 
148 
72 
40 · э(і 
1 440 
1 190 
«S8 
1 l i d ζ 1s[) 
CL (ml kn 
пин) 
4s 
-S 
14 
IK » .< 
h f l 
IS 4 
S s 
б ь 1 (> 
2d 2 
24 4 
11 4 
2S0 
2fi (1 ~ 2 Ч 
( 1 mi l кц 
nun) 
17 
27 
47 
17 ± 1 
l , ' ( l ikrs 
kel 
(147 
I I7S 
0 42 
о ss - n IS 
0 71 
0 41 
047 
0 71 _ 0 21 
1 Onus 
kel 
24 
i 1 
2 1 
1 1 _ 1 () 
12(i 
10 2 
4 7 
4 2 - 4 1 
Urin 1Г\ 
. Ч К І Ю П I ' ) 
8 
8 
14 
IO - 4 
ι, , serum diminjtiDii hall lik 
M R T m e i n n s i - k m . Iimi. 
CL r u i il J e i rann. 
' I , volumi ol clisiiihiiiion in ihi u n i r a i l o i n p n i m u i i 
1 Milinni öl ilisinhiition at su uK si m 
nulation .imi the concentrations in serum measuied in Ihe 
experiment were nol reprcseniaiivc 
DISC USSION 
As determined b\ HPLC 41 lo 9V, ol ine concenlration ol 
spuamycin in serum consisied of component I Al concentra 
tions m serum below s μ^'ηιΙ onl\ spiramycin I was ¡.¡electable 
spiramycins II and III were below ihe quantitation luci This 
is in agreement wilh ihc results ot Dow el al (12) who 
reported the detection of only spiramuin I in plasma from 
patients given therapeutic closes ot spiramycin The results ot 
the bioassay and HPLC weic in agreement lor ihc scrum 
samples obtained within 1 h after administration ol the dose 
Foi serum samples collected after I h the bioassay gave higher 
concentrations than did HP1 С The presence ol very low 
concentrations ot components II and III might explain the 
diserepancv found between the bioassav and HPLC results It 
might be possible that components II and III which cannot be 
detected bv HPLC at verv low concentrations arc biologically 
active and aie therelore measured hv the microbiological 
assay This implies however, thai components II and III would 
be more potent than component I which is not logical I he 
diHcrence between the bioassay and the HIM С results ma\ also 
mean thai a bioactrve metabolite lh.ii is tormed slowly over 
lime is measured This view is supported bv ihe dose-depen-
denl kinclics observed indicating Ihe likelihood ot formation 
ol metabolites Since these possible metabolites were active in 
a bacterial assay a Iherapeutic eBed on Ihc parasite Τ цоіиіи 
may be expected as well We therefore decided lo use Ihe 
bioassay instead ol HPI С because U was oui purpose to 
investigate ihe effectiveness ol spiramycin tor treatment of 
congenital / qondu infections (Vi) 
Ihe distribution of spiramycin, as measured with the bioas 
sav in rhesus monkevs lollows a Iwo-compaitment model as 
has been lound in humans (21 22) Ihe kinetics appear to be 
dose dependent probably as a result of saun able-drug metab 
olism Although less obvious than in ihcsus monkeys dose 
dependent disposition has also been reported lot humans 
(14) 
Ihe urinary exaction ol HKr found al a dose ol SO mg in 
rhesus monkevs is identical to the S to \>'c reported tor 
humans (22 21) 
I ABLE s Ranos ol spiramvein eoneeillralions in felal materni! si_ra al skadv stale in mnlhi.r monkevs Bl B2 and Bl 
S impili)^ ui 
(min) 
( ом.)] (μα mi) in m Hern il kl.il s.i ι li ino | ' . j) 
I I I HI 
0 
10 
MI 
120 
180 
22s 
240 
100 
Mean ζ SD 
IMI 
1 ÍS о I S s ( s -,) 
K i S I I 2 u ( 7 l | 
1 1 0 2 4 ( 7 4) 
2 4 0 1У-. (Гі 7) 
1 1 r (I 11 0 2 1 · (IOS (6 s ζ I 0 | 
Ol l 
2 M I 1 2 ( 4 S) 
2 M I l i (S 4) 
1 1'0 2 ( ) ( 7 X | 
1 I ( | s 4 ( l f i 4 | 
l s 0 7 8 ( 2 2 1 | 
4 0 0 8 7 ( 2 1 SI 
• O s i 0 4s ζ О ІМ H I s u 
0 211 
J 11114(111) 
1 M I S ( | 1 ) 
1 7 1 1 7 ( 1 8 9 ) 
I f i I 0 ( 2 7 8 1 
4 0 11 (27 S) 
•IX« 7(1-1 h) 
4 0 ζ 1 1 4 1 0 7 _ (127 ( I S (ι - 7(> | 
С ilculatid from ι - HI min Ιο [Ικ ulti ot iht eypi.rinuiil 
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serum cone spiramycin [ug/mll % 
100 
serum cone spiramycin [ug/mll 
100 
8 0 8 0 
3 Ί 6 0 6 0 
4 0 4 0 
2 0 2 0 
О * ^ 
0 0,5 1 1,5 2 2,5 
time [hours] 
3,5 
П О 2 Coni.enlr.ilions (eoiiL ) ol spiramvun in monkev Bl l i tal 
and maternal sera il a lonstanl lonisillr.i l ion in m nern.il ч rum 
Monkev BI Kccivid no spiramycin bclorc the iranskr experiment 
Svmhols < maternal k u l г mo (peranum.) 
0 $ — τ ι 0 
0 1 2 3 4 5 
time [hours] 
HCi 4 ( oiiceiur liions (ioni. ) ol spiramvcm 111 ПЮІікі B"* lel.il 
and makrnal st.rd ,il ,t consl ml loncenlralion in maknial struin 
Monkiv B4 received 100 піц ol spiramycin daiK in tuo intcrniillLnl 
dost.4 lor 7 da\s hiíore lile evpcnmeni lollowid b\ a loading dosi, ol 
ì 2*> mg kg and continuous iiilusion ol (1 1 mtkemin Svmbols -
malern il <- k ia l i.itio (pcicentigL) 
I he renal deal anee ( IS ' 4 ml mm) is on the order ot the 
glomcrulai fi ltration rale ol rhesus monkeys (A) Since si imu 
lalion ot urine production bv ni. innilol did not inliuence renal 
clearance passive icabsorption eau he excluded II seems likely 
that renal excrétion of spu mucin occurs onk through glomcr 
ular nitration 
Remarkable was the acute oliguric elicci observed it the 
hicli dose o l 2S0 mg This phenomenon ma\ explain the lo» 
excretion at 2s() mg Several drugs have been reported to causi, 
renal falline (2 s 9) Kenal lailurc due lo the use of 
spiramycin ni cither macrohdes has not been reported Since 
monkevs Л 4 AS and A d were not sacrificed alter the cxper 
imeni histological examination ol the kidnevs »as not possi 
ble 
The serum el imination hall-hie o l spiramvcm m rhesus 
monkevs was lound lo be 2 h al a dose ol •>() nig As expel led 
foi small animals this is lower lhan the value ol S h found in 
human volunteers attei lv administration (14) and the value 
ol I K h reported bv Kavi et al (21) aftci oral administration 
Studies of the transplacental t iansfci ol spiramvein in hu 
mans are poorlv documented ( M IS) Ihe duration ol treat 
meni and Ihe lime шісілаі between the last dose and sampling 
are not exacllv known Moieovei no dala arc available on 
concentrations ol spiramvcm in letal tissue Iheretoic an 
animal model was sought to investigate concentrations m letal 
tissue and sciuni Since rhesus monkevs possess a hemochonal 
placenta like humans (44) rhesus monkevs aie suitable am 
mals tor model studies ol transplacental transfer of spiramvcm 
Placental t i a u s l u »as measured in monkevs B l and B2 at a 
constant in.ilernal spiramvcm concentration D u i i n g t h e lust 4 
h al ler . к і ш п т і г а і і о п ol spiramvcm onl\ s to T~r ol the 
coiiesponding maternal concentration »as found in fetal se 
rum Although the in vivo situation cannot he compared to the 
in v i n o situation it is remarkable that this pcicciit.ige is similar 
to Ihe transler rale ol ΨΛ lound bv Qucnlm el al (43) dur ing 
a 1 h experiment using a perfusion model ol isolated cotvle-
dons Thus inii ialK a lo» concentration »as lound m letal 
serum Ihcreattci the fetal maternal ratios started to m-
s e r u m c o n e s p i r a m y c i n lug/ml] 
1,5 
0,5 
time [hours] 
N O 4 ( oncenlr liions (coni ) Ol spiramuin ni monkiv B4 telai 
scruni aller ι single dose ol so nm ol spirainvun »i\m i\ lo ihe 
mollici on d iv 2s Prior lo thi transtu ivpiil i l lent l i l i mother was 
given UH) mg ul spiramvcm iv d.nK in two nitumitleni doses lor 24 
da\s Swubols - m i u r n i l tet.il 
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telai heart 
fetal bram 
fetal spleen 
fetal liver 
placenta 
amniotic Huid t-Ohr 
amniotic fluid t-Эпг 
fetal blood t-Ohr 
fetal blood t-3hr 
maternal blood 1·0 
maternal blood t-ЭПг 
cone spiramyc η |ug/g] or [ug/mll 
I I O s С опсепі і it ions (enne ) n i spir nrivein in numke\ B4 set um 
a m n i o t i c Huid .md tissue d e t e r m i n e d 1 h i l te i a d m i n i s t r a t i o n oí a (in il 
dust ol MI n u 
cruise as fourni loi monkevs B2 LH and LU ID I IL I ihe 
IL Uil male n u l ι т о ι nei cased io 0 ^S in monkcv B4 wl ich w is 
given spil mucin loi i l 11 ¡SÌ "ΐ weeks Similar ralios have been 
UHIIKI in humans who h id bci_n treated tor several weeks ( Ι "ï 
Is) These d t l i suppoil svstcin luslercsis indicating lh.it 
distribution of spu im\Lin lo I I I L t^tus takes longer duimt: tliL 
hrsi hours aller adun imi ! i t i o n o l i h e inlibioiiL I ISSUL and L L I I 
distribution probablv L>I idmllv inert iscs until the tissues md 
cells become saturalLÜ Піе I L M I I I S ot M îcFail IDL L! al (24) 
who lound thai maximum LoiiLLiitiaiions ol spi i ,mucin in 
tissue are achieved a l k i 7 i h \ s of 11 e.H nit. ill support this 
ТІКІСІОГС СОПСсШГ. UlOllS 111 (ISSUL WelC dclL imi l lL l I .iftLl ill 
least 7 davs ol treatment (monkevs Ш B-l and US) Our 
findings support the results ol МасГаіІапс et il (2-1) Drue 
concentialions in the tissues ol nionke\s HA md B^ which 
wele tie<ltcd tor 24 da\s W L I L nol essentialia di l leiei i t fi о т 
d u m concentrations m lile tissues ol monkcv B"* which w is 
tie ited loi I week Howe\er it cannot be concluded l iotn 
these results whether the m iximiim levels in tissue aie 
ichieved e ul iei l e belore 7 da\s ol treatment 
In rhesus monkevs as m humans (24) and rais (4(1) high 
concenti liions ol чр ігат\с іп не found niailiK in tissues such 
.is the li\Lt md spleen I he mechanism h\ which such high and 
Іоііц lasuim concentialions in tissue die achieved has not been 
lesohed For the macrohde antibiotic iz i thiom\cin seven! 
obscrv liions k id lo ihc assumption lhal plugocvlcs deliver 
the antibiotic to cells through upl ike tr insporl md subsL 
ijuent leleasL into tissues ( IS 2^) λ símil ir mechanism mav 
be assumed foi spiranucm since high conccii lr l i ions ol the 
intibmtie h ivc been lound in macrophages ( 14 Я2 44) Osono 
and Ume/awa (28) have simneMed that the levels ol spir imvein 
in tissue are lone lasimi* compared with those of other 
maerolitles bee ι use spiranucm is less casiK niel iboli/ed 
Rapid uptake of spir imvein bv tissues I rom serum and slow 
redisiribution Irom tissues to serum ma\ be another explana 
l ion lor the lone lasting concentialions m tissue I ligh coliceli 
Iralions have also been found m the placLnta The finding that 
concentrations in maternal scium не highe ι than the coticen 
iralions in felal serum ma\ indicate lh.it the placenta lunclions 
is a clearance organ or as a ba ine! Moie research is needed 
loi better insight mío the piocess ol ti inspl iccntal transfer of 
spiramvem In v i t io suiches with isolated placental COIVILLIOIIS 
are in progrLss 
Penelr i l ion ol spirmivcin into eeiebiospinal l luid is re 
ported to be poor bul liiere is little documented evidence ( Id 
42) In our sludv the concenti i l ion of spu mucin in the brain 
was be Um the detection limit ol the bio iss i\ Since dam me of 
the fetal brain is the most seveie consequence lie i tmeil l ot 
consumai / \>ondu inleciioi i wi ih spiramycin wil l be нкНес 
live It is not clear whether the levels ie lehed in tissues other 
Hi m the brain are iheiapeulie Several investii» Hors hive 
lepOlted Concentrations ol spirilllVCin til It Wele e l ìcet te 
uiauisi Γ potutit in \ i l r o 1 ruong ci al (41) lound ι minimal 
mhibiloiv elieel it an inl iacellular concenti i l ion ol 10 μ_. ц ol 
tissue In then in v i l m cell culture the corresponding exit 1 
celili) η eoneeiuiai ion was I 10 μg ml Chamberlanil el al (7) 
lound ih it Ì conce η I r Η ion ol 2(1 urn ml had on I ν l imitel i acliutv 
( M f r inhibit ion) minist Τ gondii in vitro \ l lhough I X i o u i n 
et ,il ( I I ) repoited that inhibition of /oxophisma giowth in cell 
eulluie w is iliL.ich observed К a concentration t>J I μL ml ι 
maximum elicci was on К ich lev ed il a dum conce ni r i l ion ol 
2M) μμ ml Sut h high exliaeellul и concenti nions ol 201) (20) 
and 2-l(i ( Μ μϋ m) h ive been lound lo i i ihihi i the uicorpor i l ion 
ol | I (¡uracil bv / ^aitili t ieliV70iles m uiketed cells but h id 
no smnilicant kil l ing elicci Піе coiiLspondinü inlraccllulai 
spiranucin СОІІСсПІГ liions howevel lie HOI eXJelK known 
Nevertheless il is chfhcull lo compaie I lie in v i l lo situation 
with the in vivo one Whell iei the concenti Hums lound in 
tissue ire ctkcl ive in a coimenit ilK infected Ictus needs 
lui the. ι investigation I here lore we hive developed a ι I K sus 
monkev model tor congenital / gondii mlections The eliec 
liveîless of spu mucin has been investigated m this model ( Vi) 
0 1 2 3 4 5 
cone sp ramyc η [ug/g] or [ug/ml| 
I I O (ι С oneei i i i l i ions ( i nné ) ui spir u m u n in monke l 11'1 tissue 
determined 1 h al ter i dmmis i r i l i on ni ι hn il dose nl -ΊΙ nie 
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ui tile ( e n t i il A n n u i i I ihm itnrv o l ihe l nneis i tv ol N l ímele η loi 
siiJLie il mei te e lime il issisi inee m d mini il e lie We i k o i l i l l lk II ι 
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R L P t K L N t h S 
I A l u n f t I I M U K h . i h l I) \ j i h u n and M \ ( « L i s i i r PJss 
Spir l l l l M i n eoi leenir l i ions in k i l l lie pelvic tissues ele ІеПП med bv 
I I P I ( t р г е і і т ш irv report I Л п и т к і о Ь ( . І і е і т н г к і 22(Suppl 
В) 1 11 U h 
~· Пеппеі І W M ( . \ Porter S Ρ ВацІ» .nid W I M c D o n a l d 
14"s Moi iOLi iphs m elmie il pl i i r m ieoloi:\ \n l "* d i l les і т і г е і н і 
ele M шее t l i u i e h i l l I m i U M n n e N e u > o i k 
•> B t r í i o y n e - l U r t / i n L I'JSS Spu m u e in con ten i r uini is m die Im 
m m íespii π η, η к і ie\iew I \ n i i m i e r o b ( І і е т о і і і с г 
22(Suppi И) i r г : 
54 
4 Bourne, J H. 197S The rhesus i i ionkov Academic Press, Ine 
New Y o r k 
ι Brezis, M , S. Rusen, and V. H. Epste in. 199] Acute renal fa i lure 
ρ 991-1061 In В M Brenner and F С R e d o r , Jr ( c d > The 
kidne\ vol 1 4th cd The W fì Saunders Co Phi ladelphia 
π B m s o n - N o e l , Α., P. T r i e u - C u o t , a n d P. C n u n a h n . 1988 Mecha­
nism o f act ion o f spiramycin and other macrohdes J A n u m i c r o b 
C h e m o t h e r 22(Suppl B ) : 11-21 
7 C h a m b e r l a n d , S., H. A. K i r s t , and W . L C u r r e n t . 149] ( omp. i r 
ative activity o f macrohdes against Toxoplasma gondii demonstrat­
ing ul ihtv o f
 t i n in \ i l r o mieroassay A n t i m i c r o b A«cnis Che­
mother 35:901-909 
8 C h a n g , H . R., and J . F Pechère. 1988 In v i t ro effects o f fou i 
macrohdes ( r ox i t h romvun spi ramvcin a / i l h romvcm [CP-62,991] 
and A 56268) on Toxoplasma gondii A n t i m i c r o b Agents Che-
mother 32:524-529 
9 C h a p m a n , Л . 19K1) Ft iologv ot acute renal fai lure in adult pat ients 
ρ 47 57 ¡η Л С hapman (ed ), A c u t e renal fai lure C h u r c h i l l 
I iv ingsione L t d L d i n h u r g h 
10 D a t i l a . I ) . , L. k o l a c n v - B a b i c , a n d F. Plavsic. 1991 Pharmacoki­
netics o l a/ i lhromyem alter single ora l dosing o f exper imental 
animals B i o p h a r m D r u g Dispos 12:5tl*>—514-
11 D e r o u i n , F., J . N a l p a s , and C. C h a s l a n g . 1988 Mesure in v i t r o de 
I ei let inh ib i teur di. macrohdes l incosamides et svnergcstines sur 
la croissance de luwpiasma gondii Pathol Bio l 36:1204-1210 
12 Dem, J. , M . Le ma r, A. F r v d m a n , a n d J . G a i l l o t . 1985 A u t o m a t e d 
H P L C d e t e r m i n a t i o n of spiramvcin by direct injection o l plasma 
using column-switching for sample clean u p J C h r o m a i o g r 344: 
275-285 
H Forest ier , F., F. Daffos, M . R a i n a u l , J . F. Desnoties, a n d J . C. 
G a s c h a r d . 1987 Suivi thérapeut ique f o t i o m a t c n i L l de la spiramy-
cine en cours de grossesse A r c h г т Pedialr 44.519-^44 
14 F r y d m a n , \. M . , Y. I * Roux, J . F Desnoties, P. K a p l a n . h 
D j e b b a r , Α. C o u r n o l , J . üuch ie r . and J Ga i l l o l . 1988 Pharmaco-
kinetics ol spiramvcin in man J A n u m i c r o b Chemothe i 
22(Suppl B) :91-101 
15 ( , ϋ π η , J . P., J . P i l l e r a i , M . A. M a i l l a r d . R. Woehr le. and Hezc¿. 
1968 Bases théor iques de la prevent ion par la spiramvcme de la 
toxoplasmose congenitale chez la femme enceinte Presse M e d 
76:2266 
16 ( ¡a r tne r . H 19*>6 Recherches sur 1 act ion de la spiramvcme m ι nm 
comparée a celle d autres ant ib iot iques A n n Insi Pasteur 91:112-
.122 
17 G i b a l d i . M. , and D Fe rne r . 1982 Pharmacokinetics 2nd cd 
Marce l Dekker Ine New Y o r k 
18 Gladuc, K. P., G. M . B r igh t . R. F.. Isaacson, and M . I . Newborg. 
1989 In v i t ro and in vivo uptake o f a / i l h romvc in (C Ρ 62 991) b\ 
phagocytic cells possible mechanism ol delivery and release at 
sites o l i n l e c l i o n A n t i m i c r o b Agents ( he m o l l i c i 33.277-282 
19 H a r f . R., G Panteix, J . F Desmates. N. D i a l l u , and M Leclcrcq. 
1988 Spiramycin uptake by alveolar macrophages J A n u m i c r o b 
C h e m o t h e r 22(Suppl B):115 14(1 
20 H a r r i s , C . M P. Salgo. Η. В. U n o w i U . a n d M . W i l t n e r . 1988 In 
v i t r o assessment o l a n t i m i c r o b i a l agents against Toxoplasma 40ц 
du J In lect Dis 157:14-22 
21 k a \ i . J . . J M . Webberlev, J . M . Andrews, and R. Wise. 1988 A 
compar ison o f the pharmacokinet ics and tissue penetrat ion o l 
spiramvcin and erv thromvein J A n l i n m r o b С h e m o i h e r 
22(Suppl B); 11)5-110 
22 K e r n b a u m , S. 1982 La spiramvcme ut i l isat ion en thérapeut ique 
humaine Semm H o p Pans 5:289-297 
21 Kucers . Α., and N. M Bennett. 1987 I h e use o l aruibiotics ρ 
881-892 W i l l i a m I l e i n e m a n n I o n d o n 
24 M a c F n r l a n e , ) . \ , Α. A. B. M i t c h e l l . J . M Walsh, a n d J . J . 
Robertson I96S Spiramvcin 111 the prevent ion o l posi-operative 
s t a p h v l o e o u a l i n l e c l i o n I ancel 1 1-4 
25 M c D o n a l d , Ρ J . , and H. P r u u l . 1991 Phagocytic uptake and 
transport o l a z i t h r o m y c i n h u r J C l i n M i c r o b i o l Infect Dis 
10:828-831 
26 M e t z l c r , C. M . , a n d D. L. Werner. 1989 P C N O N L 1 N (3 0) 
Software for the statistical analysts t i l nonl inear models on micros 
SCI Software Lex ington Kv 
27 М о и r o t , D., B. Delcplne, J . Boisseau, and G. G a y o l . 1978 Re-
versed-phase high pressure l i q u i d chromatography of spiramycin 
J C h r o m a i o g r 161:186-188 
28 Osono, T., a n d H . Umezawa. 1985 Pharmacokinet ics o f m a c r o 
lides l incosamides and s t r c p i o g r a m m s J A n t i m i c r o b C h e ­
m o t h e r 16(Suppl A ) : 151-166 
29 Pechcre, J . C. 1991 T h e activity o f az i thromycin in an imal models 
o f i n f e c t i o n Г и г J ( I m M i c r o b i o l Infecí Dis 10:821-827 
К) Pel lerat , J „ a n d M . A. M a i l l a r d . 1958 Fixat ion l issulaire de la 
sp i ramvcme chez le cobaye comparaison avec d autres a n i i b i 
ot iques С R A c a d Sci 247:894-896 
11 P i n n e r t - S i n d i c o , S., L. N i n e t , J . Pre-d'homme, a n d C. Cosar. 1955 
A new ant ib iot ic spiramycin ρ 724-725 In Η W e l c h and F 
M a r t i Ibanev ( e d ). A n t i b i o t i c s annual 19^4-1955 M e d i c a l Г п с у 
c lopedid Ine New Y o r k 
12 Pocidalo, J . .1. , F. A l b e r t , J . F. Desnul les, and S. K e r n b a u m . 1985 
I n t r a p h a g o t v i i c p e n e t r a t i o n o l maerol ides ш wit» c o m p a r i s o n o f 
e r y t h r o m y c i n and spiramycin J A n t i m i c r o b C h e m o t h e r 16 
(Suppl A ) : 1 6 7 - I 7 1 
11 Q u e n t i n , С. F., R. M . Besnard, O. B o n n a r d , R. A k b a r a l y , A. 
B r a c h e t - L i e r m a i n , J . J . Leng, a n d C. Rebear. 1981 F l u d e p r e l i m i ­
naire m v i t r o du passage transplacental^- de la sp i ramvcme 
Pathol B i o l 31:425-428 
14 Ramsey, К. M . , a n d J . W. S. H a m s . 1966 C o m p a r i s o n o f 
uteroplacenta l vasculature and c i r c u l a t i o n in the rhesus m o n k e y 
and man C o n t r i b b m b r v o l Carnegie Insi 38:59-70 
15 R e m i n g t o n , .1. S., and G. Des monts. 1990 I oxoplasmosis 
ρ 89-195 h, S S R e m i n g t o n and J О K l e i n (ed ). l n l e c l i o u s 
diseases o f the felus and n e w b o r n infant t h i r d c d The W В 
Saunders C o , Phi ladelphia 
16 S c h o o n d e r m a r k - V a n de Ven, E., W . M e l c h e r s , W . C a m p s , T. 
Eskes. J . Meuwissen, and J , G a l a m a . 1994 T f f e c m e n e s s o l 
spi l лшуеш for t reatment o f congemia l Toxoplasma gondii mfec 
t i o n in rhesus monkevs A n t i m i c r o b Agents C h e m o t h e r 38*1910-
19K. 
17 S c h o o n d e r m a r k - V a n de Ven, E., W . M e l c h e r s , J . G a l a m a , W . 
C a m p s , T. Lskes, and J . Meuwissen. 1991 Congeni ta l toxoplas­
mosis an e x p e r i m e n t a l studv in rhesus monkevs for t ransmission 
and prenatal diagnosis Exp Parnsitol 77:200-211 
18 Shentag, J . J . , a n d С. H. Bal low. 1991 Tissue d i r e c t e d p h a r m a c o 
kinetics A m J M e d 91;5S-I1S 
19 S m i t h , C. R. 1988 T h e spiramycin paradox J A n t i m i c r o b Che 
m o t h e r 22(Suppl B ) : 1 4 1 - I 4 4 
40 T a k a h i r a , H., H K a l o . N . Sugiyama. S. I sh i ì . T . Haneda, К.. L z u , 
К. К и ma he, a n d R. K o j i m a . 1966 húndame mal studies on acetvl 
spi ramvcin J A n l i b i o t 19B:95-100 
41 T r u o n g , T . К., J . P. G a r i n , P. Ambroise-Thornas, J . Despeignes, 
a n d M . A M a i l l a r d . 1970 Spiramycin m i n i m a l i n h i b i t o r y concen 
tra i ion for two strains o l toxoplasma ( R i l Sabin and ПК 1 y o n ) 
propagated m K B cells Rev Insi Pasteur I yon 3:127-114 
-12 W a l l e r . A. M . 1956 Neue Ant ib iot ika Dtseh M e d W o c h c n s c h r 
81:1992-1997 
41 W a l l e r , A. M . , and L. H e i l m e \ e r . 1975 Spiramvcin ρ 491-494 In 
I I O l l e n M Plempel and W Siegenthaler ( c d ) A n t i b i o t i k a 
Fibel A n t i b i o t i k a und C h e m o t h e r a p e u t i k a I h e r a p i c m i k r o b i e l l e r 
I n f e k t i o n e n . 4 i h cd G e o r g I h i e m e V e r l a g S l u t l g a i l . G c i m a n x 
44 Zeneberg, Α., a n d A. T r o u e t . 1982 Cel lu lar pharmacokinet ics o f 
spiramvcin m c u l t u r e d macrophages A n n I m m u n o l Pans 1331) 
21^-244 
55 

CHAPTER 5 
Effectiveness of spiramycin for the treatment of 
congenital Toxoplasma gondii infection 
in rhesus monkeys 
published in: 
Antimicrobial Agents and Chemotherapy 1994;38:1930-1936. 
57 
Effectiveness of Spiramycin for Treatment of Congenital 
Toxoplasma gondii Infection in Rhesus Monkeys 
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The effectiveness of spiramycin Гиг the treatment of rhesus monkey Fetuses congenital!) infected with 
Toxoplasma gondii was studied. Eight monkevs were infected at day 90 of pregnancy. This is comparable to the 
second trimester of organogenelic development in humans. Transmission of infection »as found prenatali) in 
(he of the eight monkeys by detection of the parasite in the amniotic fluid. Treatment with spiramycin (20 
mg/kg/day in two intermittent doses given intravenously) was started as soon as fetal infection was proven and 
was continued until birth. Nine lu 14 days after initiation of treatment, the parasite was still detectable in 
amniotic fluid samples from tour uf these Ave cases. However, the parasite was del et led only by PC'K and not 
by mouse inoculation. T. gondii was also delected only by PCR in the placenta of one monkey that delivered 
prematurely. Ihis monkey received spiramycin treatment for only 2 weeks. In the four monkeys that received 
treatment for about 7 weeks, the parasite was not present al birth in the placenta nur in amniotic fluid or 
neonatal organs. Spiramycin accumulates mainly in maternal tissues. Although concentrations in neonatal 
tissue were found to be 5 to 28 limes higher than the corresponding concentrations in neonatal scrum, the 
concentrations in neonatal tissue were still 11 to 16 times lower than those found in the mothers. However, no 
spiramycin was found in the letal brains. Early treatment with spiramycin may prevent transmission of 
infection to the fetus but most probably cannot interrupt an existing brain infection, which is the most severe 
outcome ol congenital toxoplasmosis in humans. 
( ongcnitalls acquired Toxoplasma gondii infection can cause 
severe disorders in a letiis such as hvdrocephalus nucroceph-
alus. deafness, or blindness or it ma\ even kail lo letal death 
The risk of sc\cre abnormalities is high when the fetus 
becomes infected during the hrsl trimester ol pregnancy, but 
the rate of transmission is lelaLively low, about \A(r Ihc 
transmission rate increases lo about 60"< in the third tnmcstei 
of pregnanes, where.is ihe risk of severe damage decreases 
(12) Therefore espeuallv early in pregnane treatment ol the 
fetus is mandators to reduce the risk ol severe abnormalities 
I here are several drug regimens available tor the treatment of 
/ gondii infections I he recommendations ol ( ouvieur cited 
by Remington el al (27, 28) are generalis lollowed for the 
treatment of congenital / t^w/" infections Aceoidmg to these 
guidelines pregnani women in whom letal mleelion has been 
proven are treated with p\rimediammo in combination with a 
sullonamide usuallv sulfadiazine This drug icgmicn however 
tan cause side eflects Pvnmethaminc can Lause bone marrow 
depression and hematolomc to\ieit\ (21 27) Al high doses 
teratogenic effects have been found in rats (IS 20) Sulladia-
¿ine should not he adnunisieied during the last month ol 
pregnanes because il incieases the risk ol kerniclerus ( >6) 
The macrolide antibiotic spiramycin is also used as a diug 
against Τ condii This thug is well tolerated and sale in 
pregnanes Couvreur el al lound that treatment of humans 
with spiiamycin leduced the number ot inleLled placentas 
lesuliing in a reduced iisk ol congenital toxoplasmosis (7) The 
elìcci can probablv be explained In ihe high Loncentiations of 
spnamsLin lound in placental tissue ( P U>) HeeausL spira-
C oMisponding aulhoi M.ulini: iddixss Depii t imni ni Meditai 
Miuoniologv l mveisiiv I luspit il Sini R.ulboud Nitmeiien Ρ () 
Иоч'ЖИ (i"sl)() HB NiiriiLüLM Ihe Netherlands IMKUIL " 1 sii Ы4^г> 
I is \\ si) MiCKi 
msLin is thought to Lreate a barrier to transmission of infec­
tion it is given to piesent transplacental passage of the 
parasite in women with a pnmarv infection 
Recent investigations ol transplacental transler ol spiramv-
Lin in ihesus monkevs revealed thai spiramycin not only 
accumulates in the pluLcnta but also crosses the placenta and 
aceumulates in the soli tissues ol ihe lelus (Я|) С onccntra-
iions ol spiramscin in lelal serum were hall ol those in 
maternal serum Whether the levels that aie reached in the 
seium and tissue ol the ktus are eftective is not known 
Ihe low lrei|uenc\ ol congenital toxoplasmosis makes a 
placebo-controlled evaluation ol treatment ol humans with 
spnamsLin impractical luilhermore it is considered to be 
unethiLal to retrain liom lieatment of piegnanl women with a 
pnmarv mlection Ihereloie we have developed a model for 
congenital / »oiuhi mleelion in rhesus monkevs (42) It is 
based on the assumption that humans and ι ht sus monkevs-— 
both having a placenta ol the hemochoiial tvpe (26)—are 
similar with regaio1 to the pioeess ol matemal transmission ol 
the mleelion and (he hausier of anntoxoplasnia drugs lis 
usimi tins animal model we investigated what concenlrations 
ol spitanivcin aiL icaLhcd in leluses and whether these con­
centi.liions are ellcclive in congemtallv inleded Ictuses 
M VII RI M.S WD METHODS 
The evpeiinienis in the present studs were petloimed in 
•icLoidaiice with pioioLols dial have alreadv been described in 
detail (12 З^) Materials and Methods theieloie contains 
oiils bue I descriptions ol the original protocols supplemented 
with nunoi modilicalions 
Monkevs. All monkevs were derived hum the 1 abor.ilois 
Xiiun.ils Breeding L\pu iiiknlal 1 aim ol Shuiule Ciu.ingilong 
Hcl|lllg People s Republic ol С lima Tile temale lllonkevs We к 
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4 lo ι vcars old and weighed 4 ι lo •> ч kg Housing leeding 
and breeding ol Ihe monkeys occurred exactly as described 
betöre (12) 
The studv group consisted of eight pregnant monkevs (CI to 
( X) thai were seronegative tor immunoglobulin G and immu 
noglobuhn M antibodies to Τ gondii before the experiment 
was started Immunoglobulin G and immunoglobulin M anti 
bodies were measured by enzyme linked immunosorbent as 
says (EL ISAs) thai have been described before (12) 
The control group consisted of nine pregnant monkevs (Al 
lo A9) lh.it received no treatment The outcome of fetal 
infection in ihe control group has been described before (12) 
ihe results will be summarized in the present report The 
fetuses and babies of the monkevs from the studv group and 
the control group will be referred to as C,l lo C,í¡ and A tl to 
A,y respectively 
Experimental design and collection of samples, belai infec 
lion was tested HI days alter inoculation ol the mother and 
again at birth in the nine monkeys ol the control group (12) 
For the eight monkeys ol the studv group the protocol lor 
antenatal screening ol fetal infection was extended with the 
introduction ot two additional amniotic punctures 2S and 41) 
days after inoculation of the mothers In addition letal blood 
was sampled from an mlcrplacenl.il blood vessel 41) davs alter 
inoculation to test for parasitemia (12) 
The study design is shown in Fig 1A The eight monkeys 
were inoculated intravenously wilh S X Ut" Τ gondii RH 
parasites at dav 40 of pregnancy (this is comparable to the 
second trimester of organogenelic development in humans) 
At 8 10 2Í and 40 days afler inoculation and during 
cesarean section (70 days after inoculation) maternal blood 
was sampled to test for parasitemia Amniotic fluid samples 
were obtained by puncture 10 2S and 40 days after inoculation 
and tested for the presence ot / gondii to monitor fetal 
inlection At day 160 ol pregnancy a cesarean section was 
performed Amniotic Hind placental tissue and neonatal 
blood were collected to test for the presence of the parasite 
liaby monkeys С, 1 and C,2 were premaiurely born betöre day 
160 In these cases the amniotic fluids were lost to examination 
but the placentas were still available The neonates were 
sacrificed and autopsies were performed The heart brain 
spleen liver and lungs were examined for the presence ot Τ 
gondii 
Processing of clinical samples. All clinical samples were 
tested for the presence ol Τ gondii both by mouse inoculation 
(12) and by nested PCR based on the nbosomal DNA gene 
(10 12) 
Amnione fluid samples were collected in time to monitor 
letal infection as indicated above Six milliliters of mintone 
fluid w is collected at each imniotic puncture Two mice were 
inoculated inlrapcriloncilly wilh I ml of amniotic fluid each to 
lest for the presence of Τ gondii The rem lining 4 ml was 
divided into 1 ml portions and cenlrifuged lor 10 min at 800 X 
e. The snpernatanis were stored al -8СГС unni determination 
ol the spiramycin concentration Ihe sediments were each 
resuspended in 100 μΐ ol physiological salt solution DNA was 
isolated Irom Iwo sedimenls b\ guanidinium Ihiocvanate and 
silica particles exactly as described bv Boom ci al (4) and 
tested bv PC R I he oiher two sediments were stored directly at 
-80°C 
The placenta and maternal and neonatal organs were ho 
mogenizcd in physiological salt solution as described belore 
(Is) and tested lor the presence ot parasites bv inoculation ol 
two mice The protocol lor DNA isolation Irom [issues was 
modified as follows DNA was isolated bv incubation ot the 
tissue in (Ϊ't ρ aminosalicylic a c i d - I ^ Na( 1-10 mM LDTA-
days ot 
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FIG 1 (A) Time schedule ot sample collection during pregnancy 
1 infection 'Л) days ifier conception С conimi of parasitemia AP 
imniotic puncture TBS fel il blood sampling CS cesare in section 
During let il hlood s impling boih amniotic lluid and tela! blood were 
collected During ces ire in section amniotic fluid neonatal hlood and 
the placenta were collected С es irían section was lollowed by lulopsy 
ol the neon ite ind the heart spleen hn in and liver wert obtained 
All simples were tested for the presence of / gondii (tí) Time 
schedules lor the four monkevs in the control group that received no 
treatment Detection ol Τ gondii in the amniotic fluid and/or neonatal 
tissues is indicated bv a plus sign Premature birth is indicated bv an 
arrow and the prcgnancv duiation is given in davs ( *) fetal 
inlection proven b\ demonstration of antibodies in the neonate at 
serological follow up (C) Time schedules for the five monkeys in the 
studv group thai received treatment with spiramvcin Detection of 7 
condii in amniotic fluid is indicated bv Ί plus sien The dav on which 
spiramvcin trcalmcnt was started is marked with a dark arrow 
Premiture birth is indie ited bv a licht irrow ind the ргецпапел 
dur ilion is ці еп in d ivs (-«-) result del ived bv technic il problems ind 
imniohc fluid lound positive it rclesling 
0 ι μι; of proteinase К per ml for 4 h dl M С AIÌLT phenol 
extraction the DNA was precipitateci о егшцЫ al 2()CC One 
microgram ol ihe lissue DNA was tested for the presence of / 
Xomfabx PCR 
PCR. ЛИ DNA samples were testcel for UIL presence of 7 
gondii b\ <t nesied PCR based on ihe rtbosom<il DNA gene 
1 he reaction conditions were the sime as described before 
p 2 ) L\cepl tor the pnmtrset ot the hrst reaction of the nested 
PCR This primer set consisted ol tw-o / gondii specific 
primers which were selected in ihe second variable region 
О IGCC I C r i C C C r G O A A O G C A 1 ) and the fourth van-
able region И GIGTGGAGAAAICCAGAAGG 1 ) ot the 
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ribosomal DNA gene and generated a 54S-bp fragment The 
internal primer set lor the nested reaction was the same as 
described belore (S G T T C J A C T I C G G 1 C TGCGACG 3' and 
ί -TTCCAATCACIAGAAATGAA-3 ) and generated a / 
ewidii-spccihc product of 218 bp (30 32) The fragment was 
blotted onto a nvlon hlter and hybridized (30) with a '-P-cnd-
labclcd oligonucleotide probe (5 ATTCCGGAGAAGGAGC 
CTGA-3 ) as described previouslv (35) To prevent carrvovcr 
contamination, strici spatial partitioning of the ditteicnt steps 
of the PCR was included and the recommendations of Kwok 
ami Higuchi were followed (22) 
Treatment with spiramycin. The effectiveness of tieatment 
with spiramycin was studied in a group of five prcenant 
monkevs (CI C2 C4 Ci and CS) with a proven fetal 
inftclion 
I reatmenl was started as soon as a congenital intection was 
proven bv detection of Τ gondii in the amniotic Huid Treat­
ment was continued until cesarean section οι occurrence ol a 
spontaneous birth The mother was given 20 mg of spiramvcin 
per kg per dav intravenously in two intermittent doses Spira­
mycin adipate (Rovamycin) for intravenous application was 
from Rhone Poulenc Paris France Spiramycin was adminis­
tered intravcnouslv since и was found for humans that coad­
ministration with food can reduce bioavailability bv SOrr (14) 
The dosing schedule was derived both from recommend.) 
tions for intravenous administration of spiramvcin in humans 
(24) and from studies ol spiramycin pharmacokinetics in 
rhesus monkeys (31) Ihese studies revealed that (he pharma­
cological behavior ol spiramvcin in rhesus monkevs was similar 
to that in humans wilh regard lo the maximum concentrations 
achieved in serum tissue distribution, and urinary excretion 
As expected lor small animals the serum elimination hall hie 
was lower than in humans 
Determination ni antibiotic concentration!). The concentra­
tion of spiramvcin was determined bv a bioassav In brief the 
spnanivcin concentration was determined bv diffusion m 3 ' , 
Dilco agar medium no 11 (Brunschwig С hernie, Amsterdam 
The Netherlands) pH HO with Saiaiia luna АТС С 9341 as 
the lest organism A stock suspension of S Ішеа was diluted 
with distilled water to a test suspension with <m optical density 
at 630 nm of 0 21 The agai medium at s04 was inoculated 
with 1r( of the bacteiial suspension and subsequentlv ponied 
onto a plate on a Hal surface Inhibition zones were ineasuicd 
after incubation at 4fQ for IK h Spiramvcin coneentiations 
were determined in maternal blood fetal blood amniotic fluid 
the placenta and organs (heart spleen liver and brain) of the 
mother and neonate The blood was cenlrifuged at XIX) x g lor 
10 mm The concentration of spiramvcin was determined in a 
100 μ| sample of cilhcr maternal serum fetal plasma or 
amniotic fluid One gram of tissue was homogenized in 4 ml ol 
phvsiologic.il salt solution and clanlied bv centnfugation at 
1000 X £ for 20 mm Λ 100 μ| volume ol (he supernatant was 
tested for the concentration ol spiramycin per gram ol tissue in 
the bioassav 
Statistical evaluation. Fishers exact test lor comparison ol 
proportions was used to compare the infection probabilities in 
the studv group that received spiramvcin and the control 
group Furthermore SO and Уо'г confidence intcrv ils weie 
calculated lor an mlcction-lrcc outcome of theiapv The 
confidence intervals were based on a binomial disti ibution (2) 
RESULTS 
Maternal parasitemia tli.it lasted lor about 10 davs was 
observed in all eight monkevs of the siudv group and the nine 
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monkevs of the control group Tin. ρ irasitcmi ι was delected h\ 
mousL inoculation and PCR 
As described πι our forint г it-port Τ ЦОІЫІІІ и.is delected 
antcnalallv in thru of the nine I I lu se s ol ilie control group 
(A,6 A,Js and A/J) (Я2) Al birlh lour kuise·» wca lound u> 
bc congenilallv înltcted I hree inlections were diagnosed In 
detection ol ihe parasite m the ammolli fluid or neonatal 
organs (A,ft A,7 and A,1)) and the fourlh was diagnosed h\ 
anlibodv production bv the neonate (monkev A,h) These 
results were extrapolated to the outcome ol the present studv 
lor estimation oí the efteet oí treatment I he contiol group 
results are shown in big IB and I able 1 
Prcnatallv Τ gondii was found in the amniotic fluid oí five of 
the eieht monkevs of the studv eroup (( ,1 ( ,2 С ,4 ( ,> and 
C,<S) All hve cases of transmission were detected hv P( К 
Mouse inoculation was positive onlv in monkevs С ,2 and ( ^ 
(Tabic 1 ) Tiansmission of infection occurred in fou ι of the h\c 
C.ISLS within 10 da\s after inoculation of the mother In monkev 
С I infection of the Ictus was de le e led afte ι 2^ da\s (Fig 1С ) 
Tigure 2 shows the PC R result obtained with samples I rom this 
піопкіл 
Піс Inst amniotic fluid sample collated ihoul 12 (range У 
to 14) davs aftei onset of Ire Ument was still positive bv PC R 
lor monkevs C, 1 С
 t2 С ,4 and C,^ (Tig 1С) \l this unie 
mi tust inoculation w is пец Hive loi .ill fivi_ L ises ( 1 ible 1 ) 
At birth the p.u.isilL was delected hv PC К in the placenta ol 
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FIG. 2. Ethidium bromide-stained gel showing amniotic fluid sam­
ples and the placenta of monkey ( Ί tested by nested PCR based on the 
ribosomal DNA gene. Lanes: 1 and 2. amniotic fluid collected on day 
100 of pregnancy: 3 and 4. amniotic fluid collected on day 115 of 
pregnancy: 5 and 6. amniotic fluid samples collected on day 130 of 
pregnancy: 7. placenta obtained after premature delivery on day 133 of 
pregnancy: 8. amniotic fluid (negative control); 9, distilled water 
(negative control): 10, 10 ng of T. gondii DNA (positive control): 11. 
DNA si/e markers (l(K)-bp ladder). 
monkey CI (Tabic 1). This monkey delivered prematurely 
after a pregnancy of 133 days and was treated for only 15 days 
(Fig. 1С). T. gondii was not found in the placentas of the other 
four monkeys nor in any of the organs of the baby monkeys, 
including the premature one (monkey C',1). /. gondii was also 
never found in the fetal blood sampled 40 days after maternal 
inoculation. Statistical evaluation of these results revealed that 
the probability of fetal infection in the period from 100 to 100 
days after conception in the study group was not significantly 
different from that of the control group (Table 2; Ρ = 0.64). 
The null hypothesis of equal infection probabilities was not 
rejected. Given fetal infection, the probability that the infec­
tion would still be present at birth was lower in the study group 
than in the control group (Table 3: Ρ - 0.048). The confidence 
intervals for the outcome after treatment were calculated for 
this small number of animals. The 80% confidence limits were 
0 to 32%, and the 9Уг confidence limits were 0 to 50%. 
Four amniotic fluid samples per monkcv were collected over 
time. For the eight monkeys of the studv group, this made a 
total of 32 amniotic fluid samples. These 32 amniotic fluid 
samples were tested in duplicate for the presence of T. gondii 
by mouse inoculation and by PCR. When tested by PCR. a 
discrepancy was found in only 3 (9.4%) of the 32 samples 
tested in duplicate. In contrast, only one of the two amniotic 
fluid samples was found positive by mouse inoculation in all 
cases. 
Spiramycin was found to cross the placenta and to accumu-
TABLE 2. Probability of fetal infection in the study and control 
groups in the period from 100 to 160 days after conception 
Infection 
Yes 
N o 
Total 
Stud\ group" 
5 (63) 
3 
8 
No. ir' 1 in 
С tin! rol group' 
4 (44)' 
5' 
' Treated with spiramycin 
'' Noi treated 
:
 \> - 0.64. 
TABLE 3. Probability that the infection will still be present at birth 
in the study and control groups 
Infection 
Yes 
No 
Total 
Study group"1 
11(11',) 
5 
5 
No (' , ) in 
( ontrol group'' 
3(75%)' 
1' 
4 
" Treated with spiramycin. 
h
 Not treated 
' /> m (1.(14«. 
late in fetal tissues, but no spiramycin was found in the brain 
(Table 4). The highest neonatal concentration was measured in 
the spleen and was found to be 28 times the concentration in 
neonatal serum. The mean concentration of spiramycin in the 
placenta was 3.04 ± 0.87 μο/g (Table 4). which was similar to 
the concentrations reached in the neonatal spleen and li\er. 
These concentrations in (issue, however, did not reach the 
levels in maternal tissue, which were found to be 11 to 16 times 
higher than in the neonates. 
DISCUSSION 
Studies with mice have shown that treatment with spiramy­
cin can prolong survival after lethal infection with T. gondii 
when spiramycin is given in doses of 400 to У50 mg/kg/day. 
Spiramycin, however, fails to eradicate the parasite from the 
host (f, 15. 24. 25). The concentrations in serum and tissue at 
which this prolonged survival has been found are not known. In 
addition. Beverley et al. (3) have shown that treatment with 
spiramycin reduces the number of T. gondii-inúuceú focal 
inflammatory lesions in mice. Although they reported spira-
mycin concentrations in tissue, the concentration in the brain 
was not determined (3). The concentrations found to inhibit 
growth of the parasite in vitro vary from 20 to 250 μ^ιηΐ, but 
even high concentrations do not kill the parasite (5, 6, 10, 17, 
34), 
In a study of humans. Desmonts and Couvreur (11) found a 
reduced frequency of congenital infection in women treated 
with spiramycin. This study was. however, hampered bv a lack 
of sufficient matched control patients. In a later study by the 
same investigators (7). a reduced frequency of placental infec­
tion after spiramycin treatment was found compared with an 
untreated control group. In these studies, the decision to start 
treatment was based upon serological conversion of the 
mother and not on transmission of infection to the fetus. 
Whether spiramycin can cure an already infected fetus is not 
known, but data show no effect of spiramycin treatment of a 
pregnant mother on the severity of manifestations in the fetus 
(27). 
In the present study, treatment with spiramycin was not 
started until congenital infection was proven. The PCR has 
been used to prove fetal infection. With the PCR. a result can 
be obtained within 2 or 3 days after receipt of a clinical sample. 
This provides the possibility of a rapid test result and an 
informed decision regarding treatment. 
I-rom the results it can be concluded that spiramycin is still 
effective on T. gondii after transmission of infection has 
occurred. Only in case of the premature delivery of monkey CI 
was T. gondii still present at birth. The parasite was found only 
in the placenta. This monkey, however, should be considered 
not to have received adequate therapv since the mother 
received spiramycin for only Id days. This argument is derived 
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Irom Couvreur el al (7) who considered women run lo have 
bien treated if thev received spiramycin for less than l^ davs 
Monitoring ol letal inleuion b\ sequentiell testing ol amni 
otiL fluid samples revealed lhal spiramycin does slowlv reduci, 
the amount ol I цотіп in the host, the parasite was still 
present in the amniotic fluid aboul 12 da\s alter imitation ol 
treatment in four of five cases However Ihe parasite was 
detectable onlv by PCR and nol by mouse inoculation This 
mas indicate that spiramycin treatment reduces the parasitic 
load and that the reduced number of parasites cannot be 
detected bv mouse inoculation because this method is nol as 
sensitive as nested PCR A lower sensitivity of mouse inocu­
lation was also lound with amniotic fluid samples collected 
betöre treatment was started onlv two ot h\c PCR-posiuvc 
cases were positive by mouse inoculation (monkeys С2 and 
( ^) In 2U (90 err) ot 12 cases both amniotic fluid samples 
were tound to be positive bv the PCR at duplicate testing 
whereas only a single sample was tound to be positive by 
mouse inoculation This finding supports the sensitivity and 
rcproducibilitv of the PCR 
In our previous report however wc stated that the nested 
P( R was as sensitive as mouse inoculation (12) The detection 
ot parasites killed h\ treatment with spiramycin mav be t 
second explanation tor ihe detection bv PCR and not bv mouse 
inoculation However Chang and Pechere demonstrated that 
m.icrolidcs have an inhibitors effect but no killing effect on Τ 
^ІЧІІІИ (6) Moreover parasites were still viable after thev had 
been incubated with macrohdes and subsequently subcultured 
in medium free of drugs Since transmission of nonviable 
parasites is not likclv to occur the finding of Τ gondii in the 
amniotic fluid indicates that Ihe fetus had been infected 
Detection of Τ gondii by PCR is therefore of clinical impor 
lance although the PCR cannot discriminate between viable 
and dead parasites 
Ihe outcome ol letal mietitori in ihe tontrol group lhal 
received no treatment has been described belore (12) This 
control group therefore seems to have a historical character 
Statistical analysis ol the data revealed that Ihe transmission 
rale in the control group was nol significantly different Irom 
lhat in the sludv group This provides support for the use ot 
this historical control group 
When monkeys with a congenital / gondii iniettimi received 
no treatment parasites could be isolated at birih in three of the 
tour monkevs In contrast no parasites were tound in the five 
monkeys treated with spiramycin Statistical evaluation re 
vealed lhal this finding was significant 
The absence ot parasites trom tetal blood cannot be attrib­
uted to spiramycin treatment because tetal parasitemia was 
never tound in the untreated monkevs Monitoring ot fetal 
parasitemia is impeded bv the limitations of fetal blood 
sampling m rhesus monkevs Fetal blood sampling can be 
pei formed onlv once or occasionally twice because rhesus 
monkevs possess a limited number of intciplacent.il blood 
vessels and disturbance ol the fetal blood circulation increases 
the risk of abortion 
In the human situation parasites could still be isolated from 
the placenta despite treatment with spiramycin (7 11) Isola 
tions of parasites Irom the placentas of treated monkeys wert 
alwavs negative The difference tannul be attributed In the 
concentrations of spiiamvcin lhal can be reached in the human 
placenta since these equal those lound in rhesus monkeys (11 
16) Ihe isolation ol parasites Irom the placenta can probablv 
be explained b\ lile préseme ol cvsts in tissue which arc not 
susiepliblc to spiranncin treatment 1 ht sirulcnt Тохоріаьпиі 
strain RH that was used probablv docs not lorm tissue cvsts in 
rhesus monkevs 
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The ihcr ipcuiic benefit of spiramvcin isprohablv not limited 
lo the action of the antibiotic within the pi icenta as suggested 
bv Dcsmonts ind Couvreur (11) РгечитаЬК it ilso has an 
effect in letal tissues where n reaches concentrations that arc 
similar to thosL found in the placenta The present studv and a 
previous studv on the pharmacokinetics of spiramycin in rhesus 
monkevs (Ή) show thai spinmycin does not enter the brain 
Since brain d image is the most severe aspect of congenital 
toxoplasmosis spinmycin is not the therapy of choice Infec 
lion of the brain was not found in rhesus monkeys probably 
bee iusc letal infection was induced not earlier than during the 
second trimester of pregnancy However the possibility ih it 
spinmycin does enter the brain if severe inflammation is 
present cannot be excluded Inflammation of the brain might 
expl un ihc low eoneentr Uion of spiramycin found in the br 1111 
ol monkev ( 4 The f iet ihat spiramycin hardK diffuses or does 
not diffuse into cerebnl tissue also explains the lailure of 
spiramycin to prevent neurotoxoplasmosis in immunosup 
pressed patients (24) Antitoxoplasma drue.s that cross the 
blood brun birrier such is pvrimethamine are more appro 
pri He Studies with hum ins h ivc proven in И tre itmcnt with 
pvnmeth minie ind sulfadiazine decreases the number of cases 
of severe continual toxoplasmosis (8 9 19) The women in 
these studies however were also treated with spmmvcin 
throutïhout precnincv It is not known to what extend spiri 
mvcin inllueneed the outcome of the studies 
Therefore the effectiveness of combination thinpv with 
pvnmeth imme and sultadi izine is currently being investigated 
with our model for congenil il Τ gondii infection of rhesus 
monkevs In iddition the concentrations ot pyrimethamine 
ind sull idi ілпс in the mothers ind fetuses will be determined 
Under the present experimental conditions it is shown that 
spinmycin does hive τη eñecl on congenital Γ gondii infec 
lion The pansilemia which has been experiment lllv induced 
by mtnvenous infection with virulent strain RH с innol be 
uimpired to Hie η i h m ! situation in which an inleclion is 
І(Л|ІІІІЧЛІ by ingestion of cysts or oocysls ot other sir uns 
I lowever the results indicate that e irlv ireitmcnt with spir ι 
mvcin Ins ι benelicnl effect on ínlecled fetuses Our results 
ind those ot Couvreur el al (7) show ι reduction in the 
number ot intecled fetuses iftcr spiramycin tre-itment I hesL 
results lieue in favor of ireTtmcnt with spir imvcin as lom. is 
Iht Ictus h is nol been infected These findings ierce with the 
notion ili it spnamvcin should be used to prevent fetal mice 
lion is soon is toxopl ismic sLroconvcrsion is discovered in ι 
prc_n nil worn m (27 Tl) The hndincs also f i\or serologie il 
sLTeenniL m ne is with ι hitm incidence ol ¡oxophisnui inlec 
lions m piecn incv Lxcept in Fnnce serologie il screcninu ol 
premi ini women is nol roulinelv performed In practice 
thcrelore most cases ol contienital infection ire diiRiiosed 
when ir iiismission ol inleclion to the telus his tire id\ oc 
curred \ prolonged interv tl between onset of infection ind 
unti ilion ol tie itmcnt seems to result in a more severe tel il 
inleclion ( 19) This implies th и in most cases ire iinieni with 
spmmvcin will be started too lite to be effective 
In conclusion the eoneentr liions of spiramvcin re iched m 
Ictuses h ive been shown to be effective ilthoimh ihev do not 
e£|u il the cotiLcntr liions found to be effective in vitro Spi ι ι 
mvcin most likelv ι educes the ρ inside loid However spin 
mvcin mosl prob iblv docs not enter the brain Therefore 
tie liment with spinimeli! will be preventive г itile, г thin 
tiler ipellllC 
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Study of Treatment of Congenital Toxoplasma gondii Infection 
in Rhesus Monkeys with Pyrimethamine and Sulfadiazine 
ESTHER SCHOONDERMARK-VAN DF VEN,'* JOEP GALAMA.' TOM VREE." WIL CAMPS,' 
ITA BAARS,2 TOM ESKES,' JOFP MEUWISSLN.' AND WILLEM MELCHERS' 
Department of Medical Microbiology, ' Department of Cluneal Pharmat v, ^ anil Department υ) Obstétrica and 
Gynecology,^ Academic Hospital Stut Radboud' Nijmegen Nijmegen The Netherlands 
Received 9 August 1994/Relurned lor modification 22 September 1994/Acccpted 2S October 1944 
The efficacy of the combination of pyrimethamine and sulfadiazine for the treatment of congenital Toxo-
plasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and sulfadi-
azine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions 
of both drugs followed a one-compartment model. The serum elimination hair-lives were found to be 5.2 h for 
sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in scrum of 58.7 
μg/ml, whereas a maximum concentration in serum of 0.22 μg/ml was found fur pyrimethamine. Ten monkeys 
were infected intravenously with Τ gondii at day 90 of pregnancy, which is comparable to the second trimester 
of Organogenese development in humans. Treatment was administered to six monkeys, in whose fetuses 
infection was diagnosed antenalally. From the moment that fetal infection was proven, the monkeys were 
treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of 
sulfadiazine per kg of body weight per day orally. The therapy was supplemented with J.5 mg of folinic acid 
once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in 
the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, Τ 
gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four 
untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal 
serum varied from 0.05 to 0.14 μg/ml for pyrimethamine and from 1.0 to 5.4 μ^ιηΙ for sulfadiazine. In addition, 
pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times 
higher than the corresponding concentrations in serum. I hirly percent of the sulfadiazine was round to reach 
the brain tissue when compared with the corresponding serum drug concentration. When administered early 
after the onset of infection, the combination of pyrimethamine and sulfadiazine was clearly effective in reducing 
the number of parasites in the fetus to undetectable levels. 
A congenially acquired Toxoplasma gondii infection is gen­
erally treated with the combination of pyrimethamine ,ind sul­
fadiazine (37) Both components arc inhibitors of fol.ile me­
tabolism, acting syncrgistically to suppress the proliferation ol 
the parasite by indirect impairment of DNA synthesis (16. 48) 
Several studies in mice revealed th.it the combination ot 
pyrimethamine and sulfadiazine reduces the parasitic load and 
prolongs the survival of mice after infection with a lethal dose 
of Τ gondii (14 31 Я2) Studies on the effectiveness of py­
rimethamine and sulfadiazine for the treatment ol congenital 
7" gondii infections in humans however, have been scarce 
Those studies that have been reported in the literature are 
from France (10. 11. 20) Those studies described the effec­
tiveness of treatment with pyrimethamine and sulfadiazine af 
ter fetal infection had been proven The studies revealed that 
in utero treatment significanti) reduced the number of infected 
offspring with severe toxoplasmosis In addition, a relative de­
crease in benign to subclinical torms ol infection was found 
However, several ol the offspring were still found to have 
intracranial calcifications or retinal scars which developed into 
chorioretinitis (10. 11 20) It is not known whether these find­
ings were due to the fact that the onset of treatment was 
started too late after fetal infection or whether the concenlra-
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lions ol pyrimethamine and sulfadiazine in the Ictus were too 
low to be effective 
On the other hand the effects described by the Trench 
investigators (1(1. II, 20) cannot solelv be attributed to pv-
rimethamine and sulladiazine. since all patients were also 
treated with spiramycin throughout pregnancy, from the mo­
ment that maternal infection was diagnosed or suspected An 
effect of the antibiotic cannot be ignored A former studv in the 
rhesus monkey showed that spiranncm reduces the parasitic 
load to undetectable levels in congenilally mleued leluses 
(40) Therefore some ol the effects m the French studies mav 
have been caused bv spiramycin 
In the present study the effieacv ol puimelhamine-sultadi-
azine was investigated in infected rhesus monkev fetuses while 
treatment was started carlv after the onset of fetal infection 
Besides this, studies of the pharmacokinetics of these drugs 
were performed in this animal species tor precise determina 
lion of the dosage regimen Although extensive studies have 
been performed on the pharmacokinetics ol both p\-
nmethaminc and sulfadiazine in a \anet\ ol animals little is 
known about the phaimacokinetics ol the drugs in rhesus mon­
keys The disposition of sulfadiazine has been investigated in 
voung rhesus monkevs of 0 5 to I 5 vears ol age (29 M\) 
However results obtained in immature monkevs mav be of 
limited relevance to adult monkevs as has been found in pigs 
(Is) The kinetics of sulladiazine in adult monkevs have not 
been reportetl The pharmacological studies ol pyrimethamine 
in rhesus monke\s in behmidl et al p 8 ) locused maitilv on 
tissue localization 
66 
In the present study the k i n c l u parameters of py 
rimein.iminc and sunauiazim. were determined in adult mon 
kevs recerune a drug regimen that is applied lo hum,ins for the 
treatment of congenital Τ gondii infections hollowing this 
transplacental translcr and the distributions ol the drugs in 
tissue were investigated in pregnant monkeys The effects of 
the treatment are related to the concentrations of py 
nmethamine and sulfadiazine that are reached in the fetus 
day of pregnancy 90 9Θ 100 
day· or 
pregnancy 
AP 
115 
AP 
130 
CS 
160 
160 
monkey A6 
Λ io 
MATERIALS AND METHODS 
Мопке ь All monkey. were derived I rom the 1 abor itnrv Arum,К Breedim. 
Lxptnmui ia l F irm »t Shundi GumLilnnL. Bujme People s Republic M t hin ι 
BrecdiiiL, oi ihe monkevs ind unni il с ire hive heen deserihcd hi tor«. (41) 
T i n trcitment Lroup consisted ol 1(1 limale monkevs (monkevs Dl to D i d ) 
thai were seroneiMtivc lor intibodies to Τ contili he fore I I K experiments « u i 
snrtcd \ uroup ol tour unire ned monkevs (minkLVs Ah io ЛЯ) in whose 
fetuses infection li id hu.η proven s m u l as controls I hiv (.ontrol L.rnup li is 
heen described in del ni bifore (41) I lu purpose о Γ ihe lormu sludv w is to 
investit i u whither the rhesus rnonkcv w is ι suit lble dnim il lor usi m the siudv 
ot сопслпіПІ / gondii infections (-11) In nddition we n i l irit to use this group ol 
monkivs l i u n t n i t id lontniK The outcome ol letal infection in the contri I 
group is summ іпллі in this report T h i fetuses and bibles of the monkevs i r i 
indicated bv D 1 m 15,1(1 tor the ire ilmcnt ..roup ind \,<i lo A,9 for i h i t o n i m i 
group 
T h i ph irrmcokinencs of pvnmclh mime and sulf idia¿iin w i n studied in iwo 
nonpTiL.ua ni monkevs (monkivs t- ind H a f u r oral ulmmistntion ol a sinc.li 
dosi ol 1 mg of pvrimcihamuu pLr k(, ofhodv w i n j i i in innihin mon with M) mi. 
ol sulfadiazine p i г kc. ol hod) weight 
Pharmacokinetic studies with two nonpregnant monkevs T i b k l s ol pv 
nmelh imui i ( l ) i r i p n m ) were uhi lined horn Wi l lcomi Ph irm leeiitic ils 
L i r n l i l Thi Netherlands ind capsules lonmnin^sulfadi і л і п w m provided h\ 
i h i Depirtment ol Clime il Pharm uv of i h i University Hospn il Nijmegen 
Sulfndia/mi wis ohlamed horn i h i Onderlinge Pharm κ etnische Groothandel 
(Utrecht The Netherlands) 
The ph irm i inki inhcs ol pvnmitllamiiic nid sull idi izine w i n sludud in 
nonpriLiiant monkevs | ind F tiler oral idminisirahon Ol l mg ol p\ 
n m i i l i ш и ш per kg in combination wiih 1^1 nm of sulfidia¿ini pu kg Th is i 
elusale s wire e hitsen bee ausi the ν ire normallv used Ю i r i it inneemt tl Τ gondii 
indelions in hum ins ( Ί 7 1-1 17) 
Pulverized pyrimethamine ind sull idi слпс w m hidden m a sm ill hole within 
ι I IGA hiseuit ( ( . u n n i Biscuits Nelle ri ind BV Rozend ι il The Ne the ri nuls) 
e o v i n d with ninniel ide or in J ми til p i n i ol b in ana ind t h i monkevs w e n 
Riveli llie lood 
Blond simples t. f ^ ml win. eolketed from the vena medi m i jlisi before ind 
it 1 2 λ 4 •> 6 7 X 1(1 Ρ 24 АН 72 ind Чп li d u r driiL idnimiMraiion TIn 
blood simples wen centrilui,ed ai KIM >- с loi l i l min I he sen were collected 
ind stored at "41 С until inilvsis 
Experimental design and col lei tum «Г clmicul samples A (mu schedule ol 
simple collection is shown in T I L IA \ I <, »ulti infection vv is induced in i h i 
monkevs it dav 41) ol pregn nicv 1 he time point ol inlection is comp ir ibk to the 
second trimester ol ort, itioiAiictie development in hum ins The infection wis 
induced bv intr iveiious in imi mon ol ι x ID tachwoitcs of 7" gondii (RH 
strain) M i t c i n i l ρ i n s i l i m i ι was usUi l lor К tl ivs i l t i r inoculinoli ol i h i 
monkevs it mini tie punctures and it the t i m i ol delivers bv ces ire m section 
is described helore In brief ill clinic il s imples (blood imniotie lluid pi icent ι 
ind Ut il tissues) were Usted lor the p r i s i n c i ol 7" gondii bv inocul Ilion of mice 
(44) ind bv m s u d PC К ( U 4|) 
Γι ΐ il infection in the control gn up w is tested 111 d ivs i l t i r ι noe u I ition ol ihe 
mother bv ex шип mon of lelal b l ind ind шпионе fluid The lr insmission ot 
m f i i i i n n w ise\ iminid n u n il bul l i bv l isting the immoll i fluid nul Ihe blood 
ind tissues )l the neon lies (hii. І И ) ( 4 І ) 
Ί ο monitor Ihe e lle.il ol (re ιίπηηΐ du г mu pre μ ι mev two iddilion il s im pk s 
obt lined hv immol l i p u i i i l i i n win. included in Ihe protocol for thi i n п и ш и 
Lroup \mnioiic fluid s imples were lliiis obi mied it 111 2"» and-lOdivs i lk г 
inocul ition ol Mie nioiliei (І IL. 1С) \ ees ire in section w is piMornud il d IV Kill 
ol pr imi nicv which wis ihoul И) d i\s beton the expelled d ile ol dcliven 
Ammoll i Huid pi teenl il lisine nul nenn и il Ы І К П І Ігопі llie umbilic il cord were 
c n l k i t i d ind listed foi t in priseiiie ol Г condii The mothers md neon i t e 
were s unf i led did lUtopsies were perlornnd Ihe he iri hr un spleen Іі ц 
ind l i int^wcie ix i i l i i i led Ini (he pi isei lci ol / ^ nulli 
Pr<Kessiii|! пГі ІмшаІ sumples The p t n t n m K l o i the proeissun ι I t in eluin tl 
simplet 11 ivi h u i l described in del il pievi uislv (41) 41 44) In briel (> ml ot 
imniolie fluid w is collected il <- ich immode punclure |w<i iniee w i n e n i l 
intH.nl lted l l l lr iperiloile illv willl I ml ol immoll i fluid Ι ι UM lor lile píese нее 
Ol / с indu Tile re m ι ui un. 4 ni w |ч divided min |ЦігиопміІ I nil e ich niel e ie h 
portion w is u n i d l o ..il it MUI > e 'or III nun I In sediments H e ich роіінчі 
wire lesiispended ui ΚΗΙμΙ ol phvsi i|nt,lc il s i l l solution Γ Α A w is isnl lied II mi 
two ρ niions with L.U inidnmim ill it iv in Hi md siile ι ρ Hides es ìellv is ile 
sell imi b\ Boi m et il (( ) I Ile fe 11 mine, m i pi ΠΙ Ч . Were si fed 11 MIC 
- (• ) 
159 
v
 day of 
pregnancy 
•nhey DB — 
è 
4 
* 
4 
102 
102 
102 
102 
h i d Ι (Λ) Time schedule ol simple collection during pregmncv I infec 
lion s'il d ivs after conception ( collection ol iniUrnnl blood for control of 
p i r t s i t e m t i AP mimoiic puncture FDS fetal hlood simpling CS delivery by 
ее s ire in se e lion Π ι ιπ ικ letal blood samplint both imniotie fluid and Ie lal blood 
were collected During deliverv bv c t s i r c i n section amniotic fluid nconanl 
blood ind the phccnla were ct Heeled Delivery bv cesarean seel ion wis fol 
l i w i d bv uiiopsv of the neon Me ind the heart spleen br im ind liver were 
ibi lined \ l l s imples wife testet! for the presence ι I / gondii (U) Results for 
t in lour monkevs m t in control Ljoup ih it received no i m l m e n t The detection 
ol / gondii in I In imniotie fluid ind or neon il il lissins is indicated with a plus 
su.il A pre m itine birth is indie lied hv in urow ind the dur mon оГ ргц_п inev 
le t i l mtection proven bv llie demonstr ition ol intibodies in the neon He at 
su l o j j c i l follow up (C) Results for the six monkevs in the skid) group that 
wire treaicd with puimi lhammc sull idi izinc The detection ol / condii in i h i 
imniotie fluid is indie lted with ι plus SIL.II The d u s it which treatment with 
pvrimeth iminc suit idi i?me w is started He marked with arrows 
The pheei i l i ind ш о п it il ог^. ins weie liomoge nized in physiologic il suilt 
solulion is elescnbid bifore |4d) bach simple w is u s u d m duplicité for the 
presence ol pinsitesbv іпоші ilion into mue DNA w is iso) lied I rom ihe tissues 
In mcub ilion in ίι*" μ immosilievlie ind l r< N i C I - I H m M Ю Т А wnh 0 "» μ ι . 
ol proieinise К pei ml i l 17°( lor 1 h Alter phenol емг iction the DNA was 
preeipil lted overnujn il - ΊΠ С One niietoer im of Ihe tissue DNA w is usted 
lor the presenil ol / gondii h\ ι i lesini P( R on the π bosom 11 DMA Lene as 
described I K Ime (W 41) 
Treatment with pvnmelhanune and sulfadiazine h c i i m e n t with py 
ι inn th imim ind siili uh i/im w is si i r t i d is SIHIII is еопцеші il ink с lion WHS 
proven bv de lee lion ol ihe ρ ir isite in (he immoll i fluid ind W is continued until 
the mothci e. iv i hirlh I г insmissioil ol m i n i u m incurred in ft ol ihe 10 monkevs 
ol t in i n u n u m u o u p (monkivs ir» |>ì |)(> D7 D(> md DIO) Theetì ieicvol 
p\ι lincili ninne sull idi i/uie w is studied in these siv monkevs I he monkeVs were 
lie iled ot illv with I MIL ol pvi mie ih minie per K L I I iv ind s(l m¿ ol sulf idi tzine 
| x i k¿div T in drues wen idii i inistetid is eliserilKil ibovi in the чШОЛ c>n 
ph irm icokiiielie stuelies In iddilion (olimi nul ( 1 *> mu) wis idininisUrid 
or illv onci ι WLLk in order le» eouiltel iel llie boni m irrow suppression e lUSed 
tn pvi innt l i шипе ( 7) The co >kies uni b Ш in is eontauiim. the drilLs were 
Iw ivs ι m π e Igerlv nul lile e n n p k t i dose w |s consumid Iwo monkeVs I ) ì 
lid I ) ) lelused l lu lise ι lile 
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Ioxit bidt ι Huts as a ri.su It ol Mn. t r i d i m m i were monitor i l i b\ making м-π il 
blood count" ni k u k i x u e s and dir t iunt id l ion of h m p h i n w i s 
Détermination of drug concentrations I Ia lonienlralions «>l pMimi lh jm in i 
dnJ sulfadiazine WLTL i k i i r m m i d m the s i n <md tissues of ih i mol he г*, md 
k l u s i s and in amniotic fluids bv high perl o r m i m i liquid i h r o n n t o t r ip)i\ 
(HPI (. ) Tibsui samples w L η honiO|.ini¿t:d in prnsioloj j ial salt solution (4 nil •> 
[wet might j ol iis^ut ) with i n l Іиишглч apparatus p s t r il Cmihl I Dodingen 
Germ my) T i n t r u d i Ііотоцепаіе w i s p i l k t i d by lenlnfugalion u 1 000 x if for 
20 mm The suptrnaUni v. is used for dete inn nation of drug concini rations bv 
HPLC Fur determination ol i h i pvnmethimmi t u n i i n l r j l i o n 2iH) μ| ol tlu 
saniplib (sirum supern и ini ol ( IK tissues ind ininmin fluid) was deprotun 
ized with 200 μ! of acetonitnle I In srimpks were v o i t i x i d and t t n t n f u g i d it 
4 IXHJ * JL, lor IH mm Diprotcmi? ilion ol i h i s impies (2IH1 μ|) lor d i l i r m i n »inn 
of the sulfndi i/ im ю п и п і г л ш п w is doni »uh "ìOO μΙ of ІМЧ M pi u n i o n i and 
Aliquots of Ml μΙ ol I In pripared s ι ni pk-. \ t u i i n g n i i d onto ι In. .in ik In. al 
column 
IX l i rminal ion ot the p t r i n n l l u i i i i i i i t o n i t n i r »ion w ι·, p ir forrrnd on ι n>l 
uinn paiked with Sphmsorb ^ ()I)S ( р і г і к к sizi "< μηι -1 d b\ 2s(l mm (mii ir 
d i a i m t i r j С h rompat к Middelhuit. I h i Ntthtrlands) I ht mobil i phase ю п 
sisted (tl 2 g o l Η,ΡΟι C^'< wt wO ind <li> ц ol t t t rami lhy l iiniiionuinithloride 
in 1 liter ol w i t i r mixi i l with 1 hier ol icetomlri l t (vol u>l) and w is run <Π ι llow 
rat i of 1 s ml min l_\ d i l u t i o n w is achie\ed » " , 10 nm The qu mutation limit 
of p u i m e l h j m i n i wis (HIS μ ι . ml i l α sign il io musi r mu of 1 1 he p u n 
pvriniit rumimi ih j twas used is τ n l i r u i n in I IPI С w is kindK provided bv I In 
Wellcome К и п id al on ( K i n t b n t l i m l i 
Sull idiazim *лъ mt isured b\ g r i d n n t HPLC an il\sis ΓΙκ HPLC svstim 
tonsjsted of ι l>vnania> M l nm С S lo lumi i ( p u l i c k si¿i H μηι 4 f> pv ^ l l mm 
|ішііг diametirj Kamin histruminis ("о I m Wohuni Mass) Λΐ uni i Ziro ι h i 
i l u i i i i tonbisted of III'e n i i o n i l n k ind s'il < ol ι Ι ι α ί ι ι n id solution in 
w i t i r In IH min the d u m i Ι Π Ί Π Ι Λ Ι Ι l im ark to Is' ι n u o i u i r i k ind ~2C ι ι ι ΐ κ 
acid (Ι'»-) ΓΙκ Mow rate foi t in s o l u m w is I ·> ml nun and d i l u t i o n wis 
a i h n v i d i l 272 nin T i n detection limil ol sul f jduz i in wis ll 2 μι_πιΙ il a 
signal in noisi r mo ol 1 
T h i inlrad i\ ind in l u d u l o t f l n n n t s ol ν πι π ion w i n t a k ul » i d loi si mm 
sinipks The lOifficients w i n luuiid io be »4 ind 7 7' r isp i t l i v i l v foi pv 
r inni l iamini ind 1 2 and 1 Ψ f n s p u m t h lor sulfidi i/ im 
( u n i htliiiL C~ 0 47) md esimi mon ol prurrrutokincm ρ π m n t u s м г і 
done with t in nil ol th i tompuier proL.nmm MW P l l \ R M ( Ь ) 
Statistical evaluation his lnrs і х л і test lo i ihi_ toniparison ol propon ions 
was ustd to tompire t i n piobabili lns of m i i i l i o n m t in i n d i m m i imi conimi 
groups Furlhirmore W md Ч^ <• t o n h d i n n i n t i n ils w i n takulaied tor m 
infettion i m i m l u i m i of ther ipv Hit tonl idtnte miirv ils w i n bjsed on ι 
binomial distiihution (S) 
RtSLLTS 
Pharmacokinetic studies. The pharmacokinetics of p\-
rimclhaminc and sulfadiazine were determined etiler oral ad­
ministration of I mg ol pyrimethamine per kg with M) mg ot 
sulladiazine per kg lo nonpregnant monkevs E and F I he 
concentrations of p\nmelhaminc and sulfadiazine in scrum are 
presented in the b g 2 and 1 respectively 
lhe scrum concentration time curves of both pyrime­
thamine and sulfadiazine ht best to a one compartment model 
The pharmacokinetic parameters that were calculated from 
these data are shown in Table 1 The serum elimination half 
cone руг [ug/rnlj 
0 2 i 
0 
0 09 : t 
20 25 30 35 
time [hours] 
40 45 50 
П С 2 С oncultï limns of puirrn-th umile (pu ) m ihe ser ι ni nlonkiss h (") 
nul F (D) iltcr or il ulministriilion of 1 mg kt, wlu ι μ\ι.η m cornbin ilion v.nh 
si) πικ ol sulljdldzini. per kc 
h\es were found lo be 44 4 h for pvrimelhamine and s 2 h for 
sulfadiazine A maximum concentration in scrum of S8 7 μ(; o l 
sulladiazine per ml was reached at 1 7 h after administration 
At 2 7 h after administration of I mg ol p\nmcthamine per kg 
a peak concentration o l 0 22 μg/ιnI in serum was found 
Treatment of congenital Τ gondii mfeetmns. The 4 monkevs 
in the control group and the HI monkc\s in the treatment 
group all developed a parasitemia that lasted for about 10 days 
Parasitemia was demonstrated bv the isolation ol parasites 
troni maternal blood n\ both mouse inoculation and detection 
by PCR 
As described in detail in our previous report (41) Τ цоікіи 
was delected in tour of the nine ictuses of the control gioup 
( A / i to Λ,4) The results are summarized in Figure I B 
Fetal intention in the treatment group was monitored pre 
natalK bv sequential testing ot amniotic fluid samples obt lined 
h\ puncture at davs 100 I IS and ПО of pregnane ν Transmis 
Sion of inlection was found in ή of the 10 monkevs (D,2 f ) , l 
D/i D,7 D,y a n d D , 1 0 ) 1 he paiasue was delected b\ PCR in 
the amniotic Hind of all six monkevs whereas mouse inocula 
tion was positive only for monkeys D,2 D,l> and D, 10 In four 
ol six monkevs the transmission of inlection occurred within 
HI da\s alter inoculation ot the mother in monkc\ D7 between 
davs 10 and 2^ and in monkcv DIO between davs 25 and 40 
d i g 1С) 
TABLb I Ph irnidLukniLiK. p.ir irmters ol p\rimiiiumini' md sullddi i/tnt in rhisus inonkev 
Drug ind monki.\ 
Pyr imethamine 
F 
Γ 
M e a n (η - 2) 
Sulfadiazine 
Ь 
F 
M e in (л - 2) 
7 , >(ІЧ 
1 0 
4 1 
2 7 
J 1 
1(1 
1 7 
с , . 
( ц е і п ч і 
0 22 
ί)2~· 
(122 
s i 2 
Μ I 
s« 7 
1 (litersl 
4 S 
4 1 
-1 ч 
(ls-1 
(ls-1 
(1 s4 
M K I ( l i | 
47 tJ 
-12 7 
(i4 4 
111 ί 
ХЧ 
Ч ( і 
(Il μ ι ml) 
14 1 
X 2 
U d 
711 
ft7h 
b<)4 
AUO ir 
(h KL ml) 
K 2 
SU 
S 1 
hSll 
67s 
678 
' (h) 
M) 2 
28 ft 
-14 4 
S s 
s ( l 
s 2 
( 1 
t l i lersh) 
(IOS 
0 10 
(IOS 
t u r 
(1117 
(1(17 
I In values I ir t in ph inn i t u k i n u n par inn t u s \ 
tin ι ι » m.i\imum ю п и m mon ol drub, m м г im ( 
residí m t l inn WC ¿TL I midi r l in t o n t i mr т и п m u u m i M C ir 
t l u r ime 
. I l l u m i n i l i i l l t r r il idmimsir mon ut 1 ι u I p w m n t h inni pu k_ will -чі n i i 'I " i l ! idi ι 
и і м т и т t o n n i ti m m L I druL ι il serum l \ minn il disinh il on il il ι u n i r il ю т ρ um 
m i n l in l u n t t n i i m m tum u m i l i ψι/onl il r LI l i / li ili l i l i t pi м л ι 
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serum cone sulla lug/ml) 
time [hours) 
FIG 3 Concentrations ol sull Uli ι/ιπι (suit ι) in the s ir ι ol monkeys С (*) 
and F i'Z) after oral administration ol St) mg/ku. whi.n giM.ii in tornimi mon wnh 
) ni t <>l pvnrmlliamine per kg 
As shown in Fig 1С treatment was started in ihc six mon 
keys shortly after collection ol the amniotic fluid samples and 
infection was proven In four monkeys (monkeys D2 D3 D6 
and D9) the lime interval between collection of the amniotic 
fluid sample and the initiation of treatment was only 2 days 
The parasite was no longer detectable in the next consecutive 
amniotic fluid sample Irom any monkey collected 10 to Π days 
after the initiation of trealmeni (Figure 1С) 
Poslnalallv the parasite was not found in neonatal tissues or 
amniotic fluids The placenta ol monkey DIO which received 
treatment for 24 days was the only sample found to be positive 
at birth The placenta was found to be positive by PCR but not 
by mouse inoculation No hematological side effects from the 
administered drug regimen were found 
Statistical evaluation of these results revealed that the infec­
tion rate in the treatment group was similar to the rate in the 
control group (P = 0 66) Furthermore, the outcome of fetal 
infection afler treatment was significantly different from the 
outcome in the control group (P — ООП) The confidence 
intervals were calculated for ihis small number of animals the 
80% confidence limits were 0 to 28% whereas the 9Sr/r con­
fidence limits were 0 to 4()r/r The drug concentrations at which 
these effects occurred are given in Tables 2 and 3 The time 
interval between the last dose and the collection of samples 
was 4 h for monke\s D3 and DIO (peak levels) and about 26 h 
for monkeys D2 Do D7 and D9 (trough levels) The concen­
trations in letal serum varied from 0 05 to (I 14 μg/ml for 
pyrimethamine and trom 0 ft to S 4 μg/ml for sulfadiazine 
Pyrimethamine was found lo accumulale in ihe soft tissues 
especially in the spleen and ihe lungs Sulfadiazine was also 
found in the tissues bul the concentrations were always less 
than the concentrations in scrum Both pyrimethamine and 
sulfadiazine crossed the placenta of the rhesus monkey very 
well as shown in Table 4 Pyrimethamine penetrated into brain 
TABLE 2 Concentration ot pvrimeth imine 
Sample (day of collection) 
M i i e r n a l b l o o d ( I I S ) 
M . i l e r r u l b l o o d (130) 
M a t e r n a l b l o o d (160) 
M a t e r n a l br n n ' 
M a t e r n a l he t r i ' 
M a t e r n a i s p l e e n ' 
M a t e r n a l liver"' 
A m n i o t i c fluid ( I I s ) 
A m n i o t i c f l u i d (13(1) 
A m n i o t i c fluid (160) 
Fetal b lood ( П 0 ) 
Fetal b l o o d ( 160) 
Monkiv D2 
( I l ls 
( I 0 Ï 
11 IIS 
IMO 
1Mb 
0 9s 
0 70 
(IOS 
0 0s 
0 0s 
(IOS 
0 0s 
Monko D6 
·• (I 0s 
0 09 
0 11 
( I l l s 
1 3 
0 « 
1 0 
(MIS 
( Ids 
0 06 
oos 
0 0^ 
Pvnmuh imine 
Monk i i D9 
(Mb 
• 0 OS 
0 0s 
0 2s 
0 3S 
oso 
0 40 
0 0s 
( M b 
( K b 
- ( M b 
(Mb 
LOnUl (μβ. ml or μ^ί.ί 
Мопкіл 1)7 
N I ' 
0 0 4 
II Π 
(13(1 
•r ( M b 
1 -4(1 
1 60 
N T 
( M b 
0 07 
oos 
0 04 
Мопкіл n V 
•• 0 ( b 
•Jl 0s 
0 21 
' O O S 
< 0 OS 
' D O S 
2 0 
•-(MIS 
( M b 
( M b 
• ( M b 
0 0K 
Munkiv DIO" 
N 1 
N I 
0 30 
ons 
0 30 
2-10 
2 s 0 
N T 
N T 
0 13 
Ν Λ 
0 14 
Pílcenla (100)' (IOS 
Fti il brain' 
Fet il heart ' 
Fel il spleen' 
F-ti il Іічег*' 
Г и il lune1' 
(1 VI 
oos 
1 10 
DOS 
1 Is 
1Mb 
(Mb 
OSO 
oos 
1 (b 
1Mb 
(Kb 
oso 
OOs 
1 (i 
1Mb 
0 3S 
1 0 
(Mb 
1 Sb 
0 10 
oos 
1 OS 
·- 0 lb 
OJs 
II6S 
0 4S 
Niy 
l)s() 
6 0 
D u r i l i o n Di l a i tment (davs) SX "Λ ^К •>x 2S 
IІК (Jii\ ni s jmpk ci lk (.tinn u т_чропсК ι [ΐκ^ιι мііл di 11 κ π 
I liL KLT i^l· lime mkr\ il b e t i t l n ihe I ist il чпс, imi м і п р к t Million w ι "Vili Thus ihe umn-nir minis m si_rum p u s . 
in. икс ν s D^ un.! DIO il il ι\ IMI ol рп-^папеч ι In, time intirv il и is i h 
Μ η ι ІІЧ il т с m и tli il moiiKiit 
[ he Concilili 1 Ullis 111 11 svile, и ι, tl. ck к ІПІІПі, d ГА UM Πι. llsMje I. VI Γ IL I s ЧЧ hl», h « L U СІ11(1 lu] ||\L I NIK \ III ph\M(i|OtIk il s ill S 
fi und io bc Ulis μι, ml l im mi ins l ini ihis v. is ihe ю п и л Н г л ю п in ihc diluted s i m p k 
N \ bjmpk nol a\ nl h k 
S D m i Ji ili. 
IIILLI iKn. ііч. mainly [rough levels hoi 
iluiion It ι concent r mon in іічми. ^чь 
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T A B L F 1 C o n c e n t r a t i o n o f sulfdcluzmc. 
Sample (day of collection) 
M a t e r n a l b l o o d ( I l i ) 
M i ternal b l o o d ( П О ) 
M a t e r n a l b l o o d (160) 
M a t e r n a l brain ' ' 
M a t e r n a l heart' ' 
M a t e r n a l s p l e e n ' 
M a t e r n a l liver1' 
A m n i o t i c fluid (115) 
A m n i o t i c fluid (130) 
A m n i o t i c f lu id (160) 
Fetal b l o o d (130) 
Fetal b l o o d (160) 
Monkev К 
4 I 
5 1 
4 6 
1 7s 
2 IS 
3 45 
2 85 
7 5 
5 3 
4 0 
4 8 
4 0 
Mc nkcv D6 
7 4 
2 3 
1 9 
< 0 2 
< 0 2 
< U 2 
< 0 2 
4 0 
2 6 
2 7 
2 0 
1 9 
bull idnzine concn (μί/ΐηΙ or 
Monkev D9 
176 
2 2 
3 3 
1 6 
1 2 
2 0 
2 25 
0 75 
1 7 
2(1 
1 7 
3 2 
Monkev 
Ν Γ 
1 1) 
3 4 
1 2 
1 4 
2 3 
< 0 2 
N T 
1 2 
5 4 
0 6 
3 7 
μ&8) 
D7 Monkey D t 
3 9 
2 5 
3 7 
2 3 
2 1 
4 55 
2 15 
3 9 
2 9 
4 2 
1 0 
5 1 
Monkev D l i r 
N T 
N T 
6 0 
1 95 
1 25 
3 2 
3 6 
N T 
N T 
4 4 
N A r 
5 4 
Placenta' 3 I < 0 2 M5 24 
Tetal bram' 
Fetal heart' 
Fetal spleen1* 
Fetal liver** 
Fetal lung" 
Duration ol treatment (davs) 
1 3 
27 
3 95 
2 75 
3 0 
0 55 
< 0 2 
< 0 2 
< 0 2 
10 
1 0 
14 
215 
2 0 
1 95 
145 
2 0 
2 3 
2 0 
2 2 
12 
19 
2 65 
2 85 
2 25 
2 35 
1 95 
35 
3 75 
2 75 
58 58 58 40 58 25 
The day of sample collection corresponds In pregnancy durjuun 
Λ
 The average lime interval between the last dosing and sample collection was 26 h Thus the concentrations in serum presented here are mainly trough levels For 
monkevs Dt and DIO л das 160 ol pregmncy the lime interval wis 4 h 
NT no treatment at that moment 
'The concentrations m tissue were determined hv using tissue extracts which were diluted five times in phssiological salt solution If a concentration in tissue was 
lound to he 0 2 μ&ΓηΙ this means that this was Ihe concentr mon in the diluted sample 
NA sample not available 
tissue belter than sulfadiazine, the concentrations, of py 
nmcthamine in Ihc brain were about three to four limes 
greater than the corresponding concentrations in serum 
whereas the concentrations of sulfadiazine were found to be 
about 30% of the corresponding concentrations in serum (Ta 
ble 4) 
DISCUSSION 
The anliloxoplasma activities of pyrimethamine and sulfadi 
azine have been demonstrated bolh in vitro and in vivo Py 
nmcthamine' and sulfadiazine act synergistically on Τ gondii, 
and it appeared thai the combination of Ihese drugs inhibits 
the growth of the parasite in vitro (12, 24 42) The inhibition 
of growth was associated with a reduction in the number of 
parasitized cells and the number of intracellular parasites (12 
24) Pyrimethamine and sulfadiazine also cause morphological 
changes in the parasite, as demonstrated by electron micros 
copy (42) 
Studies in mice have shown that treatment with pv 
nmethamine and sulfadiazine prolongs survival after infection 
with a lethal dose of Τ gondii by reducing the parasite load (14 
32) Nguyen and Stadtsbaeder (31) found thai mice treated 
with pyrimethamine and sulfadiazine acquired no resistencc to 
a lethal challenge with Τ gondii Treatment with pyrimethamine 
TABLE 4 Transplacental passage ind penetration into the brain of pyrimethamine and sulladiazine 
Drug" Drue ratio between the samples' Dat Ol 
collection Monkev Dh Monkev D9 Monkev 1)7 Monkev D3 Monkev D i l l 
Ρ Fetal blood/maternal blood 
Ρ Fetal bram/fclal blood 
Ρ Maternal brain maternal blood 
S Fetal blood maternal blood 
Ь Fetal blood/maternal blood 
S Fetal brain/fetal blood 
S Maternal brain maternal blood 
160 
160 
160 
130 
160 
160 
160 
N D ' 
N D 
N D 
0 90 
0 87 
0 33 
0 38 
N D 
N D 
N D 
0 87 
1 t) 
0 29 
N D 
N D 
N D 
N D 
0 77 
0 97 
0 31 
0 48 
0 81 
N D 
2 7 
0 60 
1 0 
0 39 
0 35 
0 38 
3 75 
N D 
0 40 
(189 
0 24 
0 40 
0 46 
4 6 
2 8 
N D 
0 90 
0 44 
0 32 
Ρ psrinietlnnune S sulfadiazine 
I ransphcental passage, is expresad f. the ratio between ι hi. concentration ol the drug in fetal scrum and l he conespnnding conccnlr ilion in m j terna I scrum The 
ilio between the concentration in the brain and the l o m t p o n d i n g concentration in serum gives in impression ol the level of penar ition ol the drug into the br nn 
I he dav nf sample collection corresponds lu prcgn inc. dur ition 
' N D nol delermmed because Ihe druj. contenir il ion * j s below ihe detLil ion le\el or bee luse there «as no tre iimeni Li\en it thai moment 
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and sulfadiazine also prevenled squirrel monkeys trom dying of 
an acute toxoplasmosis ( 17) 
Studies in humans revealed that treatment with py 
rimethamine and sulfadiazine significantly reduced the number 
of offspring with severe congenital toxoplasmosis (9-11 20) 
Several children, however were born suffering from subclinical 
or even symptomatic toxoplasmosis, despite treatment with 
pyrimethamine and sulfadiazine (7, 10 11. 20) The treatment 
of these children was started after fetal infection had been 
proven The prenatal diagnosis of infection was Ume-consum-
mg most of the time and the studies contained no information 
about the duration of infection at the moment that thcrapv was 
started The time ïnters.il between the onset of fetal infection 
and the initiation of therapv was therefore possibly too long In 
the present study the moment of infection was adequatdy 
known Because antenatal detection ot Τ gondii was per 
formed bv PCR a result can be obtained within 2 davs of 
receiving the sample and treatment could he started carl·, 
after the onset of fetal infection in our experimental setup Bv 
PCR transmission of infection was detected antenaiallv m six 
monkeys whereas mouse inoculation was positive for onlv 
three monkeys The high degrees of sensitivitv and reproduc 
ibihtv ul the PCR were also found in our former study (4(1) It 
has been stated before that PCR cannot discriminate between 
viable and dead parasites However, since transmission ol dead 
parasites is unlikely the detection of Τ gondii in amniotic fluid 
by PCR is considered to be of clinical imporlance 
Statistical analysis of the results revealed that the rale ol 
transmission of infection to the fetuses in the control group 
was similar to the rale in the treatment group In addition 
treatment with pyrimethamine and sulladiazinc sigmhcantlv 
reduced the number of infected offspring compared with the 
numbcr of infected untreated controls 
The efficacy of treatment was related to the concentrations 
of (he drugs that were reached in the tetus Both pv 
rimethamine and sulfadiazine can cross the placenta frcclv and 
are therefore thought to be appropriate drui>s for use in the 
treatment of congenital / condii infection (Π) The conten 
trations of pvnmethaminc in the scia ol neonates varied from 
18 to M'r ol the corresponding concenti.liions in the sera ol 
the mothers The concentrations ol sulladiazinc in the sera ol 
the fetuses were similar to those in the sir,ι of the mothers 
The same results have also been found for transplacental pas 
sage ol pvnmethaminc and sulfadoxinc in humans (Π) I his 
was expected because rhesus monkevs and humans both pos 
sess a placenta ot the hemochonal tvpe p s ) Since brain dam 
age is the most severe consequence of congenital tosoplasmo 
sis the concentrations m the brain ate of special interest It was 
found that pvnmethaminc and sulfadia/ine both can cross the 
blood-brain harrier in the rhesus inonkev 1 he concentrations 
of sulladiazinc in the brain were found to be about W ,
 0 | the 
concomitant concentrations in serum lor both the fetus and the 
mother These percent, ige s are in close agreement with the 
levels ol sulladiazinc that have been lound in the cercbiospinal 
fluid ol dogs (4s) and humans (46) Pvrimelhamine was found 
to penetrate and accumulate in monkev brain tissue and con 
ccnlrations up 10 4 s nmes the concomitant levels in sellini 
were lound This was alrcadv expected troni experiments in 
humans (21) rhesus monkeys p 8 ) and rats (S) m which sun 
ilar ratios of levels in brain to levels in su um were lound 
Pharmacokinetic studies revealed that pviimethamine and 
sulfadiazine have serum hall-lives of 44 4 and s 2 h lespee 
tivclv in the rhesus monkev Sulfadiazine has a shorter cluni 
nation hall hie in rhesus monkevs than in humans (I 2s Щ 
In addition the elimination half-life found in ululi monkevs in 
the present studv is shortci than thai reponed for voting mon 
keys (24. 40) AsimilarhndingwasreportedbyFriiset. i l (l'i) 
in pigs, who found that the half life of sulfadiazine decreased 
with an increase in the ages of the pigs 
The pvnmethaminc half life of 44 4 h lound in rhesus mon­
kevs is shorter than the SS lu 114 h reported in humans (S 26) 
When compared with those in babies however the halt-lile in 
scrum was onlv shghllv shorter than the reported 64 ± 12 h 
(28) On the basis of the serum halt-life of pyrimethamine 
observed m the rhesus monkey a frequency of one dose every 
1 or 2 davs would be appropriate Because the half life of 
sulfadiazine is S 2 h however a more frequent dosing would be 
required 
The pharmacokinetic studies were performed with nonpreg 
nani monkeys Given the cflects ot prcgnancv on Ihe volume ot 
distribution and renal blood flow diug clearance could be 
difieren! Further investigation ot these paiamelers needs to be 
perlormed to establish the dosages of the drugs in the treat­
ment ot humans 
Weiss et al (47) demonstrated that the concentration ot 
pyrimethamine in the sera of mice should he at least 0 ^ μg/m] 
to be effective in inhibiting Towplaww growth When py­
rimethamine was used in combination with sulfadiazine the 
concentrations in scrum should be at least 0 1 μρ/ml tor pv­
nmethaminc and 2s μgιnl for sulladiazinc' The concentra­
tions that were found lo be effective in viso were in close 
agreement with those thai were lound to be effective in viiro 
(24, 42) lower concentrations ol (102 μg ot pyrimethamine 
per ml in combination with U 1 μg ol sulfadiazine per ml, 
however also had an inhibitory effect (12) Such concentra­
tions were easilv reached m the rhesus monkevs bv the inves­
tigated dose regimen Concentrations of ^2S μg of sulladia­
zinc per ml were present in the sera ol aduli monkevs for about 
10 h and concentrations ot -?0 I μg of pyrimethamine per ml 
were present in sera lor more than 24 h alter single oral dosing 
Given the high rate ol transplacental passage of both drugs it 
is assumed that such effective concentrations in serum are also 
present in the Ictus On the basis of these lindmgs a single dose 
pvnmethaminc given evcrv dav would be appropriate The 
hall hie ot sulfadiazine of S 2 h and the time during which 
efleclivc concentrations arc present in scrum, howevei would 
require two doses per dav For practical reasons py 
rimethamine and sulfadiazine were administered together in a 
sinele dose 
Conccntiationsof U 1 lo 0 s μι; of pyrimethamine per g were 
also reached in Ihe tissues ol the rhesus monkev Because in 
most cases trough levels were mcasuied concentrations in 
scrum wcie often below the quantitation limit of 0 OS μ£/πιΙ In 
two monkevs (monkevs LH and DIO) the levels in serum were 
measured approximated 4 h after administtation of the last 
dose In these cases concentrations in scrum greater than 0 I 
μgml were reached No toxic side effecls from Ihe adminis­
tered drug regimen weie lound in the rhesus monktys Py-
iinielhainine howevei should not be given in excess ol dos­
ages ol I 2S mg'kgdav since higher dosages cannot be 
tolerated bv rhesus monkevs when thev .ire administered re 
pealcdlv p 8 ) Il should be mentioned however that in Ihe 
studv cil Schmidt et a] p S ) the Irealmcnl was not supple 
menleil with (olirne acid as was the case in the present studv 
Λ1 high doses pyrimethamine has been lound to have leiat-
ogenic cllects in rats (14 21 41) and miniature pigs (IS) 
Besides this sulfadiazine should noi hi administered during 
the last month of prcgnancv because II increases the risk of 
kcrmctcrus (48) Kciiuclcrus was nol investigated in ihe mon­
kevs used in the picseiil siudv which were killed immediately 
alter birth 
1 he risk ol tcratogime с llccls caused bv pyrimethamine and 
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ihe risk ot kernicterub caused by sulfadiazine create a relue 
Lance lo use this drug combination for ihe prevention ot trans 
mission of infection I herefore the safer antibiotic spirarmcin 
is given as long as letal infection has not been proven A 
former studv in rhesus monkeys showed that spiramycin is able 
to reduce the number ol parasites in amniotic fluid to unde­
tectable levels (40) However spiramycin had to be adminis­
tered for at least 1 weeks to be effective (40) Treatment with 
pyrimethamine and sulfadiazine on the. other hand showed 
the same effect within 10 to 13 davs 
Because of the risk of malformations the use ot pv 
nmethaminc and sulfadiazine during pregnancy has been dis 
cussed The published work, however revealed no grounds tor 
contraindication during pregnancy (2) On the basis of these 
hndings the drug combination instead ol spiramycin should he 
used to prevent the transmission ot infection because of the 
potent aclivitv of the combination against 7 gondii parasites 
During the last month of pregnancv (i e alter 36 weeks or 
earlier if an anamnesis exists for premature birth) sulfadiazine 
should be left out becaust of the risk ot kernicterus 
ft appears from the results of the present study that the 
combination of pyrimethamine and sulfadiazine is an effective 
drug regimen for the treatment of congenital Γ qoiulii mfee 
lion Pyrimethamine and sulfadiazine act on the proliferative 
stage of the parasite but not on cvsis in tissues The eradication 
of cysts is verv important because of the risk of developing 
chorioretinitis later in lite (22) Studies should focus on new 
drugs that cross the blood-brain barrier and that act on the 
cysts as well Initial studies with alovaquonc showed promising 
results (3 4) On long term probation however alovaquonc 
was not able to eradicate the cvsts from infected mouse brains 
(2a) 
In conclusion, when administered early after the onset oí 
tela! infection Ihe combination of pyrimethamine and sulfadi 
azine is an effective drug regimen for the treatment of congen 
itdl 7 gondii infections 
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CHAPTER 7 
Isolation, identification and determination of sulfadiazine 
and its hydroxy metabolites and conjugates from man 
and rhesus monkey by high performance 
liquid chromatography 
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Abstract 
From monkey urine the following metabolites of sulfadiazine (S) were isolated 
by preparative HPLC: 5-hydroxysulfadiazine (50H), 4-hydroxysulfadiazine 
(40H) and the glucuronide (50Hgluc) and sulfate conjugate of 50H 
(50Hsulf) The compounds were identified by NMR, mass spectrometry, 
infrared spectrometry, hydrolysis by ß-glucuronidase 
The analysis of S, the hydroxymetabolites (40H, 50H), and conjugates N4-
acetylsulfadiazine (N4), 50Hgluc and 50HsuIf, in human and monkey plasma 
and urine samples was performed with reversed-phase gradient HPLC with 
UV detection. In plasma, S and N4 could be detected in high concentrations, 
while the other metabolites were present in only minute concentrations. In 
urine, S and the metabolites and conjugates were present 
The quantitation limit of the compounds in plasma varies between 0.2 and 0.6 
Mg/ml (S 0.31 Mg/ml, N4 0.40 Mg/ml, 40H 0.20 /xg/ml, 50H 0 37 Mg/ml; 
50Hgluc 0.33 Mg/ml, 50Hsulf 0.57 μg/mΓ). In urine it varies between 0.6 
and 1 1 Mg/ml, (S 0 75
 Mg/ml, N4 0.80 Mg/ml; 40H 0 60 Mg/ml, 50H 0.80 
/ig/ml; 50Hgluc 0 80g/ml, 50Hsulf 1.1 Mg/ml) The method was applied to 
studies with healthy human subjects and Rhesus monkeys. The metabolites 
50H, 50Hgluc and 50Hsulf were present in Rhesus monkey and not in man. 
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Introduction 
Sulfadiazine is used for the prophylaxis and treatment of Toxoplasma gondii 
infection, and bacterial infections like Pneumocystis carinii [1,2]. The known 
metabolism of sulfadiazine (benzenesulfonamide-4-amino-N-pyrimidine; CAS 
number 68-35-9; S) involves acetylation and oxidation at the N4 nitrogen atom 
leading to N4-acetylsulfadiazine (N4) and N4-hydroxysulfadiazine (N4OH). 
The latter compound is thought to be responsible for the occurrence of side 
effects of long term prophylactic treatment of Pneumocystis carinii pneumonia 
in HIV positive patients [1]. Hydroxylation takes also place at the C4 carbon 
of the pyrimidine ring leading to 4-hydroxysulfadiazine (40H) and at the C5 
carbon atom, leading to 5-hydroxysulfadiazine (50H). The hydroxy 
metabolites can be conjugated with glucuronic acid and sulfate [3-5]. This 
metabolic picture of sulfadiazine, as shown in Fig. 1, is obtained by means of 
TLC with detection reagents and isocratic HPLC analysis [3-5]. 
Recently we investigated the pharmacokinetics of sulfadiazine in Rhesus 
monkeys Macaca Mulatta and human volunteers by gradient HPLC and 
noticed novel conjugates of the hydroxysulfadiazines. 
The aim of this investigation was to isolate metabolites of sulfadiazine from 
monkey urine, to develop a gradient HPLC analysis and give preliminary 
results of the pharmacokinetics of S in Rhesus monkey and human. 
Experimental 
Chemicals 
S and N4 were obtained from Astra (Södertälje, Sweden). The metabolites 
40H, and 50H, were isolated from monkey urine and were HPLC pure. 
N4OH was synthesized by Synthon (Nijmegen, Netherlands). All reagents 
were of p.a. quality and obtained from Merck (Darmstadt, Germany). 
Amberlite XAD-2 absorption resin and Cel ite 545 were obtained from Fluka 
(Perstorp Analytical, Oud Beyerland, Netherlands). 
Subject and monkeys 
To one healthy human subject (male, 35 y, 85 kg, slow acetylator of 
sulfonamides) a single oral dose of 500 mg S was administered with 100 ml 
tap water after an overnight fast. The study had the approval of the hospital 
ethics committee and informed consent was obtained from the volunteer. 
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Fig. 1. 
Structures of sulfadiazine and its metabolites. 
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Rhesus monkeys were obtained from the Central Animal Laboratory, 
University of Nijmegen and The Laboratory Animals Breeding Experimental 
Farm of Shunde Guangdong, Beijing, Peoples Republic of China. 
One Rhesus monkey (female, 5 years old and weighing about 5 kg) was 
housed in a metabolic cage, fed orally with 50 mg/kg sulfadiazine and serial 
plasma and urine samples were collected for 2 days. 
Three Rhesus monkeys (female, 4 to 5 years old and weighing about 5 kg) 
obtained from the Central Animal Laboratory, University of Nijmegen, were 
housed in a metabolic cage, fed orally for 5 days with 50 mg/kg sulfadiazine 
and all urine was collected for 6 days. 
The study had the approval of the ethics committee of the Aninal Laboratory. 
Sampling 
Blood samples of 2 ml of the volunteer were drawn and collected in 
heparinized eppendorf vials (2 ml) at regular time intervals during 2 days after 
administration by means of fingertip puncture with MonoletR lancets 
(Monoject, St. Louis, USA). After centrifuging at 3000 g for 5 min plasma 
samples were stored at -20°C pending analysis. 
Urine was collected upon untimed voiding. The total time of sample collection 
was 96 h. Three samples of 7 ml of each void were stored at -20°C pending 
analysis. 
Blood samples of 2 ml of the monkey were drawn by puncture of the vena 
mediana and collected in heparinized eppendorf vials at the following times 
after administration: 0. 1,2, 3, 4, 5, 6, 7, 8, 10, 12, 24, and 48 hours. Urine 
was collected at the same time intervals 
The remainder of the urine was collected for 48 h in a tank and stored at -
20°C, pending isolation. 
Sample treatment 
Plasma samples (200μ1) were deproteinized with 300 μΐ perchloric acid 0.33 
N, centrifuged at 3000 g for 5 min, and 50 μΐ of the supernatant was injected 
onto the column. 
Urine samples: the urine was centrifuged at 3000 g, and the supernatant was 
diluted 1:5 with 0.6% AcOH and 50 μΐ was injected onto the column. 
Gradient HPLC analysis of S and metabolites 
The HPLC system consisted of a Marathon autosampler (Separations, Hendrik 
Ido Ambacht, Netherlands), a Spectra System™ Ρ 4000 quaternary gradient 
pump, a Spectroflow 757 UV detector (Separations) and a Hitachi D2500 
integrator (Merck, Amsterdam, Netherlands). 
The column was a Dynamax 60Á 8 μιτι, 150 mm χ 4.6 mm ID (Meyvis, 
Bergen op Zoom, Netherlands) with a guard column (15 mm χ 4.6 mm), 
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packed with 8 μιη C8 reversed phase (Meyvis). 
The mobile phase was a mixture of acetonitrile and a mixture of 0.5% AcOH 
plus 0.5 g AcONH4/l (pH 3.3). 
At t = 0, the mobile phase consisted of 0% acetonitrile, 100% AcOH + NH4Ac 
(%v/v). During the following 5 min, the mobile phase changed linearly until 
it attained a composition of 10% acetonitrile and 90% AcOH + NH4Ac 
(%v/v). From 5 to 18 min it was changed to 18% ACN and 82% 
AcOH + NH4Ac. At 18 min, the mobile phase was changed within 1 min to 
the initial composition, followed by equilibration for 4 min. The flow rate was 
1.5 ml/min. The effluent was monitored at 273 nm. 
Isolation of the metabolites from urine 
Column chromatography 
Two liters of monkey urine (48 h, pH 9.3) was brought to pH 5.0 and 
allowed to stand overnight for precipitation of endogenous urates. Celite 545 
(40 g) was added to the urine, and the suspension was filtered. The pH of the 
filtrate was adjusted to 5.0. 
A preparative column (40cm χ 6cm, packed with 1 kg XAD-2) was rinsed 
with 2 1 of methanol, 2 1 of water and with 1 L of 0.2 M KH2P04 buffer (pH 
5.0). Thereafter, 1 1 of urine was passed through the column, followed by 2 1 
of the 100-fold diluted phosphate buffer (pH 5.0). The column was dried by 
air suction for 10 min. 
Elution of the column was carried out by a mixture of methanol-water 
according to the following scheme: First, 500 ml CH3OH/H20 (20:80; v/v) 
was passed through the column, followed by 8 fractions of 250 ml with the 
methanol concentration increased by steps of 10% to 100% CH3OH and 0% 
H20. 
The effluent fractions 1-2 (20/80 - 30/70%, v/v) contained 5-
hydroxysulfadiazineglucuronide. 
The effluent fractions 2 till 4 (30/70 - 50/50%, v/v) contained 5-
hydroxysulfadiazine sulfate and the fractions 5 till 7 (60/40-80/20%, v/v) 
contained the hydroxy metabolites 4-hydroxy-, and 5-hydroxysulfadiazine. 
This procedure was repeated with the second liter of urine on a regenerated 
column, and fractions 2-4 and 5-8 from both procedures were combined. 
Methanol was evaporated under reduced pressure. The combined fraction 5-8 
was brought on the column, and the gradient elution was repeated. Fraction 
40/60 and 50/50 contained the sulfate conjugate and the fractions 70/30 and 
80/20 both contained the unconjugated hydroxysulfadiazines. Most of the 
yellow-brown urine color had now been removed, together with the parent 
compound and its N4-acetyl conjugate. 
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Preparative high performance liquid chromatography 
The volume of the isolated fraction containing the hydroxy sulfadiazines from 
the preparative column was concentrated to 100 ml by evaporation under 
reduced pressure (Rotavapor), and acidified with 5M HCl to pH 2.0 in order 
to prevent precipitation of the hydroxy sulfadiazines. 
The preparative Gilson HPLC consisted of a Gilson 302 sample pump 
(Gilson, Meyvis, Bergen op Zoom, Netherlands), two 305 Gilson gradient 
pumps, a 811 В Dynamic mixer, a Kratos 757 UV detector (Separations, 
Hendrik Ido Ambacht, Netherlands), an LKB 2211 superrac fraction collector 
(LKB, Woerden, Netherlands), and a BD7 recorder (Kipp & Zonen, Delft, 
Netherlands). The column was a C8, 8 μιτι particle size, 250 mm χ 10 mm 
ID, Rainin Dynamax 60 A column (Meyvis). 
The mobile phase consisted of 1 % acetic acid in water and acetonitrile 
(85:15%, v/v). The flow rate was 4.7 ml/min and peaks were detected at 271 
nm. 
Concentration of the separated metabolites was carried out on an IKA 
rotavapor (Janke and Kunkel, Staufen, Germany) equipped with a Trivac 
vacuum pump (Leybold-Heraeus, Woerden, Netherlands). Two crude samples 
each containing a metabolite were collected. 
Final purification by preparative HPLC 
4-hydroxysulfadiazine (40H) 
Isolation: The mobile phase was acetonitrile-1% AcOH (18/82%, v/v. 
The collected sample was concentrated to 20 ml under reduced pressure with 
the rotavapor, and thereafter reduced in volume in a smaller flask to 0.5 ml. 
The final volume of 0.5 ml was transferred to a small tube for freeze drying. 
5-hydroxysulfadiazine (50H) 
Isolation: The mobile phase was 15% THF- 1% AcOH 1% (v/v), 
The collected sample was concentrated to 20 ml under reduced pressure with 
the rotavapor, thereafter further reduced in a smaller flask to 0.5 ml. The 
final volume of 0.5 ml was transferred to a small tube for freeze drying. 
5-Hydroxysulfadiazine sulfate (SOHsulf) 
First isolation: The mobile phase was acetonitrile/1% AcOH. Start with 8% 
acetonitrile/92% AcOH 1% (v/v) which changed linearly in 18 min to 26% 
acetonitrile and 74% AcOH. 
Second isolation: The mobile phase was 40% methanol/ 60% water, (v/v). 
Third isolation: mobile phase acetonitrile/1% AcOH. Start with 12% 
acetonitrile/88 % 1% AcOH (v/v) during 10.5 min, which changed in one min 
to 26% acetonitrile/74% 1% AcOH (v/v). 
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Final isolation: The mobile phase was acetonitrile/water 40/60% (v/v). 
The collected sample was concentrated to 20 ml under reduced pressure with 
the rotavapor, thereafter further reduced in a smaller flask to 0.5 ml. The 
final volume of 0.5 ml was transferred to a small tube for freeze drying. 
5-hydroxysulfadiazine glucuronide (50Hgluc) 
First isolation: The mobile phase was acetonitrile/1% AcOH. Start with 10% 
acetonitrile/90% AcOH 1% (v/v) which changed linearly in 16 min to 26% 
acetonitril and 74% AcOH. 
Second isolation: The mobile phase was THF/AcOH 1% (12/88%, v/v). 
Third isolation: The mobile phase was methanol/ ACOH 1%. Start with 10% 
methanol/90% AcOH (v/v) which changed linearly in 15 min to 25% 
methanol and 75% AcOH. 
The collected sample was concentrated to dryness under reduced pressure with 
the rotavapor (43 mg). 
Identification of the metabolites 
Mass spectrometry 
A double focussing VG 7070E mass spectrometer was used (Fisons 
Instruments, Weesp, Netherlands). EI (70 eV), and FAB (matrix 
nitrobenzylalcohol, Xenon 8 KeV, acceleration voltage 6-7KV) were 
performed. 
Nuclear magnetic resonance 
'H-NMR spectra were recorded on a Bruker AM 400 spectrometer (400 
MHz.FT; Bruker, Wormer, Netherlands) on solutions in CÖ^OD/CDCl·, 
(internal standard Me4Si). 13C-NMR spectra with 'Η-decoupling were recorded 
with a Bruker AM 400 spectrometer operating at 100.6 MHz on solutions in 
CD3OD/CDCI3 (internal standard Me4Si). Chemical shift values are reported 
as δ-values relative to Me4Si as internal standard deuteromethanol/deutero-
chloroform were used as solvents. 
Infrared spectrometry 
Infrared spectra in KBr were recorded on a Perkin Elmer 881 infrared 
spectrophotometer (Perkin Elmer, Gouda, Netherlands). 
Melting point 
Melting points were recorded with a Schmelzpunktbestimmungsapparat 
(Buchi, Flawil, Schweiz). 
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Deconjugation 
Deconjugation reactions with ß-glucuronidase (urine-ßgluc.-buffer 1:1:8, 
v/v/v, 9 days, 37°C) were carried out. 
Four different ß-glucuronidase enzymes were tested (all from Sigma, St. 
Louis, MO, USA): 
A. 20,000 U/ml ß-glucuronidase type Bl (Bovine liver, Cat. No. G-0251) 
in phosphate buffer at pH 5.0. 
B. 120,600 U/ml ß-glucuronidase type H2 (Helix pomada, Cat. No. G-
0876) in phosphate buffer at pH 5.0. 
С 100,000 U/ml ß-glucuronidase type LII (lyophilized powder from 
limpets Patella vulgata, Cat. No. G-8132) in phosphate buffer at pH 
3.8. 
D. 20,000 U/ml ß-glucuronidase type VIIA (Escherichia coli, Cat. No. G-
7646) in phosphate buffer at pH 6.8. 
Deconjugation with sulfatase was carried out with 19 U/ml Sulfatase VI 
(Aerobacter aerogens, Sigma, Cat. No. S-1629) in Tris solution of pH 7.1. 
Deconjugation reactions with 5 M HCL (urine-HCl 1:1, v/v, 75°C, 1 h) were 
carried out. 
Limits of quantitation 
The limits of detection in water and quantitation of sulfadiazine and its 
metabolites in plasma and urine were determined at a signal to noise ratio of 
3. 
Standard solutions 
Standard solution of S and metabolites were prepared as follows: S 10.9 
mg/ml in DMF, N4 3.55 mg/ml in DMF, 40H 1.16 mg/ml in DMF/0.1M 
HCl 1:1 (v/v), 50H 1.78 mg/ml in 0.1M HCl, 50Hgluc 1.78 mg/ml in water 
and 50Hsulf 2.0 mg/ml in water. 
Recovery 
A calibration curve of 4 concentrations (0.5-60 ^g/ml) of S and its metabolites 
in 0.9% NaCl solution was compared with a calibration curve of the same 
concentrations in plasma. All samples were treated with acetonitrile 1:1 (v/v). 
Pharmacokinetics 
The pharmacokinetic parameters were calculated using the MediWareR 
computer package [6]. 
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Sulfadiazine in plasma 
A OH 50H 
blank 
monkey 
10 
" Τ " 
15 
~~Γ~ 
20 25 mm 
Fig. 2. 
Chromatograms of Rhesus monkey plasma containing sulfadiazine (S) and its 
metabolites, a blank monkey plasma and the isolated reference compounds. 
The concentrations of the compounds in the standard are respectively: S 52.6 
Mg/ml, 40H 5.6 μg/ml, 50H 8.6 Mg/ml, 50Hgluc 5.7 ßg/πύ, 50Hsulf 7.1 
^g/ml and N4 9.0 μg/ml. 
Sulfadiazine in plasma 
40H 50H 
human 
monkey 
10 15 20 25 mi η 
Fig. 3. 
Chromatograms of a Rhesus monkey and human plasma sample containing 
sulfadiazine (S) and its metabolites. 5-Hydroxysulfadiazine with its conjugates 
is not present in human plasma. 
The concentrations of the compounds in the human plasma sample are 
respectively: S 12.6 μg/ml, 40H 0.6 μg/ml, and N4 1.5 μg/ml. The 
concentrations of the compounds in the monkey plasma sample are 
respectively: S 57.7 μg/ml, 40H 1.1 μg/ml> 50H 1.6 μg/ml, 50Hgluc 2.3 
pg/ml, 50Hsulf 2.1 μg/ml and N4 2.2 μg/ml. 
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44*- J'uJU-I 1' 
_ДлЩ 
40H 
50Hgluc 
10 15 
Sulfadiazine in urine 
-standard 
-blank 
monkey 
20 25 min 
Fig. 4. 
Chromatograms of Rhesus monkey urine containing sulfadiazine (S) and its 
metabolites, a blank monkey plasma and the isolated reference compounds. 
The concentrations of the compounds in the urine are respectively: S 653 
Mg/ml, 40H 32.4 μg/ml, 50H 10.2 /ig/ml, SOHgluc 25.7 /xg/ml, 50Hsulf 
13.4 /ig/ml and N4 85.5 /xg/ml. 
4 0 H 
N. 
LAJUUfll \AJ 
50Hgluc 50Hsult 
"T" 
10 1 ^ 15 
Sulfadiazine in urine 
human 
monkey 
20 25min 
Fig. 5. 
Chromatograms of Rhesus monkey and human urine containing sulfadiazine 
(S) and its metabolites. 5-Hydroxysulfadiazine with its conjugates is not 
present in human urine. The concentrations of the compounds in the human 
urine sample are respectively: S 67.5 μ§/πι1, 40H 12.3 Mg/ml, and N4 85.5 
μg/ml. The concentrations of the compounds in the monkey urine sample are 
given in Fig 4. 
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Fig. 6. 
Plasma concentration-time curve of Sulfadiazine (S), N4-acetylsulfadiazine 
(R,), 4-hydroxysulfadiazine (40H), 5-hydroxysulfadiazine (50H) with its 
glucuronide (50Hgluc) and sulfate (50Hsulf) conjugates in a Rhesus monkey 
after an oral dose of 50 mg/kg of sulfadiazine. 
Fig. 7. 
Plasma concentration-time curve and renal excretion rate-time profiles of 
Sulfadiazine (S), N4-acetylsulfadiazine (N4), 4-hydroxysulfadiazine (40H) in 
a human volunteer after an oral dose of 500 mg of sulfadiazine (6mg/kg). 
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Results 
Identification: 
Metabolites of S were detected in (figure 1 and Table I) a urine sample of a 
human volunteer after oral intake of 500 mg of S and in urine of a Rhesus 
monkey treated with 50 mg/kg S orally. Four metabolites of S were isolated 
from the monkey urine sample: 40H, 50H, 50Hgluc and 50Hsulf. The 
isolated compounds were identified as follows: 
4-Hydroxy sulfadiazine: 
The EI Mass spectrum of 4-hydroxysulfadiazine (C10H10N4O3S, Mr 266) m/z, 
relative intensity; reads: 267 [M+l] 12.1%; 266 [M+] 100%; 201, 17.9%; 
202, 23.2%; 109, 12.3%; 108, 44.3%; 93, 11.6%; 92, 79.5%; 28, 70.5%. 
The EI Mass spectrum of sulfadiazine (C10H10N4O2S, Mr 250) m/z, relative 
intensity; reads: 251 [M+l] 0.14%; 250 [M+] 0.06%; 186, 100%; 109, 
11.9%; 108, 19.6%; 93, 37.9%; 92, 51.6%. 
The NMR spectrum in CD30D/CDC13 (3:1, v/v) reads: 
0 = 7.48 ppm (2H,d,Ha+Ha., Jab = 8.4 Hz); 7.48 ppm (lH,d,Hc, Jcc= 7.6 Hz); 
6.57 ppm (2H,d,Hb+Hb., Jab=8.8 Hz); 5.90 ppm (2H,s,NH2); 5.70 ppm 
(lH,d,Hc.; Jcc. =7.6 Hz); 3.16 ppm (lH,d,OH). 
Melting point 269-270QC under decomposition. 
The IR spectrum shows the sulfone moiety at 1600 and 1630 nm. 
5-Hydroxysulfadiazine: 
The EI mass spectrum of 5-hydroxysulfadiazine (C10H10N4O3S, Mr 266) reads: 
m/z, relative intensity; 267 [M+l] 0.65%; 266 [M+] 0.62%; 203,13.7%; 
202,100%; 201,80.9%; 156, 14.3%, 109 3.5%; 108 45.2%; 93, 11.6%; 92, 
94.2%; 65, 65.3%. 
The FAB' mass spectrum reads: 267 (M + H+) 100%; 289 (M+ + Na) 25%, 
533 (2M + H+) 4%; 555 (2M + Na+) 4%. 
The NMR spectrum in CD3OD/CDCl3 (3:1, v/v) reads: 
0 = 8.02 ppm (2H,s,Hc + Hd); 7.69 ppm (2H,d,Ha + Ha·, Jab = 8.8 Hz); 6.62 ppm 
(2H,d,Hb + Hb., Jab = 8.8 Hz). 
Melting point 182-183°C under decomposition. 
The IR spectrum shows the sulfone moiety at 1600 and 1630 nm. 
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The NMR spectrum of sulfadiazine in CD3OD/CDCI3 (3:1, v/v) reads: 
δ = 8.39 ppm (2H,d,H
c
 + H
c
., ^ = 4 . 8 Hz); 7.76 ppm (2H,d,H
a
 + H
a
-, J
ab = 
7.0 Hz); 6.88 ppm (lH,t,Hd, ^ = Jc-d=4.8 Hz); 6.62 ppm (2H,d,Hb + Hb·, 
J
ab =7.0 Hz). 
Melting point: 252-256°C. 
5-Hydroxysulfadiazine sulfate: 
The FAB+ mass spectrum of 5-hydroxysulfadiazine sulfate (C10H10N4O6S2, MT 
345) reads: m/z, relative intensity; 347, 5%; 345 4%; 369 7% (M+ + Na); 
NMR spectrum in CD3OD reads: 
0 = 8.28 ppm (2H,s,H
c
 + H
c
); 7.63 ppm (2H,d,H
a
 + H
a
., J
ab = 8.7 Hz); 6.65 
ppm (2H,d,Hb + Hb., Jab = 8.7 Hz). 
Hydrolysis: Acid hydrolysis in 5M HCl at 50°C for 2 h resulted in 5-
hydroxysulfadiazine. Treatment of the isolated compound with arylsulfatase 
(VI) resulted in 5-hydroxysulfadiazine. 
The IR spectrum shows the sulfone moiety at 1640 nm. 
Melting point: 169°C under decomposition. 
5-Hydroxysulfadiazine-O-glucuronide: 
Mass spectrum 
The FAB+ mass spectrum showed the 443 [M + H+] 20% and the 465 
[M + Na+] 12% ions; base peak 273 100%. 
NMR spectrum in CD3OD (T=40°C) reads: 
0 = 8.30 ppm (2H,s,H
c
 + H
c
); 7.71 ppm (2H,d,H
a
 + H
a
., J
ab = 8.8 Hz); 6.63 
ppm (2H,d,Hb + Hb., Jab = 8.8 Hz); 4.86 ppm (lH,m,H,); 3.94 ppm (lH,d,H5, 
J 4 5 = 10 Hz); 3.59 ppm (lH,m,H4); 3.46 ppm (2H,m,H2 + H3). 
Hydrolysis: Acid hydrolysis in 5M HCl resulted in 5-hydroxysulfadiazine. 
Treatment of the isolated compound with ß-glucuronidase (system C) for 1 h 
at 37°C resulted in 5-hydroxysulfadiazine. 
Melting point: 167°C under decomposition; phase and colour transition at 104-
105°C from yellow to rose/red. 
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The IR spectrum shows the sulfone moiety at 1600 and 1630 nm, the 
glucuronide carbonyl moiety at 1730 nm, and a broad maximum 3200-3450 
nm of the glucuronyl group. 
Table I shows the retention times, the capacity factors of parent drug and its 
metabolites. Fig. 2 shows the chromatograms of a monkey plasma with bank 
and standards, and Fig. 3 compares the chromatograms of monkey and human 
plasma after an oral dose of sulfadiazine. The chromatograms show the 
presence of S and its metabolites. Fig.4 and Fig. 5 show the chromatograms 
of monkey and human urine and urine sample respectively after oral 
administration of S. 
Table II shows the equations of the calibration curves of S and its metabolites 
in plasma and urine. Table III shows the limits of detection in water and 
limits of quantitation in plasma and urine of S and its metabolites. 
Samples of pH 5 and kept in the dark were stable in the autosampler of the 
HLPC during 24 h. 
Table IV and V show respectively the intra- and inter-day variations of S and 
its metabolites in plasma. 
Table VI and VII show respectively the intra- and inter-day variations of S 
and its metabolites in urine. 
Fig. 6 shows an example of the plasma concentration-time curves of S and the 
metabolites in a Rhesus monkey and Fig.7 the plasma concentration-time 
curve and renal excretion rate-time profiles of S and its metabolites after a 
single oral administration of 500 mg of S in one male volunteer. 
Table VIII summarizes some pharmacokinetic parameters of S calculated from 
the plasma and urine concentrations of parent drug and metabolites in the pilot 
experiment after a single oral administration of 500 mg S to the human 
volunteer. 
Discussion 
The presence of metabolites of sulfadiazine and its availability for isolation 
strongly depends on the species. For instance when only human urine were 
investigated, 5-hydroxysulfadiazine with its conjugates would not have been 
detected and isolated is not present. 
The metabolites 4-hydroxy, and 5-hydroxysulfadiazine were already described 
[4]. Vree et al. isolated by preparative TLC the metabolite from the urine of 
dogs [5] and excreta of fresh water turtles Pseudemys scripta elegans [7]. The 
dog's urine is relatively easy to analyse, because they are unable to acetylate 
sulfonamides [Vree]. Excreta of turtles diluted in tank water give clean 
chromatograms containing the 4-hydroxy, and 5-hydroxysulfadiazine [8]. 
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Table I: Retention times and capacity factors of sulfadiazine, its metabolites 
and conjugates. 
Compound 
to 
50Hgluc 
40H 
Hippuric acid 
50H 
50Hsulf 
S 
N 4 
t
r 
min 
к' 
1.80 
6.99 
9.85 
11.35 
12.00 
12.70 
12.70 
15.56 
2.88 
4.47 
5.31 
5.67 
6.06 
6.06 
7.64 
Introduction of the hydroxyl group in the sulfadiazine structure at the 4 position reduces 
the capacity factor by a factor 0.74, while at the 5 position the reduction is 0.94. 
Introduction of the acetyl group in the sulfadiazine structure increases the capacity factor 
by a factor 1.26. Introduction of the glucuronide group in 50H reduces the capacity 
factor by a factor 0.51, while introduction of the sulphate group has less effect, reduction 
0.89. Hippuric acid is an endogenous compound present in urine. 
Table II: Calibration curves of sulfadiazine and its metabolites. 
plasma 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
urine 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
concentration 
Mg/ml 
0.20 - 2.32 
0.37 - 3.56 
0.33 - 2.36 
0.57 -4.00 
0.31 -218 
0.40 -7.10 
concentration 
/ig/ml 
0.6 - 116 
0.8 - 356 
0.8 - 118 
1.1 - 50 
0.8 -2180 
0.8 - 187 
У 
У 
У 
У 
У 
У 
У 
У 
У 
У 
У 
У 
curve 
- 702.x + 41.2 
- 420.x - 30.4 
= 500.x - 3.62 
= 243.x + 20.5 
= 484.x - 141 
= 379.x + 10.7 
curve 
= 93.2.x + 53.1 
= 78.6.x + 77.8 
= 89.3.x + 73.0 
= 65.0.x + 77.8 
= 95.7.x + 466 
= 75.5.x + 2.4 
correlation 
г 
0.9981 
0.9989 
0.9981 
0.9960 
0.9999 
0.9998 
correlation 
г 
0.9997 
0.9982 
0.9997 
0.9982 
0.9997 
0.9997 
Peak height у (integration units) and concentration χ (/ig/ml). 
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Table III: Recovery and limits of detection and quantitation of sulfadiazine 
and its metabolites. 
Compound 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N< 
Detection 
limit in 
water 
/xg/ml 
0.07 
0.12 
0.11 
0.11 
0.08 
0.12 
Quantitation 
limit in 
urine 
Mg/ml 
0.6 
0.8 
0.8 
1.1 
0.8 
0.8 
Quantitation 
limit in 
plasma 
Aig/ml 
0.20 
0.37 
0.33 
0.57 
0.31 
0.40 
Recovery 
(%) in 
plasma 
(N=4) 
95.6 
92.8 
101.7 
96.6 
98.4 
84.3 
C.V. 
4.1 % 
8.3 % 
1.3 % 
4.9 % 
3.5 % 
6.1 % 
Detection limit in water; quantitation limit in the biological matrix. 
C.V. = coefficient of variation. 
Table IV: Inter-day coefficient of variation (%cv) of spiked sulfadiazine and 
its metabolites in human plasma (n=4, in vitro). 
Compound 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
Concentration 
added 
Mg/ml 
2.32 
3.56 
2.36 
4.00 
218 
7.10 
1.16 
1.78 
1.18 
2.00 
109 
3.55 
0.56 
0.86 
0.57 
0.32 
5.25 
0.90 
Concentration 
measured 
Mg/ml 
2.64 
3.56 
2.34 
3.76 
222 
6.93 
1.26 
1.76 
1.16 
1.80 
111 
3.45 
0.61 
0.78 
0.58 
n.d. 
5.63 
0.83 
Precision 
% C.V. 
11.6 
3.0 
5.2 
15.1 
2.4 
1.0 
14.6 
3.3 
3.3 
13.2 
3.4 
2.7 
16.4 
9.1 
12.8 
-.-
9.6 
12.2 
Accuracy 
% 
13.8 
0 
0.8 
6.0 
1.7 
2.4 
8.6 
1.1 
1.7 
10.0 
1.4 
2.8 
7.1 
9.3 
1.8 
-.-
7.0 
7.8 
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Table V: Intra-day coefficient of variation (%cv) of spiked sulfadiazine and its 
metabolites in human plasma (n=4, in vitro). 
Compound 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
Ν, 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N< 
Concentration 
added 
Mg/ml 
2.32 
3.56 
2.36 
4.00 
218 
7.10 
1.16 
1.78 
1.18 
2.00 
109 
3.55 
0.56 
0.86 
0.57 
0.32 
5.26 
0.90 
Concentration 
measured 
Mg/ml 
2.27 
3.55 
2.42 
4.01 
216 
6.98 
1.11 
1.82 
1.15 
1.98 
106 
3.41 
0.60 
0.83 
0.62 
n.d. 
5.71 
0.93 
Precision 
% C.V. 
4.8 
1.7 
3.5 
4.4 
1.1 
0.6 
3.6 
0.8 
3.5 
7.6 
1.1 
1.3 
10.0 
9.0 
8.3 
-.-
4.6 
12.7 
Accuracy 
% 
2.2 
0.3 
2.5 
0.0 
1.0 
3.0 
4.4 
2.2 
2.5 
1.0 
2.6 
4.0 
7.1 
3.5 
8.8 
-.-
8.6 
3.3 
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Table VI: Inter-day coefficient of variation (%cv) of spiked sulfadiazine and 
its metabolites in human urine (n=4, in vitro). 
Compound 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
Concentration 
added 
Mg/ml 
116 
89.0 
118 
70.0 
215 
178 
58.0 
44.5 
59.0 
35.0 
107 
89.0 
14.5 
11.1 
14.8 
8.8 
26.9 
22.3 
5.8 
4.5 
5.9 
3.5 
10.8 
8.9 
Concentration 
measured 
Mg/ml 
113 
93.8 
116 
64.9 
217 
177 
56.4 
44.2 
58.4 
33.5 
110 
89.8 
14.8 
11.5 
14.2 
8.6 
27.8 
22.7 
5.9 
4.3 
6.0 
2.9 
10.5 
8.7 
Precision 
% C.V. 
1.8 
6.5 
1.4 
2.3 
3.9 
3.7 
2.7 
2.5 
2.1 
1.5 
3.1 
2.6 
4.1 
7.0 
11.3 
12.8 
3.6 
2.6 
10.1 
5.8 
12.5 
12.4 
4.4 
5.3 
Accuracy 
% 
2.5 
5.4 
1.4 
7.3 
1.1 
0.4 
2.8 
0.7 
1.0 
4.3 
2.2 
0.9 
2.1 
3.6 
4.2 
2.3 
3.3 
1.8 
1.7 
4.4 
1.7 
17.1 
2.8 
2.2 
93 
Table VII: Intra-day coefficient of variation (%cv) of spiked sulfadiazine and 
its metabolites in human urine (n=4, in vitro). 
Compound 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
40H 
50H 
50Hgluc 
50Hsulf 
S 
N4 
Concentration 
added 
Mg/ml 
116 
89.0 
118 
70.0 
215 
178 
58.0 
44.5 
59.0 
35.0 
108 
89.0 
14.5 
11.1 
14.8 
8.8 
26.9 
22.3 
5.8 
4.5 
5.9 
3.5 
10.8 
8.9 
Concentration 
measured 
Mg/ml 
113 
88.4 
115 
64.3 
214 
171 
58.4 
45.7 
59.0 
33.8 
111 
88.4 
15.3 
11.4 
14.7 
9.1 
27.7 
22.5 
6.1 
4.5 
6.7 
3.2 
11.0 
8.7 
Precision 
% C.V. 
1.5 
0.9 
0.9 
1.0 
0.9 
0.7 
1.1 
1.5 
1.2 
0.9 
1.0 
0.4 
2.5 
3.7 
2.9 
1.3 
1.8 
1.2 
5.4 
10.5 
4.8 
5.9 
2.2 
1.7 
Accuracy 
% 
2.2 
0.7 
2.5 
8.1 
0.2 
3.9 
0.7 
2.7 
0.0 
3.4 
3.3 
0.7 
5.5 
2.7 
0.7 
3.4 
3.0 
0.9 
5.2 
0.0 
13.6 
8.6 
1.9 
2.2 
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Table Vili: Some pharmacokinetic parameters of sulfadiazine, its metabolites 
and conjugates from a healthy human subject and from a rhesus monkey after 
a single oral administration of sulfadiazine. 
Parameter 
Subject 
Gender 
Body weight [kg] 
Acetylator status 
Dose [mg] 
Compound 
Bioavailability F (%) 
C
max
 Oig/ml) 
La* (h) 
tl/2 absorption ( П ) 
tl/2 formation ( П ) 
t,/2 (h) 
MRT S (h) 
Total body clearance (L/h) 
Volume of distribution (L) 
Renal clearance (L/h) 
Percentage of the dose 
excreted (% mol) 
Total 
S 
94.2 
16.9 
3.7 
0.49 
16.6 
25.9 
1.06 
25.3 
0.61 
45.8 
94.2 
value 
human 
male 
85 
slow 
500 
N4 
35.1 
1.54 
10.1 
2.7 
20.7 
34.7 
3.84 
84.7 
3.35 
35.1 
40H 
13.3 
0.64 
7.7 
2.0 
17.5 
28.8 
3.11 
78.2 
3.44 
13.3 
monkey 
female 
10 
50a 
S 
100 
46.2 
3.8 
1.25 
5.9 
10.6 
0.084a 
0.71a 
0.071 
39.7 
100b 
a
 mg/kg, values/kg; b Renal excretion (%mol) 40H 19.9%, 50H 17.4%, 50Hgluc 9.1%, 
50Hsulf 5.9%, S39.7%, N, 8.0%. 
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Other reported conjugates of sulfadiazine were the deaminated metabolites 
[9]. 
O-glucuronides can be hydrolyzed by ß-glucuronidases; of the four ß-
glucuronidase systems tested, system С and D were the most active ones for 
O-deglucuronidation. 
The 5-hydroxy group in the pyrimidine ring in the meta-position to the 
nitrogen atoms acts as a phenolic hydroxyl group and is extremely vulnerable 
for conjugation. The 4-hydroxy group is not accessable for conjugation in 
the species man, monkey and turtle. 
Differences in the metabolism of sulfonamides between humans and monkeys 
may be related to the differences in rates of metabolism and differences 
between the urine pH of both species. In man, urine pH varies between pH 5 
and 7, resulting in renal excretion of the parent drug (45%), acetylation 
(35%) and oxidation of sulfadiazine (13%). Monkey urine pH varies between 
8 and 9.5, resulting in a similar renal excretion of the parent drug (40%), 
but minimal acetylation (8%), which is compensated by an enhanced 
oxidation (50%). A similar difference in the N-glucuronidation was reported 
earlier, human urine contained the N
r
glucuronide of sulfamethoxazole [9], 
which is absent in monkey urine [Schoondermark- van de Ven, unpublished 
results]. Also in humans sulfadimethoxine is mainly glucuronidated at the N, 
position [10], while in pigs it is only acetylated at the Ν,-position [12]. 
Addition of AcONH4 to the eluent is essential for a stable retention time of 
sulfadiazine-O-sulfate. Without AcONH4, the retention time and the peak 
shape of the sulfate depend on the concentration. A similar behaviour was 
observed for paracetamol sul fate (Vree et al, unpublished results). 
In conclusion: The hydroxy metabolites of sulfadiazine, 4-
hydroxysulfadiazine, 5-hydroxysulfadiazine with its corresponding sulfate 
and glucuronide conjugate were isolated from monkey urine and their 
structures could be confirmed with those reported in the literature. 
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Sulfadiazine and the metabolites N4-acetyl-sulfadia¿ine, 4-OH-sulfadiuzine, 5 OH sulfadiazine, 5-OH-glu-
curonide sulfadia7ine, and 5 OH-sulfate-sulfadiazine »ere tested separately and in combination with py-
rimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro Except for N4-autvl-sulfadiazine, 
all sulfa compounds possessed anU-ToxopIasma activity The addition of 0 (15 μξ of pyrimethamine per ml, a 
concentration which in itself is nol inhibitory, potentiated the microbial activity of sulfadiazine and its 
metabolites 100 fold 
The combination of sulfadiazine and pyrimethamine is fre 
quently used for the treatment of Toxoplasma gondii infections 
(9 14) Both drugs .id synergistically in Ihe metabolic pathway 
ol folic acid which in turn is required for the biosynthesis of 
purines pvnmidines and certain amino ïcids (4) 
Studies on the antimicrobial activity of sulfadiazine metab 
oliles arc scarce Pharmacokinetic studies of sulfadiazine so tar 
have been performed bv the method ol Bratton and Marshall 
(1) This method however cannot discriminate between dif 
ferent hydroxylaled metabolites of sulfadiazine By using high 
performance liquid chromatography (HPLC) a variety oí hy 
droxy metabolites ot sulfadiazine have been discovered in 
diflerent animal species (11 12 19) Recently HPLC delermi 
nation of sulfadiazine in the plasma and the urine ol rhesus 
monkevs revealed the presence of li\e metabolites of sultadi 
azinc N4 icetyl sulfadiazine (N4 acetyl) 4 Oil sulfadiazine 
(4-OH) •> OH sulfadiazine (S OH) S OH glucuronic sulfa 
diazine (S OH Glue) and S OH sulfate sulfadiazine (S OH 
Sulf) (16a) It was thought previously that rhesus monkevs and 
humans were similar in their metabolization ol sultadi i/ine 
(10) However the three *> OH metabolites have not been 
found in humans 
A previous study with rhesus monkevs on the efficacy ot 
pyrimethamine and sulfadiazine tor the treatment of congen 
ilal / gondii infection (15) raised the question ol whclhcr the 
metabolites of sulfidiazine possess antiparasitic iclivily 
Nouwsetal (Π) demonstrated that ι hydroxylaled metabolite 
of sulfadiazine had intimicrobial activity against Fuiunchia 
ioli at 2 5'f of the iclivily ot the parental drug N4 acetyl on 
the other hand showed no antimicrobial activity against this 
bacterium 
In the present study the anil Towplauna activities ol sulta 
diazine and the met ibohtcs i h n have been found in rhesus 
monkevs were investigated in vitro The activities of these 
drugs were also studied in combination with pyrimethamine 
Anil Toxoplasma activity was measured bv quantitation of 
parasite growth using an enzvme linked immunosorbent assay 
which was performed directly on Γ condii infected HFp 2 
cells The in vitro tests were performed as described previously 
Corresponding nilhor Mailing iddress Dcparlmeiil of Medical 
Microbiology Univcrsilv Hospital Nijmegen bint Radhoud P O Box 
01(11 ósTlOHBNijmcüen The Nclhcrl inds Phone II Ml fH44-.f, F i s 
Ή SO s40'4i 
bv Deroum and Chastane (1) HEp 2 cells were prepared in 
96 well tissue culture pi lies (Costar Cambridge Mass ) and 
grown to confluence At the start of the assay Τ gondii para 
sites of the RH strain were transferred to fresh culture medium 
at a concentration of 10s parasites per ml Culture medium 
consisted of Dulbecco s modified eagle s medium (Gibco 
Breda The Netherlands) with 1Ü mM NaHCO, and 4 S g of 
glucose per ml supplemented with Yt felli call scrum 2 mM 
glulaminc 100 U of penicillin per ml 0 ** mg ol gcnlamicin per 
ml 1 mM sodium pyruvate and the desired concentrations of 
drugs to be studied The HLp 2 cells were overlaid with I sO μΐ 
of a parasite suspension (parasite 10 cell ratio ΙΟ/λι) The 
parasites were grown at 5 rr CO %'r humidity and a tern 
pcrature ol 36°C lor 40 h Lach test included eight wells with 
out parasites (bickground staining of ihe HLp 2 Cells) and 
eight wells with parasites but no drugs (positive control) Lach 
drug concentration was tested eightfold ind each test was 
performed three times The HEp 2 cells were stained with 
0 2'<- trvpin blue ind examined microscopically for Iheir via 
bility 
After 90 h of incubation the cultures were w ished twice with 
wash buffer (116 mM NaCl 27 mM KCl 14 mM KH P 0 4 8 
mM Na ПРО., 2H О 0 \', phenol red ind 0 0^9! Twcen 
20) hxed with cold meth inol and air dried Ihe cells were 
incubated with a human antiserum aeainst Τ gondii at Yl С for 
2 h The cells were subsequently incubated overnight at 4 С 
with a horseradish peroxidase labeled rabbit anil human im 
munoglobuhn Ci 1 10 000 (Dakopitls Kopenhagen Den 
mark) I he substrate was KH) μΐ of 4 niiiml υ phenvlcncdia 
mine (Sigma St I ouis M o ) with l~> μΙ ml perhydrol W"< 
Η,Ο (Merck D irmsladt Gcrminv) The color reaction was 
terminated after 1 s nun incubation it room temperature wilh 
100 μΐ ot 0 s M H S 0 4 One hundred fifty microliters of the 
substrati, was then transferred to a 4ft well plate for spectro 
photometric analysis at 492 11m Blank readings were per 
formed on the eiiihl control wells without parasites Pv 
rimelhaminc was obtained from the Wellcome Foundation 
(Kent Enghnd) sulfadiazine was obtained from Ihe Onder 
linge Pharm iceulischc Giooiliindel (Utrecht The Nether 
lands) and N4 acetvl was obt lined from Asti 1 (Sodertaljc 
Sweden) The met ibohtcs of sulfadiazine 4 OH s OH S OH 
Glue and S OH Suit were isolated Irom rhesus monkey urine 
hv prep ir une HPLC 116 1) 
•> OH Glue ind s OH Suit were dissolved 111 culture mc 
100 
j-^Q — ^-®Ч-и-© — СН^^Ь-І> 
4 HydroxysulfadiaziiiG 
О 
Sulfadiazine N4 acetylsulfadiazine 
у-®-!^-©-0" 
5 Hyciroxysulfadiazine 
1
 ^
N
 4O^-^4O)-0-s c 
5 Hydroxysulladiazine sulfate 
I 
г
 г У II н \)¿j он он 
5 Hydroxysulfadiazine glucuronide 
TIG 1 Slruclunl formuljs of sulfadiazine and Us metabolites N4 acetyl and hydroxy di.rivaiives 
dium at a concentration of 10 and 2 mg/ml respectively Sul 
fadia/ine and N4-acetyI were dissolved in culture medium at a 
concentration ot 2 mg/ml by adjusting the pH to 8 4 with 1 M 
NaOH When the drugs were completely dissolved the pH was 
slowly reduced to 7 5 with 1 M HCl S OH and 4 OH were 
dissolved in 100% /VjV dimethylformamide at a concentration 
of 10 mg/ml and subsequently diluted in culture medium Py 
nmcthaminc was dissolved in methanol-acetone (iU 50 vol/ 
vol) at a concentration oí 0 1 mg/ml Tnd further diluted in 
culture medium Methanol and acetone had no inhibitory ef 
feet on Toxoplasma growth or foxic effect on the monolayer 
cells at the concentrations that were used in the experiments 
/vVV dimethylformamide alone or in combination with meth 
anol and acetone also had no inhibitory or toxic effect at 
concentrations <\% NN dimethylformamide nc\cr reached 
concentrations of more than 0 5% 
fifty percent inhibitory concentrations (ICs,,s) were deter 
mined for the sulfa compounds both alone and in combination 
with 0 0*1 μg of pyrimethamine per ml At this concentration 
pyrimethamine alone showed no inhibitory effect Fifty percent 
inhibitory concentrations were determined bv si ltistical anal 
vsis using a linear regression model as described bv Derouin 
and Chastang (1) In brief the optical densities (OD) obtained 
from the experiments were displayed as sigmoid с rves when 
expressed as a function of the logarithms of the drug concen 
trations The middle part of the sigmoid curve showing the 
increase ot inhibition approximated a linear regression line 
This line was adjusted to tht basic OD measurements for three 
successive concentrations Assuming a constant coefficient ot 
variation a weighted least squares method was applied The 
mean OD measurements corresponding lo a concentration of 
0 (noninhibitory concentration) and to a maximum inhibitory 
concentration (background) served as the limiting values The 
ICS (, was obtained bv inserting the OD value halfway between 
these limiting values in the equation of the adjusted regrtssion 
line 
The structures ol sulfadiazine and its metabolites which 
were investigated for their in vitro effects on Τ gondii growth 
are shown in Fig 1 ICSM could not be determined for the sulfa 
compounds separately because the maximum concentrations 
of the drugs that could be dissolved had only a paitial or 
negligible inhibitory effect on parasite growth Besides this 
sulfadiazine and N4 acetvl were toxic for HEp 2 cells at con 
centrations higher than 1 000 μg/ml As a consequence the 
concentration ranges that were tested did not result in a sig 
moid curve The maximal concentrations that were tested are 
shown in Table 1 
IC\(,s were determined for sulfadiazine and its metabolites in 
combination with a constant concentration of 0 OS μg of py 
nmcthamine per ml Except for N4 acetyl the activities of 
sulfadiazine and its metabolites were enhanced in the presence 
of pyrimethamine The concentrations of the sulfa compounds 
in combination with pyrimethamine were tar below those of 
the drugs alone (Table 1) The IC^0 of pyrimethamine alone 
was 0 2 •+• 0 04 μgƒml The IC
s l ls of pyrimethamine in combi­
nation with 2S and 100 μg of the parental drug sulfadiazine 
were 0 02 ± 0 011 and 0 00S - 0 001 μg/ml respectively Con 
centrations of 2S and 100 μg of sulfadiazine per ml are far 
below the inhibiting concentration of sulfadiazine alone (Table 
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TABLE 1 Inhibitory effects of sulfadiazine and its metabolites 
alone and in combination with pyrimethamine on the growth of 
Τ gondii 
Compound (g) 
Sulfadiazine (250) 
N4 acetyl (292) 
4 OH (267) 
5 OH (267) 
5 OH Glue (442) 
5 OH Sulf (346) 
IC„, (μ£πι|) 
pyrimethamine' 
> 1 (XXr" 
>i (mt 
> 1 W 
>51HP 
> 2 5(KC 
>25ir' 
Wiih 
pyrimethamine 
(0 0S μκήηΙ)" 
0 5 ± U 25 
> 1 000* 
0 6 + 0 18 
0 5 + 0 09 
70 » 0 32 
40 - 0 34 
" T h e data are means ± standard errors fur three experiments 
h
 1С; ι not determined because the drug was (oxic for H E p 2 cells at higher 
concentrations 
' IC 1 ( , nor determined because the maximum solubility of the drug was 
reached 
d
 I C 4 | not determined because no more drugs were available 
1), but enhanced activity was found when these concentrations 
were tested in combination with pyrimethamine 
Metabolites of sulfadiazine which possess a free para amino 
phenyl group are able to interfere in the folinic acid synthesis 
of Τ gondii The hydroxylated metabolites 4-OH and ^ OH 
have anti Toxoplasma activities similar to that of the parental 
drug when used in combination with a concentration of py 
nmethamine that is by itself not inhibitory The metabolites 
5-OH-Gluc and 5 OH Sulf have lower anti Toxoplasma activ­
ities On the molar level, both components arc 100 to HO times 
less active than the parental drug The extent of antimicrobial 
activity depends on the penetration of the metabolite into the 
parasitic cell, as has also been suggested for E coli (13) 5 OH-
Gluc and 5-OH Sulf both dissolved very well in the culture 
medium Conjugation of the OH group increases the hydro-
philic character of the metabolite and results in an enhanced 
excretion from the body in vivo The hydrophilic character may 
cause poor penetration through the lipophilic parasitic mem­
brane The N4 acetyl metabolite possesses no free para amino-
phenyl group and is therefore unable to interact with the fo­
linic acid synthesis 
Sulfadiazine was found to inhibit Τ gondii growth in vitro 
only at high concentrations This finding is in agreement with 
those of other in vitro studies (7, 8, 16) but contrasts with the 
results of Derouin and Chastang (3) Since the assay we have 
used in this study is similar to the assay as described by Der­
ouin and Chastang (3), the discrepancy is difficult to explain 
Genetic differences have been found between RH strains from 
different laboratories (6) A variation in sensitivity to antimi 
crobial agents between different Toxoplasma RH strams can 
not be excluded Another explanation may be the 10 fold 
higher concentration of parasites used in our study When 
sulfadiazine or its metabolites were combined with py 
nmethamine, enhanced activity was found for all the combi 
nations tested, except for N4 acetyl Again, the IC 5 0s we have 
found were higher than those reported by Derouin and Chas 
tang (3) On the other hand, the results are in good agreement 
with the in vitro results reported by others, with regard to the 
parental drug (2, ^ 8) It is interesting that the IC 5 0s we have 
found correspond to the plasma drug concentrations which are 
effective in vivo (20) 
This study shows that hydroxylatcd metabolites of sulfadia 
zine possess antimicrobial activity against Τ gondii The extent 
of hydroxylation depends on the type of species, age, and dose 
(11, 12 17 19) The presence of antimicrobially active metab 
olites may have consequences for the efficacv of treatment 
when these metabolites are present in high concentrations or 
when effective concentrations in plasma are reached There­
fore extrapolation from animal studies to the human situation 
concerning the pharmacokinetics and efficacy of sulfadiazine 
should be done with care 
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Summary and general discussion 
The general discussion presented in this chapter is limited to some general 
remarks, since the results of the different studies have already been discussed 
extensively in each chapter. 
The present thesis describes the investigations on a new diagnostic test for the 
direct demonstration of Toxoplasma gondii. The new diagnostic test was 
developed to improve the prenatal diagnosis of congenital T. gondii infections. 
The PCR was chosen because this technique has already proven its 
applicability as a diagnostic test in a variety of other microbiological 
infections. 
Initially, the PCR described by Burg et al [3] was chosen. This PCR is based 
on the detection of a 35-fold repetitive gene (BI-gene), which is specific for T. 
gondii. The applicability of this PCR was tested on clinical samples in which 
the presence of T. gondii was proven by conventional diagnostic techniques, 
such as mouse inoculation, tissue culture, and/or microscopy [13]. The PCR 
on the BI-gene was also applied to cerebrospinal fluid samples obtained from 
AIDS patients who were suspected of having cerebral toxoplasmosis. The 
PCR showed the highest diagnostic yield when compared to intrathecal 
antibody production and response to treatment [12]. The PCR on the BI-gene, 
however, failed to detect T. gondii in amniotic fluid samples and blood 
samples which were found positive by mouse inoculation. To improve the 
sensitivity of the PCR, a nested PCR was developed with the small subunit 
ribosomal DNA gene (ss rDNA) as target (see Chapter 2). For this purpose 
the complete nucleotide sequence of the ss rDNA was elucidated (see 
appendix). The rDNA gene was chosen because it contains several T. gondii-
specific sequences. In addition, the gene product, the ribosomal RNA, is 
present in about 10,000 copies per cell (or per parasite) and can also be used 
as target in PCR (Chapter 2). 
The nested PCR on the rDNA gene appeared to be more sensitive than mouse 
inoculation, and fulfilled the qualities of a diagnostic test for the prenatal 
detection of T. gondii. It was possible to demonstrate the presence of T. 
gondii within two days of receiving the clinical sample by using the PCR. 
Using the conventional mouse inoculation, a test result was obtained one to 
three weeks later. 
In summary, the PCR is a suitable test for the direct demonstration of T. 
gondii in the congenitally infected fetus. PCR should be added as a diagnostic 
tool or it may even replace the conventional techniques. Amniotic fluid 
samples appeared to be the clinical sample of first choice for the prenatal 
diagnosis of T. gondii infection (Chapter 3). 
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A recent study among pregnant women with a primary T. gondii infection 
supports our finding that a PCR on amniotic fluid performed better than 
conventional parasitological methods for the prenatal detection of the parasite 
[7]. The investigators demonstrated congenital infection in all of the 34 cases, 
in which transmission of infection had occured, by PCR. Follow-up testing, 
using the conventional methods, confirmed the presence of congenital 
toxoplasmosis [7]. 
The PCR is currently used as an additional diagnostic tool for the prenatal 
diagnosis of congenital T. gondii infection at the department of Medical 
Microbiology of the Academic Hospital "St. Radboud" in Nijmegen. 
After the investigations on the improvement of a diagnostic technique for the 
detection of T. gondii infections, the study focused on the effect of treatment 
in the infected fetus when the drugs are given to the mother. The rhesus 
monkey seemed a suitable animal to perform these investigations. Former 
studies have shown that this monkey served well as a model for human 
congenital T. gondii infections (Chapter 3). The frequencies of transmission of 
infection which were found in the rhesus monkey after maternal infection in 
the second and third trimester of gestation equal those observed in humans. 
Two drug regimens were investigated. The first was treatment with the 
macrolide antibiotic spiramycin and the second was the synergistic 
combination of pyrimethamine with sulfadiazine. Both drug regimens 
necessitated pharmacokinetic studies in the rhesus monkey, since such data 
were not available for this animal species. The results of the pharmacokinetics 
of spiramycin and the effectiveness of this antibiotic in the infected fetus are 
described in the Chapters 4 and 5, respectively. It appeared that spiramycin 
reduced the number of parasites in the amniotic fluid to undetectable levels 
within a period of three weeks. The pharmacokinetic studies revealed that 
spiramycin accumulated in the tissues of mother and fetus, but spiramycin was 
not found in the brain tissue. The effect of pyrimethamine in combination with 
sulfadiazine on congenital T. gondii infection is described in Chapter 6. T. 
gondii parasites were no longer found in the amniotic fluid after 10 to 13 days 
of treatment with pyrimethamine and sulfadiazine. Chapter 6 also contains 
pharmacokinetic data of pyrimethamine and sulfadiazine in rhesus monkeys. 
In contrast with spiramycin, both pyrimethamine and sulfadiazine were able to 
cross the blood-brain barrier. Moreover, pyrimethamine was found to 
accumulate in the brain tissue and reach therapeutic levels. 
The pharmacokinetic studies of sulfadiazine in the rhesus monkey revealed the 
presence of 5 metabolites. Three of these metabolites have not (yet) been 
found in humans. The isolation, characterisation, and determination of the 5 
metabolites is described in Chapter 7. The metabolites appeared to be present 
not only in the urine, but in plasma as well. It was not known whether these 
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metabolites possessed anti-Toxoplasma activity and thus whether they 
contributed to the efficacy of treatment. Therefore, anti-Toxoplasma activity 
of these metabolites has been studied in vitro. The results are presented in 
Chapter 8. The therapeutic consequences of these findings, finally, are 
discussed in this chapter. 
The improvement of the prenatal detection of congenital T. gondii infections 
and the effect of treatment in the infected fetus logically leads to the question 
whether there is a place for a routine serological screening on a primary 
infection during pregnancy or not. Acute T. gondii infection in pregnant 
women almost always goes unrecognized and will continue to be missed 
unless a systematic antenatal toxoplasmosis screening programme is initiated. 
However, before any screening programme can be introduced, the benefits 
and risks of such a programme have to be thoroughly evaluated. It should also 
be taken into account that what seems appropriate for one country is not 
always appropriate for another, since the frequency of infection differs per 
geographic area. In fact, the following factors need to be investigated before 
considering such a screening programme: 
1. The prevalence of immunity to toxoplasmosis in women of childbearing 
age. 
2. The incidence of primary infection in pregnancy 
3. The rate of transmission to the fetus 
4. The predictive value (sensitivity, specificity, and reproducibility) of a 
serological screening test to diagnose a primary infection in the 
pregnant woman. 
5. The reliability of diagnosing infection of the fetus. 
6. The efficacy of treatment for the fetus, when the drugs are given to the 
mother. 
The items 5 and 6 are the topics of this thesis, and they are both conditions 
for introduction of a serological screening programme. Some remarks are 
made with regard to these items, before going into the discussion of 
serological screening. 
With PCR a test result can be obtained within two days of receiving the 
clinical sample. In addition, PCR is suitable to monitor the effect of treatment 
by analysis of amniotic fluid before and after initiation of therapy. Thanks to 
the considerable gain of time a pregnant woman, suspected of a primary T. 
gondii infection, can await the test result of the PCR before taking a well 
considered decision. 
Based on the findings in humans that treatment with spiramycin reduces the 
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number of infected offspring, treatment with spiramycin might be considered 
for primary prevention (i.e. prevention of transmission of infection) when 
transmission of infection has not (yet) occurred. The findings in rhesus 
monkeys, however, do not support the use of spiramycin to prevent 
transmission of infection. Although spiramycin accumulates in the placenta, it 
never reaches the high concentrations that are reported to be necessary to 
inhibit T. gondii in vitro. Pyrimethamine and sulfadiazine on the other hand, 
do reach effective serum and tissue concentrations. In addition, with 
pyrimethamine and sulfadiazine it takes 10 to 13 days to reduce the parasite to 
undetectable levels in the amniotic fluid. It is therefore expected that it will 
take about the same time to reduce the parasite in the blood circulation of the 
mother. Based on these findings, one cure of 4 weeks of pyrimethamine with 
sulfadiazine for prevention of transmission of infection is preferred over that 
with spiramycin. This regimen also corresponds with that for healthy 
neonates, born to women with a proven primary infection during pregnancy, 
but in whom congenital infection is not definitely proven. 
Treatment with spiramycin for secundary prevention (i.e. after transmission of 
infection has occurred) is only partially effective. It appears from the results 
that spiramycin should be administered for at least three weeks to reduce the 
number of parasites in the amniotic fluid. Moreover, spiramycin does not 
reach the brain. Spiramycin will not be the treatment of choice for secundary 
prevention, since cerebral infection is the most severe consequence of T. 
gondii infection in the fetus. The combination of pyrimethamine and 
sulfadiazine is preferred over spiramycin to prevent symptoms in the fetus at 
proven antenatal infection. The results indicate that treatment with 
pyrimethamine-sulfadiazine efficiently reduces the number of parasites in the 
fetus; as mentioned before no parasites were detected in the amniotic fluid 10 
to 13 days after initiation of therapy. In contrast with spiramycin, both 
pyrimethamine and sulfadiazine reach the brain tissue. Pyrimethamine even 
accumulates in the brain. 
Our study thus shows that treatment with pyrimethamine and sulfadiazine is 
effective in reducing the number of parasites in the infected rhesus monkey 
fetus. The results have been found under experimental conditions, in which 
rhesus monkeys have been treated for congenital T. gondii infections with a 
dosage regimen that is also used in humans. Extrapolation of the results to the 
human situation, however, should be interpreted with care, since the 
pharmacokinetics of pyrimethamine and sulfadiazine in rhesus monkeys differ 
in some ways from the pharmacokinetics in humans. For instance, the serum 
elimination half lifes of both pyrimethamine and sulfadiazine are shorter in 
rhesus monkeys than in humans (Chapter 6). However, whether it is valid to 
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extrapolate the effect of a treatment in monkeys to the human situation 
depends on the serum and tissue concentrations which are achieved and the 
period of time during which these effective concentrations are present. 
Effective serum concentrations of pyrimethamine and sulfadiazine as found in 
rhesus monkeys appear also to be present in humans. In addition, the period 
of time during which these effective serum concentrations are found in 
humans is at least as long- or even longer- as found in the rhesus monkeys 
[1,9,10]. 
The finding of metabolites of sulfadiazine in the rhesus monkey which are not 
present in humans (Chapter 7) raises the question whether these metabolites 
contribute to the efficacy of treatment. Except for N4-acetyl-suIfadiazine, all 
metabolites possess anti-Toxoplasma activity as found by in vitro studies 
(Chapter 8). Pharmacokinetic studies in the rhesus monkey revealed that the 
metabolites 5-OH-glucuronide-sulfadiazine and 5-OH-sulphate-sulfadiazine do 
not contribute to the efficacy of treatment, since effective serum 
concentrations are not reached. The contribution of two other metabolites, 5-
OH-sulfadiazine and 4-OH-sulfadiazine, to the efficacy of treatment is rather 
low, since they appear to be present in small proportions in the plasma of the 
rhesus monkeys. All together, the proportion of active sulfa-compounds in 
serum of humans appears to be similar to what has been found in rhesus 
monkeys. These arguments suggest that extrapolation of the findings in the 
rhesus monkey to the human situation is justified. 
It must be realized that the results described in the present thesis were 
obtained under experimental conditions in which the time of maternal infection 
was exactly known, prenatal detection of the parasite was frequently 
performed to monitor fetal infection, and treatment was started early after 
fetal infection. This is at variance with the natural situation, in which maternal 
infection is often not recognized because the infection is mostly asymptomatic 
and serological screening is not routinely performed. As a consequence, a 
majority of the fetal infection will remain unrecognized or diagnosed too late 
in order to guarantee that treatment still will be effective. 
The findings plead for early treatment of the infected fetus and thus plead, 
indirectly, for introduction of a screening programme for a primary T. gondii 
infection during pregnancy. However, before adopting this policy the 
seroprevalence, incidence of primary infection, and frequency of transmission 
of the infection to the fetus during pregnancy should be assessed in the 
population as well as the reliability of such an assessment by serological 
screening. The present situation in The Netherlands with regard to the 
seroprevalence and the incidence among pregnant women has been 
investigated 4 years ago [4]. Among 27.667 pregnant women, 12.797 (45.8%) 
appeared to be seronegative for antibodies against T. gondii. Primary infection 
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was found in 44 cases (incidence of 2 to 3 per 1000 pregnancies), of which 12 
resulted in congenital T. gondii infection. These figures were obtained from 
pregnant women who participated in a primary prevention programme (i.e. 
they were instructed how to avoid primary infection). Based on the low 
number of maternal infections that occured, Conijn-van Spaendonck 
recommended for The Netherlands to rely on primary prevention and not to 
introduce a secondary preventive programme with serological screening, as 
screening would not be cost-effective. The results of a primary prevention 
programme depend on how effectively the health message reaches the target 
population and leads to a change in behaviour. The low number of maternal 
infections in The Netherlands, as found by Conijn-van Spaendonck, are most 
probably the result of primary prevention, and may be attributed to the fact 
that the women were reminded of the preventive measures at the repeated 
blood controls during pregnancy. On the other hand, the results of her study 
should be interpreted with care; the effect of primary prevention was not 
definitely proven since the study was not a controled one. 
Based on the findings of Conijn-van Spaendonck a tendency towards primary 
prevention exists. However, educational measures must be continually 
reinforced throughout pregnancy to be effective [14]. Foulon et al [5], for 
instance, reported a non-significant reduction of the rate of seroconversion 
from 1.26% to 0.95% among non-immune pregnant women in Belgium when 
these women were given a written list of recommendations. In addition, in 
one study in the United States, up to 95% of pregnant women who attended 
an antenatal class that included instruction on the primary prevention of T. 
gondii infection were unable to recall this instruction 4 months later [14]. 
A high number of seronegative women (about 80%) and a low incidence of 
congenital infections (1 to 2 per 1000 live births) is found in the United 
Kingdom. It is based on these figures that Greenough [6] and Peckham and 
Logan [11] share the opinion not to introduce a serological screening 
programme because screening cannot be cost-effective. 
In France, a country with a high prevalence for chronic toxoplasmosis (70-
90%) screening is routinely performed. The high prevalence reported was 
based on historical data obtained for the Paris area only. More recent studies 
have shown that in some areas of the country the seroprevalence is much 
lower (only 45%). This finding raises the question whether to continue with 
screening [8]. 
Others, on the contrary, are in favor of a screening programme, despite the 
fact that it will not be cost-effective. Aspöck et al [2] argue that the severity 
of congenital toxoplasmosis in its fully developed form justifies a general 
screening programme for all pregnant women. This opinion is shared by 
Wong and Remington [14], who propose a screening programme for the U.S. 
(seroprevalence for chronic toxoplasmosis 20%, incidence of congenital 
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toxoplasmosis 1 in 1000 to 1 in 8000 live births). It is remarkable that Aspöck 
et al. and Wong and Remington take this point of view with the knowledge 
that prenatal diagnosis was still shortcoming. In addition, little was known 
about the effect of treatment in the infected fetus when the mother was treated 
with drugs. 
The work described in the present thesis gives a better insight into the effect 
of treatment. The results show that early treatment with the combination 
therapy of pyrimethamine and sulfadiazine is clearly effective in reducing a 
congenital T. gondii infection to undetectable levels within a respectable 
period of time (10 to 13 days). Rapid diagnosis of fetal infection is possible 
with the development of a diagnostic PCR for T. gondii. This creates the 
possibility to start treatment early after fetal infection has occured. Although 
congenital toxoplasmosis may be a preventable disease, the effect of primary 
prevention is expected to be not sufficient as it is difficult to change the 
behavior of pregnant women or women who are attempting to conceive with 
regard to taking preventive measures. This, the improvement of the prenatal 
detection of T. gondii and the knowledge that pyrimethamine and sulfadiazine 
are effective in the infected fetus are three arguments in favor of reconsidering 
the need and practical implementations of introducing a serological screening 
programme in the Netherlands. As long as vaccination is not yet feasible, 
follow up in serological negative women, starting before or early after 
conception, has to be reconsidered, despite the fact that it is recognized not to 
be cost-effective. 
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Samenvatting 
Infecties, veroorzaakt door de parasiet Toxoplasma gondii, komen frequent 
voor bij mens en dier. Over het algemeen verloopt de infectie asymptomatisch 
en is er geen behandeling nodig. Soms gaat een infectie gepaard met algemene 
malaise, koorts, hoofdpijn, of lymfadenopathie. De infectie kan tot ernstige 
aandoeningen leiden zoals bijvoorbeeld hersenvlies ontsteking, myocarditis, 
pneumonitis of hepatitis en kan zelfs de dood tot gevolg hebben. De 
levensbedreigende vorm komt met name bij twee groepen individuen voor: 
(1) De foetus waarvan het immuun systeem nog steeds in ontwikkeling is, 
en waarvan de moeder tijdens de zwangerschap een primaire infectie 
oploopt. 
(2) Immuungecompromiteerde patiënten (transplantatie patiënten, AIDS 
patiënten, en patiënten die immuno- suppressiva toegediend krijgen). 
Het onderzoek dat beschreven is in dit proefschrift is met name gericht op de 
congenitaal geïnfecteerde foetus. Het risico op een foetale infectie is 
afhankelijk van het stadium van de zwangerschap, en loopt op van circa 7% 
tijdens het eerste trimester tot 65% tijdens het derde trimester van de 
zwangerschap. De ernst van de congenitale infectie is eveneens afhankelijk 
van het stadium van de zwangerschap waarin de foetale infectie wordt 
opgelopen; hoe vroeger, hoe ernstiger. De infectie kan hydrocefalus, 
microcefalus, chorioretinitis en intracraniale calcificaties veroorzaken, en kan 
leiden tot de dood van de foetus. 
Voordat de Polymerase Chain Reaction (PCR) ontwikkeld was, werd de 
prenatale diagnostiek van de congenitale T. gondii infecties bemoeilijkt door 
het ontbreken van een betrouwbare, gevoelige, en snelle diagnostische test. 
Zwangere vrouwen, die tijdens hun zwangerschap een primaire infectie 
opliepen, moesten een beslissing tot therapie te nemen, zonder de zekerheid te 
hebben of de foetus geïnfecteerd was. Er kon echter geen garantie gegeven 
worden over een heilzaam effect van de therapie. In studies naar de 
effectiviteit van de behandeling ontbrak tot nu toe een "gerandomizeerde" 
groep van controle patiënten. Daarnaast ontbraken dikwijls gegevens over (1) 
of de foetus daadwerkelijk geïnfecteerd was, (2) het stadium waarin de 
maternale infectie zou zijn opgelopen, en (3) in welk stadium de foetale 
infectie was opgelopen. Met andere woorden, er was geen duidelijkheid 
omtrent de vraag of behandeling van de moeder nodig was en effect zou 
hebben ter preventie van de foetale infectie of als therapie. 
Het alternatief van abortus is mogelijk voor die vrouwen die de infectie voor 
de 26ste week van de zwangerschap oplopen. De keuze voor het afbreken van 
de zwangerschap zou echter tot een hoog aantal van volstrekt onnodige 
abortussen leiden, omdat met name tijdens het eerste trimester van de 
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zwangerschap slechts een zeer gering percentage van de foetussen geïnfecteerd 
raakt. Uit een recente studie van P. Hohlfeld et al. [1] bleek dat dit 
percentage slechts 7.2% is. 
Het belang van de verbetering van de prenatale diagnostiek van T. gondii 
infecties en de behoefte aan onderzoek naar de effectiviteit van behandeling 
van de geïnfecteerde foetus komt hiermee duidelijk naar voren. Om logistieke 
en praktische redenen is in dit onderzoek besloten om gebruik te maken van 
de rhesus aap als model voor de mens. Naar verwachting zou transmissie van 
infectie en transplacentaire overdracht van tegen de parasiet gerichte 
medicamenten bij de rhesus aap op overeenkomstige wijze verlopen als bij de 
mens omdat de rhesus aap, evenals de mens, een hemochoriale placenta bezit. 
Het onderzoek beschreven in dit proefschrift kende aldus twee doelstellingen, 
te weten: 
(1) Hoe kan met zekerheid worden vastgesteld of de foetus met T. gondii is 
geïnfecteerd indien er serologisch bij de moeder aanwijzingen zijn voor 
het doormaken van een primaire infectie. 
(2) Wat is het effect bij de van infectie verdachte foetus als de moeder 
gedurende de graviditeit chemotherapeutisch wordt behandeld ter 
secundaire preventie van congenitale toxoplasmose. 
Voor het verbeteren van de prenatale diagnostiek is gebruik gemaakt van de 
polymerase chain reaction (PCR), een techniek waarbij een gedeelte van het 
genoom dat specifiek is voor het organisme van interesse (in dit geval 
Toxoplasma gondii) zodanig vermenigvuldigd wordt dat het zichtbaar gemaakt 
kan worden. In de eerste studies is gebruik gemaakt van een in de literatuur 
beschreven PCR. Deze PCR is gebaseerd op de detectie van het BI-gen, een 
Toxoplasma specifiek gen dat circa 35 maal op het genoom voorkomt. Met 
behulp van deze PCR bleek het mogelijk te zijn om in patiënten materiaal het 
T. gondii DNA aan te tonen [2,3]. Nadat echter is gebleken dat de PCR op 
het BI-gen niet zo gevoelig is als het inoculeren van muizen, is een "nested" 
PCR ontwikkeld. Bij deze nested PCR wordt tweemaal achtereenvolgens een 
PCR uitgevoerd, waarbij het amplificatieprodukt uit de eerste reactie fungeert 
als target in de tweede reactie. Het small subunit ribosomal DNA gen (rDNA) 
is gebruikt als target voor de ontwikkeling van een nested PCR omdat het 
meerdere Toxoplasma-spec'iüeke sequenties bevat. Bovendien komt het 
genprodukt, het ribosomaal RNA (rRNA), in vele copieën (tot 10.000) voor in 
de parasiet. Dit rRNA is eveneens geschikt als target in de PCR (zie hoofstuk 
2). Alvorens het rDNA-gen als target te kunnen gebruiken diende het volledig 
gekarakteriseerd te worden. De nucleotide-sequentie is te vinden in de bijlage 
van dit proefschrift. De nested PCR op het rDNA gen bleek gevoeliger te zijn 
dan de muisproef, en te voldoen als diagnostische test voor de prenatale 
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detectie van T. gondii (hoofdstukken 3, 5, en 6). Tevens is met de PCR een 
enorme tijdwinst bereikt. Liet het resultaat van muis inoculaties soms 4 tot 6 
weken op zich wachten, dankzij de ontwikkeling van de PCR kan binnen 48 
uur na ontvangst van het klinisch monster een uitslag gegeven worden. 
Uit het onderzoek is gebleken dat het vruchtwater het meest geschikte 
klinische materiaal is om transmissie van infectie naar de foetus vast te 
stellen. De frequentie van transmissie in de aap blijkt overeen te komen met 
de frequentie die gevonden wordt bij de mens (zie hoofdstuk 3). 
Met behulp van de PCR blijkt het tevens mogelijk te zijn het effect van 
behandeling te vervolgen. Analyse van vruchtwater kan voor en na 
behandeling aangeven of er een infectie van de vruchtholte is opgetreden en of 
de parasiet nog aantoonbaar is. De resultaten wijzen uit dat de combinatie van 
pyrimethamine-sulfadiazine effectief werkt in het reduceren van het aantal 
parasieten in de foetus; binnen 10 tot 13 dagen na initiatie van de therapie is 
de parasiet niet meer aantoonbaar in het vruchtwater (hoofdstuk 6). 
Spiramycine moet daarentegen ten minste 3 weken gegeven worden om 
hetzelfde resultaat te bereiken (hoofdstuk 5). Bovendien bereikt spiramycine 
de hersenen niet (zie hoofdstukken 4 en 5). Aangezien een cerebrale infectie 
de meest ernstige aandoening is, zal spiramycine niet de therapie van keuze 
zijn om symptomen bij de foetus te voorkomen. Pyrimethamine en 
sulfadiazine zijn in staat de bloed-hersen barriere te passeren. Pyrimethamine 
blijkt zich zelfs in het hersenweefsel op te hopen waarbij concentraties bereikt 
worden welke ook in vitro werkzaam zijn (hoofdstuk 6). 
Het extrapoleren van de resultaten die gevonden zijn bij de rhesus aap naar de 
situatie bij de mens moet echter met enige voorzichtigheid gebeuren. Tijdens 
het onderzoek is namelijk gebleken dat het metabolisme van sulfadiazine in de 
rhesus aap enigszins verschilt van het metabolisme in de mens. Naast de 
metabolieten die zowel bij rhesus aap als mens voorkomen, blijken er bij de 
aap 3 metabolieten voor te komen die tot op heden niet bij de mens gevonden 
zijn (zie hoofdstuk 7). In vitro onderzoek heeft uitgewezen dat deze 3 
metabolieten anti-Toxoplasma activiteit bezitten (hoofdstuk 8). In de rhesus 
aap worden in het plasma de effectieve concentraties van deze metabolieten 
echter slechts gedurende korte perioden of zelfs helemaal niet bereikt. De 
metabolieten dragen waarschijnlijk niet of nauwelijks bij aan de effectiviteit 
van de behandeling. 
Tenslotte zijn er bij de apen geen toxische effecten ten gevolge van de 
therapie gevonden. Omdat de neonaten direct na de geboorte geofferd werden 
voor verder onderzoek, kan geen uitspraak gedaan worden over een eventuele 
kernicterus ten gevolge van sulfadiazine. Van pyrimethamine is bekend dat het 
teratogeen is. Deze gegevens zijn afkomstig uit proeven bij ratten waarbij 
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extreem hoge doses gegeven werden. Dergelijke doses worden bij de mens 
nooit toegepast. De teratogeniciteit van pyrimethamine is bij de mens nooit 
aangetoond. Een kernicterus veroorzaakt door sulfadiazine werd in het 
verleden frequent gevonden bij de neonaat. Tegenwoordig wordt een 
kernicterus echter vermeden door geen sulfadiazine te gebruiken tijdens de 
laatste 4 weken van de zwangerschap. De combinatie van pyrimethamine en 
sulfadiazine blijkt een veilige en effectieve therapie te zijn ter behandeling van 
een congenitale T. gondii infectie. 
Het werk dat beschreven is in dit proefschrift geeft een beter inzicht in het 
effect van de behandeling van de met T. gondii geïnfecteerde foetus. De 
resultaten wijzen uit dat een vroegtijdige behandeling met de combinatie 
pyrimethamine en sulfadiazine een duidelijk effect heeft op een congenitale 
infectie. Het aantal parasieten in het vruchtwater reduceert namelijk binnen 10 
tot 13 dagen tot een niveau dat niet meer met behulp van de PCR te 
detecteren is. De PCR biedt de mogelijkheid tot een snelle diagnostiek, zodat 
men vroegtijdig kan starten met de behandeling nadat foetale infectie heeft 
plaats gevonden. 
De verbetering van de prenatale diagnostiek en het effect van de behandeling 
bij een bewezen foetale infectie pleiten beiden voor introductie van een 
serologisch screenings programma op Toxoplasma bij zwangeren. De behoefte 
aan een dergelijk screeningsprogramma moet in het licht van de bevindingen 
in dit proefschrift opnieuw overwogen worden, ondanks het feit dat een 
dergelijk screenings programma waarschijnlijk niet kosten-effectief zal zijn. 
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APPENDIX 
Complete nucleotide sequence of the 16S-like small subunit 
ribosomal DNA gene of Toxoplasma gondii 
1 cctgccagta gtcatatgct tgtcttaaag attaagccat gcatgtCTAA 
51 GTATAAGCTT TTATACGGCg aaactgcgaa tggctcatta aaacagttat 
101 agtttatttg atGGTCTTTA CTACATGGAT AACCGTGGTA ATTCTATGGC 
151 TAATACATGC GCACATGCCT CTTCCCTGGA AGGCAGTGTT TATTAGATAC 
201 AGAACCAACC ACCTTCCGGT GGTCCCTCAG GTGATTCATA GTAACCGAAC 
251 GGATCGCGTT GACTTCGGTC TGCGACGAAT CATTcaagtt tctgacctat 
301 cagctttcga cggtactgta ttggactacc gtggcagtga cgggctaaac 
351 ggataattag ggttcgattc cggagaagga gcctgaaacg gctaccacat 
401 ctaaggaagg cagcaggcgc gcaaattacc caatcctgat tcaggaggta 
4 51 gtgacaagaa ataacaaCAC TGGAAATTTC ATTTCTAGTG ATTGGAATGA 
501 TAGGAATCCA AACCCCTTTC AGAGTAACaa ttggagggca agtctggtgc 
551 cagcagccgc ggtaattcca gctccaatag cgtatattaa agttgttgca 
601 gttaaaaagc tcgtagttgG ATTTCTGCTG GAAGCAGCCA GTCCGCCCTT 
6 51 CAGGGTGTGC ACTTGGTACG AATTCTAGCA TCCTTCTGGA TTTCTCCACA 
701 CTTCATTGTG TGGAGTTTTT TCAGGACTTT TACTTTGAGA AAATTAGAGT 
751 GTTTCAAGGC AGGCTTGTCG CCTTGAATAC TGCAGCATGG AATAATAAGA 
801 TAGGATTTCG GCCCTATTTT GTTGGTTTCT AGGACTGAAG TAatgattaa 
851 tagggacagg ttgggggcat tcgtatttaa ctgtcagagg tgaaattctt 
901 agatttgtta aagacgaact actgcgaaag catttgccaa agatgttctt 
951 aatcaagaac gaaagttagg ggctcgaaga cgatcagata ccgtcgtagt 
1001 cttaaccata aactatgccg actAGAGATA GGAAAAACGT GCATGCTTGA 
1051 CTTCTCCTGC ACCTTATgag aaatcaaagt ctttgggttc tggggggagt 
1101 atggtcgcaa ggctgaaact taaaggaatt gacggaaggg caccaccagg 
1151 cgtggagcct gcggcttcaa tttgactcaa cacggggaaa ctcaccaggt 
1201 ccagacatag gaaggattga cagattgata gctttttttg attctatggg 
1251 tggtggtgca tggccgttct tagttggtgg agtgatttgt ctggttaatt 
13 01 ccgttaacga acgagacctt aacctgctaa ATAGGATCAG GAACTTCGTG 
13 51 TTCTTGTATC ACTTCTTAGA GGGACTTTGC GTGTCTAACG Caaggaagtt 
1401 tgaggcaata acaggtctgt gatgccctta gatgttctgg gctgcacgcg 
1451 cgctacactg atGCATCCAA CGAGTTTATA ACCTTGGCCG ATAGTCTAGG 
1501 TAATCTTGTG AGTATGCATC GTGATgggat agattattgc aattattaat 
1551 cttcaacgag gaatgcctag taggcgcaag tcagcagctt gcgccgatta 
1601 cgtccctgcc ctttgtacac accgcccgtc gctcctaccg attGAGTGTT 
1651 CCGGTGAATT ATTCGGACCG TTCTGTGGCG CGTTCGTGCC CGAAATGGAA 
1701 GTTTTGTGAA CCTTAACACt tagaggaagg agaagtcgta acaaggtttt/c 
1751 cgtaggtgaa cctgcagaaa gatcaagc 
The variable regions are indicated by capitals 
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